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Abstract 
 
Hepcidin has been identified as the principle regulatory peptide essential for iron 
homeostasis. Expression of this cysteine-rich peptide is up-regulated by inflammation 
and iron overload, whereas hypoxia, iron deficiency and erythropoiesis suppress 
hepcidin expression. The quantitative analysis of hepcidin in bodily fluids will provide 
an insight into the pathogenesis of disorders of iron metabolism such as hereditary 
hemochromatosis. 
 
A mass spectrometry-based approach was taken to detect and quantify urinary hepcidin 
as urine is readily available and collection of this sample type is non-invasive. Samples 
were first purified using micro solid phase extraction (μSPE), followed by matrix 
assisted laser desorption/ionization-orthogonal-time-of-flight mass spectrometry 
(MALDI-TOF-MS) with inclusion of an internal standard for the quantitative analysis of 
unlabelled urinary hepcidin.  
 
Monoisotopic resolution of hepcidin-25 was observed with the MALDI-TOF-MS and 
extraction recovery of more than 70% was achieved. Spot-to-spot variations of less than 
3.5% RSD and intra- and inter-day precision of less than 9.5% RSD was observed. 
 
In our study, average hepcidin-25 levels of 1.7 nmol/mmol creatinine were observed in 
healthy subjects, compared to an average of 1.1 nmol hepcidin-25/mmol creatinine in 
iii 
    
hemochromatosis patients. In one of the patients, the hepcidin level was below the 
detection limit (1.25 nM). From the stability experiments of hepcidin-25, it is 
recommended that urine samples be stored at -80
oC and undergo minimal freeze-thaw 
cycles. It is also advised that extraction be carried out within 3 hours of thawing.    
 
Preliminary analysis using LC-ESI-IT-MS showed multiple charge states of hepcidin-25. 
However, a variation of less than 5% in hepcidin-25 concentration was observed when 
the same sample was analyzed with both LC-MS and MALDI-TOF-MS, and thus they 
can be used to counter-validate each other. 
 
In summary, a validated method has been developed for the quantification of unlabelled 
urinary hepcidin-25 which can be used to investigate the levels of hepcidin-25 in iron-
related disorders. 
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1.  Chapter 1 –  
Introduction of Iron and Hepcidin 
     Chapter 1 
1.1.  Iron 
 
Iron is the fourth most common element in the Earth’s crust and the most abundant 
transition metal in the human body. Iron is an essential element required for a variety of 
biochemical processes such as in enzymatic reactions for energy production, oxygen 
transport and DNA synthesis. It is also an essential cofactor for non-heme enzymes such 
as ribonucleotide reductase and lipoxygenase. When excess iron is present, it generates 
superoxide anions and hydroxyl radicals, which react readily with biological molecules 
resulting in cell toxicity. Thus, a functional control mechanism for the regulation of iron 
absorption, iron recycling and mobilization of stored iron to maintain iron homeostasis 
in humans is essential (The British Nutrition Foundation, 1995; Solomon et al., 2003; 
Hugman, 2006; Nemeth and Ganz, 2006; Chua et al., 2007; Malyszko and Mysliwiec, 
2007; Olynyk et al., 2008; Zhang and Enns, 2009).  
 
1.2.  Iron Absorption, Distribution and Recycling in the body 
 
The chemistry of iron is complex, due to its dual valencies [ferrous (Fe II) and ferric (Fe 
III)] and its reactivity with oxygen. Ionic iron is an active promoter of free radical 
reactions and is toxic to living cells. Therefore, strict biological regulations has been 
developed in the human body system to limit the entry of iron into the body and to 
convert any absorbed iron into a ‘safe’ bound or inactive form. Unregulated iron 
absorption causes free iron to be deposited in the parenchymal tissues causing organ 
damage due to free radical formation. Excessive prolonged tissue iron deposition can 
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cause liver cirrhosis, pancreatic dysfunction leading to diabetes mellitus and cardiac 
dysfunction (Cohen et al., 1981; Liu and Olivieri, 1994; Hentze et al., 2004; Hugman, 
2006; Nemeth and Ganz, 2006; Malyszko and Mysliwiec, 2007). 
 
The total iron in an adult is around 3000-5000 mg, of which 65-75% is contained in the 
hemoglobin of erythrocytes in the form of heme. The liver stores about 10-20% in the 
form of ferritin which can be mobilized easily when required and about 3-4% is stored 
as heme-bound myoglobin in the muscle. The remaining iron is distributed in other 
tissues.  
The distribution of iron in the body is shown in Figure 1-1. Absorption of iron occurs 
mainly in the duodenum in response to the level of body iron stores and the amount of 
iron needed for erythropoiesis. An average adult absorbs approximately1-2 mg of iron 
daily from the diet and the daily loss of iron from the body is about 1-2 mg, mainly from 
the gut epithelia, skin cells, sweat, blood, and small losses in the urine (Chua et al., 2007; 
Olynyk et al., 2008; Zhang and Enns, 2009). 
The daily requirement for erythropoiesis is about 20-25mg.  This is obtained largely by 
iron recycled to circulation by macrophages, which have phagocytosed senescent 
erythrocytes. Excess iron is stored in hepatocytes and macrophages (Hentze et al., 2004; 
Debnam and Srai, 2005; Donovan et al., 2005; Hugman, 2006; Olynyk et al., 2008).
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Figure 1-1: Iron distribution and metabolism within the body (Adapted from The British 
Nutrition Foundation 1995). Arrows in red, blue and black refers to loss of iron from the 
body, absorption of iron into the body, and the distribution of iron in the body 
respectively. 
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1.2.1. Iron uptake and export 
 
Dietary iron absorption occurs mainly in the duodenum. There are 2 forms of dietary 
iron, non-heme iron (inorganic iron) which is found in vegetables and grains, and heme 
iron (ferrous ion protoporphyrin IX) which is found in red meat. Heme iron is more 
efficiently absorbed than non-heme iron, however only about 10 to 15% of daily iron 
intake is comprised of heme iron and most intake is from non-heme sources (Carpenter 
and Mahoney, 1992; Chua et al., 2007; Zhang and Enns, 2009).  
Heme iron is transported from the gut lumen into the intestinal epithelial cells via a 
heme transporter which is yet to be identified. Dietary non-heme iron which exists 
mainly as Fe
3+ is reduced to Fe
2+ by duodenal cytochrome b (DcytB), a reductase whose 
expression is induced by iron deficiency and is localized in the apical membrane of 
intestinal enterocytes, prior to transport across the cell membrane (refer to Figure 1-2) 
(McKie and Barlow, 2004). 
Ferrous ion (Fe
2+) is transported by the divalent metal transporter (DMT1) across the 
apical membrane of the gut lumen (Gunshin et al., 1997). This inorganic ferrous iron is 
exported across the basolateral membrane via ferroportin (Abboud and Haile, 2000; 
McKie et al., 2000) into the bloodstream, where it is bound by transferrin (Tf) and 
delivered to the tissues (refer to Figure 1-2). 
Ferroportin (also known as SLC11A3, IREG1, MTP and FPN1) is the only mammalian 
transmembrane iron exporter identified to date that carries absorbed iron from 
enterocytes into circulation, participates in the recycling of iron from macrophages into 
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circulation (Delaby et al., 2005). Two forms of FPN1, known as FPN1A and FPN1B 
have been identified. FPN1A contains an iron responsive element (IRE) in its 5’ 
untranslated region and is expressed mainly in the liver. FPN1B, which lacks the IRE 
region, is expressed mainly in the intestine and is not repressed by iron regulatory 
proteins (IRPs) in iron deficient conditions (Zhang et al., 2009b). Mutations of 
ferroportin lead to iron overload disorders. 
During iron-replete conditions, both FPN1A and FPN1B are translated into FPN1 
protein. This protein is localized on the basolateral membrane and transports duodenal 
iron into circulation. When iron stores are high, hepcidin an iron regulatory peptide (see 
Section 1.3), which is produced by the liver, internalizes and degrades ferroportin, 
blocking iron absorption (Nemeth et al., 2004b). During iron deficient conditions, 
hepcidin expression is suppressed and the IRE/IRP regulatory system is also activated, 
which suppresses FPN1A but not FPN1B translation. Thus in iron deficient conditions, 
FPN1B gene expression is greatly increased to enhance iron absorption to satisfy 
systemic iron demands (Zhang et al., 2009b).   
The cellular exportation of iron by ferroportin is dependent on the multicopper oxidase 
(ceruloplasmin, Cp) in circulation and hephaestin on the basolateral membrane of 
enterocytes, which converts ferrous to ferric ion which is bound by plasma protein 
(Harris et al., 1995; Vulpe et al., 1999).  
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Heme 
 
Figure 1-2: Mechanism of iron absorption in the duodenal mucosa. Refer to text for the 
description of heme and non-heme iron absorption. When there is sufficient iron in the 
body, hepcidin (circulating in the blood) binds to the FPN at the cell membrane, induces 
internalization and degradation by lysozymes. 
 
1.2.2. Cellular iron transport 
 
Iron is essential for many cellular processes such as erythropoiesis. Proteins involved in 
iron uptake, storage, utilization and export must be strictly regulated in a coordinated 
fashion (Hentze et al., 2004). The majority of cells obtain their iron requirements by  
Tf-mediated iron uptake via transferrin receptor 1 (TfR1). 
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Tf is the major iron-binding protein that circulates through interstitial spaces in the liver, 
spleen and bone marrow, and more slowly in muscles and skin.  It is returned to the 
blood via the lymphatics. Each transferrin protein is able to bind to 2 ferric ions to form 
a diferric-Tf complex. The diferric-Tf in turn binds to TFR1 at the cell surface and is 
internalized into endosomes where iron is released from the Tf by endosomal 
acidification (Bali et al., 1991; Sipe and Murphy, 1991). The ferric ion is then reduced to 
ferrous ion by ferrireductase, a six-transmembrane epithelial antigen of prostate protein 
(STEAP3), and transported across the endosomal membrane for utilization within the 
cell and/or for storage (Hentze et al., 2004; Ohgami et al., 2005; Zhang and Enns, 2009). 
The amount of iron required by the cell is roughly proportional to the number of TfR1 
on the cell surface. The regulation of TfR1 expression is achieved by IRPs and the 
mRNA stem-loop structures, IREs. When cytosolic iron levels are low, IRPs bind to the 
IREs in the 3’ untranslated region (UTR) of the TfR1 mRNA increasing mRNA stability 
and TfR1 expression. Under high iron conditions, IRPs do not bind to the IREs, reducing 
mRNA stability and decreasing TfR1 levels (LaVaute et al., 2001; Rouault, 2006). 
 
A second TfR (TfR2), which is highly expressed by the hepatocytes, is capable of 
mediating the internalization and recycling of Tf and the delivery of iron to the cells by a 
mechanism similar to that described for TfR1. However, it has a lower binding affinity 
for holotransferrin than TfR1 abd evidence suggests that it has a limited role in hepatic 
iron transport (Kawabata et al., 1999; Siah et al., 2006; Graham et al., 2008). 
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Another cellular iron transporter mediates the uptake of non-transferrin bound iron 
(NTBI). The concentration of NTBI in the plasma is normally low and the transporter 
has a low binding affinity to iron (Grootveld et al., 1989; Olynyk et al., 2008). However 
saturation of plasma transferrin with iron leads to the formation of NTBI which is 
extremely toxic and is cleared rapidly from the plasma by the liver (Wright et al., 1986). 
The concentration of plasma NTBI is increased during iron overload conditions, such as 
in hereditary hemochromatosis (Chua et al., 2004). 
 
1.2.3. Iron storage 
 
The main site of iron deposition and storage is in the liver, or more specifically in the 
hepatocytes. During iron-replete conditions, iron is stored in the hepatocyes and also in 
the macrophages of the liver, spleen and bone marrow. However when body iron levels 
are low, the stored iron in the hepatocytes and macrophages can be mobilized to meet 
erythropoietic and cellular demands (Chua et al., 2007). 
In iron-replete conditions, the majority of cytosolic iron (80%) is stored in the cellular 
iron storage protein known as ferritin, a small amount of iron is stored as heme (2-3%) 
and the remainder in diferric-Tf complexes (Young et al., 1985; Graham et al., 2007).  
Ferritin stores iron in a non-toxic but bioavailable form. Ferritin is a 450 KDa protein 
consisting of 24 subunits that forms a hollow sphere that houses up to 4500 atoms of 
iron (Harrison, 1977; Harrison and Arosio, 1996). Ferritin synthesis is regulated by the 
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IRE/IRP system, where it is up-regulated during iron-replete conditions and is 
suppressed when iron is depleted (Ke et al., 1998; Chua et al., 2007).  
In normal healthy adults, high concentrations of ferritin are normally present in the liver, 
spleen and bone marrow, while low concentrations of ferritin, which appears to be 
glycosylated, are found in the plasma. Serum ferritin levels are used as a diagnostic 
measure of iron storage levels (Finch et al., 1986). Ferritin which is an acute-phase 
reactant, is induced during infection, inflammation, liver disorders and malignancies and 
could actually mask the actual iron deficiency (Di Santolo et al., 2008). 
 
1.2.4. Iron recycling 
 
Erythropoiesis is the process by which red blood cells or erythrocytes are produced. For 
erythropoiesis, a healthy adult requires about 20 mg of iron. However, dietary iron only 
accounts for about 2 mg of iron a day, thus the majority of iron required is recycled and 
derived from the phagocytosis of senescent erythrocytes by macrophages. 
The heme is catabolized by the heme oxygenase-1 to release iron. The freed iron is then 
exported from the macrophages by FPN and binds to transferrin in the blood which is 
taken up by erythroid precursors in the bone marrow and incorporated into hemoglobin 
(Hemmaplardh and Morgan, 1977; Donovan et al., 2005). Recent studies also showed 
that heme can also be exported directly into the circulation via the heme exporter, 
FLVCR (feline leukemia virus subgroup C receptor) (Keel et al., 2008).  
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Macrophage recycling of iron is very important and it supplies approximately 20-fold 
more iron for erythropoiesis than is absorbed by the intestine each day (Hentze et al., 
2004; Chua et al., 2007). 
 
In summary, systemic iron homeostasis is achieved by regulating the major iron flow 
into the plasma by: 1) the release of iron from macrophages recycling senescent red 
blood cells, 2) the release of stored iron hepatocytes, and 3) the absorption of dietary 
iron by duodenal enterocytes, and during fetal development, the transfer of iron from 
mother to fetus across placenta (Nemeth and Ganz, 2006). As humans are not able to 
excrete surplus iron, a tight control on body iron homeostasis is essential to provide 
sufficient iron for erythropoiesis and to ensure that excess iron is stored safely to prevent 
tissue damage (Bothwell, 1995). 
 
1.3.  Hepcidin 
1.3.1. Structural and distribution of hepcidin 
 
Human hepcidin also known as hepatic antimicrobial peptide (Hamp) is synthesized 
mainly by the liver hepatocytes and plays a major role in regulation of iron homeostasis 
(Nicolas et al., 2001b; Kartikasari et al., 2008).  
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Preprohepcidin is the pre-propeptide for the conserved hepcidin and is 84-amino acids 
long. The cDNA structure of preprohepcidin (GenBank
TM accession numbers 
AAG23966 and P81172 for the corresponding hepcidin precursor) consists of three 
exons and two introns (Park et al., 2001).  The third exon encodes the sequence of the 
peptides found in urine  (Park et al., 2001) and serum (Krause et al., 2000; Kemna et al., 
2007) as shown in Figure 1-3. 
Park and colleagues proposed that a strong consensus sequence for a signal sequence 
cleavage site is located between Gly
24 and Ser
25 that would produce a 60-residue 
propeptide. Another possible processing site is the carboxyl terminal to Arg
59, which is a 
consensus site for the subtilisin/kexin family of mammalian propeptide processing 
enzymes (propeptide convertases furin) with a preference for cleavage after the based 
paired basic residues Lys-Arg and Arg-Arg. The precursor is then cleaved by propeptide 
convertases to generate one or more bioactive peptides (Park et al., 2001; Valore and 
Ganz, 2008).  
Three isoforms of hepcidin (Hepc-20, -22 and -25) which differ by amino-terminal 
truncation are produced from the propeptide with Hepc-20 and -25 being the 
predominate forms. These contain 20 and 25 amino acid residues respectively, with four 
intersubunit disulfide bonds. All 3 isoforms are found in urine (Park et al., 2001; Kemna 
et al., 2005b; Kemna et al., 2007; Swinkels et al., 2008) and only the Hepc-20 and -25 
are found in plasma (Kemna et al., 2007; Swinkels et al., 2008).  The bioactive form of 
hepcidin is Hepc-25. Several studies have reported that neither serum nor urinary 
prohepcidin is related to iron absorption in healthy human subjects (Kemna et al., 2005a; 
Hadley et al., 2006). 
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Figure 1-3: Hepcidin gene and precursor peptide. An intron-exon diagram and the 
peptide sequence encoded by three exons A, B and C. The exons encode an 84-amino 
acid prepropeptide. Arrows denote three processed isoforms of hepcidin (hepcidin-20, -
22 and -25). An arrow indicates the putative signal sequence (SS) cleavage site. 
(Adapted from Park et al., 2001) 
 
 
Figure 1-4: Amino acid sequence and a model of the major form of human hepcidin. 
The amino and carboxyl termini are labeled as N and C respectively. The disulfide 
bridges are in yellow, basic amino acids are in blue and acidic amino acids are in red. 
The pattern of disulfide linkages between the 8 cysteines is shown in the sequence. 
(Adapted from Ganz, 2003) 
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Hepcidin forms a hairpin structure containing 8 cysteine residues all engaged in four 
intramolecular disulfide bonds as shown in Figure 1-4 (Krause et al., 2000; Park et al., 
2001; Ganz, 2003). This arrangement of disulfide bonds allows possible β-turns and 
provides a fold with the least steric hindrance among the side chains (Park et al., 2001). 
The symmetric arrangement of cysteine pairs around a cationic segment resemble that of 
antimicrobial protegrins and tachyplesins. These peptides, like hepcidin, have two-strand 
β-sheet structures which are stabilized by the disulfide bonds. Hepcidin was first 
identified to be in the same class as the defensins and cathelicidins (Park et al., 2001). 
In the initial hepcidin structure proposed by Hunter et al., the disulfide connectivity of 
Cys
1-Cys
8, Cys
2-Cys
7, Cys
3-Cys
6 and Cys
4-Cys
5 was reported (Hunter et al., 2002). 
Recently Jordan et al. demonstrated a new pattern of disulfide mapping using partial 
reductive alkylation, with disulfide connectivity of Cys
1-Cys
8, Cys
2-Cys
4, Cys
3-Cys
6 and 
Cys
5-Cys
7 (refer to Figure 1-5). The initial hepcidin structure consists of a distorted β-
sheet shape with a hairpin loop (Hunter et al., 2002), whereas the revised hepcidin 
structure consists of a stable β-sheet element and a β-hairpin loop (Jordan et al., 2009). 
 
Hepcidin is highly conserved across vertebrate species such as in pig, rat, mouse, dog 
and human as shown in Figure 1-6 (Park et al., 2001). This conserved peptide is highly 
expressed in the liver where the highest concentration is found to be in the periportal 
region of hepatocytes and its concentration deceases towards the central veins and 
sinusoids. Lower level of expression is also detected in the kidney, heart, skeletal 
muscles and brain (Kulaksiz et al., 2004). Kulaksiz et al. reported that hepcidin was 
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produced by the epithelial cells in the ascending limbs of the cortex and the collecting 
ducts in the kidney, suggesting that the localization of hepcidin implicates an iron 
regulatory role in the renal tubular system and the possible connection with DMT1 
which is also highly expressed in the kidney (Kulaksiz et al., 2005). Hepcidin expression 
has also been found in adipose tissues which may play an important role in hypoferremia 
of inflammation in obese conditions (Bekri et al., 2006; Vokurka et al., 2009). 
(B)  (A) 
25  22  20 
 
Figure 1-5: Amino acid sequence of human hepcidin with, A: disulfide connectivity 
proposed by Hunter et al. (2002). B: the revised disulfide connectivity proposed by 
Jordan et al. (2009). The three processed isoforms (Hepc-20, -22 and -25) differ by 
amino-terminal truncation as denoted by arrows (as shown in A). 
 
Figure 1-6: Amino acid sequence of vertebrate hepcidins. The mammalian species are 
h= human; p= pig; r= rat; m= mouse hepcidin-1; d= dog and z= zebrafish hepcidin-1. 
The conserved cysteines are boxed. (Adapted from Nemeth and Ganz, 2006) 
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1.3.2. Systemic signals that regulate hepcidin 
 
Hepcidin is a key homeostatic regulator of iron metabolism and also a mediator of host 
defense and inflammation. It is regulated by many factors including body iron levels, 
inflammation, hypoxia, erythropoiesis and oxidative stress. However, the iron dependent 
regulation of hepcidin is not completely understood (Viatte and Vaulont, 2009).  
 
Hepcidin acts as a negative regulator of iron export in enterocytes, macrophages and 
hepatocytes which are important sites of iron absorption, recycling and storage 
(Andrews, 2004; Malyszko and Mysliwiec, 2007). Hepcidin binds to ferroportin which 
is expressed on the basolateral surface of duodenal enterocytes, macrophages and 
hepatocytes, inducing internalization and degradation (refer to Figure 1-2) (Nemeth et 
al., 2004a; Nemeth et al., 2004b; De Domenico et al., 2007b). In a study by Nemeth et 
al. using a stable cell line over-expressing mouse ferroportin-labeled with green 
fluorescent protein (GFP), the addition of hepcidin caused the redistribution of 
ferroportin from the cell surfaces to punctuate intracellular vesicles. The ferroportin was 
not recycled to the cell surface even after hepcidin was removed, demonstrating that 
hepcidin not only induced internalization, but also the degradation of ferroportin by the 
lysosomal protease. This internalization of ferroportin is specific to bioactive   
hepcidin-25 (Nemeth et al., 2004b; Ganz, 2005). In the same study, Nemeth et al. 
identified that the first five amino acids at the N-terminal of hepcidin (DTHFP) is 
required for the binding to ferroportin, as shown in Figure 1-5 (Nemeth et al., 2004b). 
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De Domenico et al. demonstrated that the binding of hepcidin to ferroportin resulted in 
the activation of the protein, Janus Kinase 2 (Jak2). This resulted in ferroportin 
phosphorylation, followed by its internalization (De Domenico et al., 2009).  
As mentioned above, hepcidin expression is influenced by systemic stimuli such as iron 
stores, the rate of erythropoiesis, inflammation, hypoxia and oxidative stress (Fleming, 
2008; Darshan and Anderson, 2009). These stimuli act on the hepatocyte cell surface 
proteins such as hereditary hemochromatosis protein (HFE), TfR2, hemojuvelin (HJV), 
matriptase-2 (TMPRSS6) and interleukin-6 (IL-6) receptor to control hepcidin 
expression. These proteins activate several cell signal transduction pathways such as 
bone morphogenetic protein-mothers against decapentaplegic, drosophila homologs 
(BMP-SMAD), Janus kinases/signal transducer and activator of transcription-3 (JAK-
STAT3), hypoxia-inducible factor-1 (HIF-1) and CCAAT enhancer-binding protein 
alpha (C/EBPα) pathways to alter the transcription of the HAMP gene (refer to   
Figure 1.7). Conditions such as dietary iron deficiency, hypoxia (Leung et al., 2005) and 
hemorrhage are associated with decreased hepcidin expression and this leads to adaptive 
increases in iron absorption.  In contrast, hepcidin expression is increased by iron 
overload, inflammation (Ganz, 2006) and endoplasmic reticulum (ER) stress (Vecchi et 
al., 2009). 
 
 
 
17 
    Chapter 1 
18 
 
1.3.3. Regulation of hepcidin expression 
 
Several hepcidin regulatory processes such as inflammation, hypoxia and erythroid 
factors together with several proteins such as HJV, BMPs, HFE, TfR2, GDF15 and 
transferrin have been identified to be critical in iron homeostasis (refer to Figure 1-7). 
 
1.3.3.1.  HJV/BMPs/SMADs pathway 
 
HJV plays a pivotal role in iron homeostasis. Homozygous or the compound 
heterozygous mutations in HJV are responsible for a juvenile iron overload disorder 
called hereditary hemochromatosis (Papanikolaou et al., 2004). The membrane-bound 
HJV (mHJV) is a glycophosphatidylinositol (GPI)-anchored protein, which is highly 
expressed in the skeletal muscle and the heart, at a moderate level in the liver, and at low 
levels in other tissues (Papanikolaou et al., 2004). Studies using Hjv
 knockout mice and 
patients with juvenile hemochromatosis have shown that hepcidin expression is severely 
suppressed (Huang et al., 2005). This indicates that HJV plays an essential role in the 
regulation of hepatic hepcidin expression and is an upstream regulator of the peptide 
(Olynyk et al., 2008). 
    Chapter 1 
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Figure 1-7: Signal transduction pathways in the regulation of hepcidin production. 
Defective erythropoiesis increases serum GDF15 levels and blocks HAMP transcription. 
HIF-1α is stabilized by hypoxia or iron deficiency, which down-regulates hepcidin. 
HFE/TfR2 up-regulates hepcidin expression via the ERK pathways and the SMAD 
pathway. HJV is a co-receptor for BMPs. A cascade of SMADs phosphorylation follows, 
which up-regulates hepcidin expression, whereas sHJV competes with BMP to bind to 
the BMP receptor and inhibits SMAD signaling and hepcidin transcription. Matriptase-2 
is a protease that cleaves mHJV, thus affecting the BMP/SMAD pathway. Inflammatory 
cytokines (IL-6) is able to stimulate the JAK/STAT3 pathway leading to the up-
regulation of hepcidin expression. Arrows in red represent signaling leading to 
suppression or inhibition of HAMP transcription. (Modified from Darshan and Anderson, 
2009; De Domenico et al., 2008; Ramsay et al., 2009) 
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HJV belongs to the repulsive guidance molecule (RGM) family of proteins that function 
as co-receptors for BMP signaling. It binds to both type I BMP receptors (ALK2, ALK3 
and ALK6) and neogenin (Zhang et al., 2007; Verga Falzacappa et al., 2008; Xia et al., 
2008). In vivo and in vitro studies have shown that HJV is a co-receptor for BMP2, 
BMP4, BMP5, BMP6 and BMP9 where it enhances the BMP signaling and increases 
hepatic hepcidin expression (Babitt et al., 2006; Xia et al., 2008). BMPs are cytokines 
which belongs to the TGF-β superfamily. The BMP subfamily signals through the 
phosphorylation of SMAD proteins which consists of SMAD1, SMAD5 and SMAD8 
(Babitt et al., 2006). Basal hepcidin expression was shown to be regulated by BMP2  
and 4 in vitro (Babitt et al., 2007).  
 
Whereas, more recent studies have identified BMP6 as a key regulator of hepcidin 
expression and iron metabolism in vivo. Increased levels of BMP6 induces hepcidin 
mRNA expression (Andriopoulos et al., 2009; Nemeth, 2010). Studies using Bmp6-
deficient mice showed a significant reduction in hepatic hepcidin mRNA expression 
with elevated serum and liver iron content (Arndt et al.; Andriopoulos et al., 2009; 
Meynard et al., 2009). 
 
SMAD4, which is the central mediator in SMAD signaling in response to iron overload 
or IL-6 (Wang et al., 2005), forms heteromeric complexes with the receptor-activated 
SMAD. This heteromeric complex translocates from the cytoplasm into the nucleus to 
regulate hepcidin expression (refer to Figure 1-7) (Babitt et al., 2006).  
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Studies in mice with liver-specific knockout of the SMAD4 gene had reduced hepcidin 
expression and developed iron overload in the liver and other organs (Wang et al., 2005). 
In human hepatoma Huh7 and Hep3B cell line, hepcidin mRNA expression increased 
upon BMP treatment and was suppressed upon HJV siRNA-knockdown (Verga 
Falzacappa et al., 2008; Xia et al., 2008). This demonstrates the importance of the 
SMAD and the BMP signaling pathway in the regulation of hepcidin expression.  
HJV is regulated at the post transcriptional level and recent studies reported the 
involvement of another HJV isoform, the soluble HJV (sHJV), in the regulation of iron 
homeostasis in the body (Lin et al., 2005; Malyszko, 2009). The level of sHJV increases 
during hypoxia, which is due to the up-regulation of furin in association with the 
stabilization of hypoxia-inducible factor-1α (HIF-1α) (Silvestri et al., 2008a). Furin is a 
serine protease which cleaves precursor proteins to their biologically active form (Weiss, 
2008b). 
The sHJV originates from a furin cleavage at HJV position 332-335, and has been 
shown to repress hepcidin expression by interfering with BMP signaling. Interestingly, 
furin activation rapidly reduces mHJV and promotes the expression of sHJV (Babitt et 
al., 2006; Lin et al., 2007). Iron deficiency can cause hypoxia due to the low levels of 
circulating red blood cells in the body. Thus, under these hypoxic conditions, HIF-1α is 
directly or indirectly stabilized which leads to the activation of furin and the secretion of 
sHJV with an inhibitory effect on hepcidin production as demonstrated in Figure 1-8 
(Silvestri et al., 2008a).  
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Exercise has been shown to increase HIF-1α levels (Lundby and Steensberg, 2004). 
Thus the HIF-furin-induced sHJV release will suppress hepcidin production to 
accommodate the iron demand during exercise (Darshan and Anderson, 2009). However, 
significant increases in levels of hepcidin and IL-6 in athletes (after 3 hours post-
exercise) have been observed (Peeling et al., 2009), due to the injury sustained during 
exercise causing hemolysis. The increase in hepcidin levels showed that IL-6 exerts a 
greater effect on the regulation of hepcidin than HIF-1α and sHJV.  
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Figure 1-8: Hepcidin regulation in hypoxia. In iron deficiency-induced hypoxia and 
systemic hypoxia, HIF-1α is stabilized which upregulate furin and enhance HVJ 
shedding (sHJV). sHJV which is postulated to compete with mHJV on hepatocytes 
cascading to the suppression of BMP signaling and decreased hepcidin expression. 
(Adapted from Silvestri et al., 2008). 
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Neogenin is a membrane HJV receptor widely expressed in different tissues such as liver 
and muscle (Zhang et al., 2007). Controversial findings have been reported on the 
interaction of HJV protein with neogenin (Zhang et al., 2007; Lee et al., 2010).  
Zhang and colleagues reported that the when HJV protein interacts with neogenin, it 
undergoes regulated release (shedding) from cells. The release is negatively regulated by 
iron-loaded transferrin and possibly non-Tf bound iron (Zhang et al., 2005). They 
compete with membrane HJV on hepatocytes for the limited BMP2, 4 and 9 in serum, 
leading to the down regulation of BMP signaling, thus reducing hepcidin expression 
(Zhang et al., 2009a). Studies with the knockdown of endogenous neogenin exhibit 
suppressed HJV shedding and over expression of neogenin enhances HJV shedding 
(Zhang et al., 2007). However, Lee et al. reported that neogenin stabilizes HJV and 
suppresses HJV secretion, leading to down-regulation of hepcidin in both in vivo and in 
vitro models (Lee et al., 2010). The reason underlying this difference remains unclear 
and further investigation is required. 
 
Recently, serine protease TMPRSS6 (also known as matriptase-2) has been identified 
and was postulated to be involved in the HJV/BMP pathway (refer to Figure 1-7) (Du et 
al., 2008; Finberg et al., 2008). This type II plasma membrane protein is mainly 
expressed in the liver (Horl, 2008; Viatte and Vaulont, 2009). Studies using a mask 
mouse phenotype showed high hepcidin levels whereas the over-expression of 
TMPRSS6 protein showed suppression in HAMP promoter transcription (Du et al., 2008; 
Folgueras et al., 2008). Patients with iron-refractory iron deficiency anemia (IRIDA) 
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have also been reported to carry various genetic matriptase-2 mutations (Finberg et al., 
2008; Ramsay et al., 2009). In a study by Silvestri et al., mHJV and not sHJV (42 kDa), 
was specifically cleaved by matriptase-2, generating 25-30 kDA soluble fragments, and 
leading to the suppression of hepcidin expression (Silvestri et al., 2008b).  
They also observed that sHJV does not down-regulate hepcidin in the presence of mHJV 
(Silvestri et al., 2008b).  Thus the sHJV produced by furin cleavage (refer to Figure 1-8) 
behaves like matriptase-2 (in the absence of mHJV) to inhibit BMP2/4, leading to 
decrease hepcidin expression. However, the cleavage sites of mHJV by matriptase-2 
remain to be determined. In another study, the lack of HJV and matriptase-2 had a major 
effect on the HAMP expression, thus supporting that that HJV is the major substrate for 
TMPRSS6 protease activity (Truksa et al., 2009).   
   
1.3.3.2.  HFE with TfR1 and TfR2 
 
The HFE protein is a non-classical major histocompatibility complex (MHC) class 1 
molecule, which is highly expressed in the hepatocytes of the liver and at low levels in 
other tissues (Feder et al., 1996). 85-100% of patients with hereditary hemochromatosis 
type 1 have been shown to be due to a mutation at chromosome position 282, where 
cysteine was mis-coded to tyrosine (C282Y) (refer to Table 1-1, pg 35 for the 
classification of several type of hereditary hemochromatosis). This mutation prevents the 
association of HFE with β2-microglobulin (β2m) leading to the loss of cell surface 
expression (Feder et al., 1998). Studies in mice and patients with hemochromatosis type 1 
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have shown that mutations or the absence of HFE suppresses hepcidin expression (Bridle 
et al., 2003) resulting in the up-regulation of iron absorption and increased deposition of 
iron in tissues particularly in the liver (Nicolas et al., 2001a; Fujita et al., 2007). 
The HFE protein has been shown to bind to TfR1 at the site where it overlaps with the 
binding site for transferrin, thereby reducing its affinity for diferric-Tf (Feder et al., 
1998; Lebron et al., 1998; West et al., 2000). However, diferric-Tf can displace the HFE 
from the TfR1 due to its higher binding affinity and the unbound HFE then binds to 
TfR2 and stimulates hepcidin synthesis. In mice where HFE and TfR1 interact, the mice 
had low hepcidin expression and developed iron overload, whilst mice with mutations 
that interfered with the HFE/TfR1 interaction had inappropriately high hepcidin 
expression and developed iron deficiency (Schmidt et al., 2008).  
Schmidt and colleagues proposed that the unbound HFE displaced from TfR1 by diferric 
Tf can interact with TfR2 and up regulate hepcidin expression (refer to Figure 1-9) 
(Schmidt et al., 2008). TfR2 is the second and distinct transferrin receptor which is a 
type II membrane glycoprotein with a large C-terminal ectodomain and small N-terminal 
cytoplasmic domain (Kawabata et al., 1999; Fleming et al., 2000; Fleming, 2009). TfR2 
is stabilized by increased serum transferrin saturation or differic-Tf levels (Johnson and 
Enns, 2004; Robb and Wessling-Resnick, 2004; Chen et al., 2009). Goswami and 
Andrews demonstrated in CHO-TRVb-1 cells that TfR2 competes with TfR1 for binding 
to HFE irrespective of diferric-Tf concentrations (Goswami and Andrews, 2006). The 
authors also demonstrated the interaction between HFE and TfR2 in cultured cells where 
mutation in TfR2 leads to low hepcidin levels as seen in the mutation of HFE (Nemeth 
et al., 2005; Goswami and Andrews, 2006). 
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Figure 1-9: Model for serum iron sensing. In low serum iron or basal state, HFE is 
bound onto TfR1 (left). As serum iron transferrin  saturation increases (right), HFE is 
dissociated from TfR1 by diferric-Tf. Unbound HFE then interact with TfR2 and up 
regulate hepcidin expression to maintain iron homeostasis.  
 
Under normal homeostatic conditions, HFE is partitioned between TfR1, TfR2 and 
possibly other proteins (Schmidt et al., 2008). However as transferrin saturation 
increases, diferric-Tf is likely to displace HFE from TfR1 and binds to TfR2 and stabilize 
it (Robb and Wessling-Resnick, 2004; Pelucchi et al., 2009). The binding of HFE to 
TfR2 is at a distinct site from the transferring binding site in TfR2 (Chen et al., 2007). 
This cascade of events shifts HFE away from TfR1 and towards the interaction with 
TfR2 as shown in (refer to Figure 1-9). Schmidt et al. reported up-regulation of hepcidin 
when HFE was uncoupled from TfR1 in a TfR1 mutant mouse model. Thus, it is 
proposed that HFE/TfR2 complex helps to propagate a signaling cascade resulting in the 
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up-regulation of hepcidin, which leads to the decrease of dietary iron uptake and 
macrophage iron release (Schmidt et al., 2008). TfR2 also plays an important role in 
signal transduction of hepcidin (Calzolari et al., 2006). The activation of TfR2 by the 
binding of diferric transferrin has been shown to activate the ERK1/2 and p38 MAP 
kinase pathway, which acts upstream of hepcidin (Calzolari et al., 2006; Ramey et al., 
2009).  
 
1.3.3.3.  Inflammation STAT3 pathway 
 
The pro-inflammatory cytokine IL-6 regulates hepcidin by binding to the IL-6 receptor 
in the cell surface of hepatocytes and activates the Janus kinases/signal transducer and 
activator of transcription-3 (JAK/STAT3) signaling pathways and subsequently binds to 
the hepcidin promoter (refer to Figure 1-7) (Wrighting and Andrews, 2006; Verga 
Falzacappa et al., 2007). STAT3 is necessary for the IL-6 responsiveness of the hepcidin 
promoter as knockdown of STAT3 by RNAi reduced hepcidin mRNA expression in 
Huh7 cells. This suggests that STAT3 controls hepcidin transcription in both the absence 
and presence of experimental inflammatory stimuli (Verga Falzacappa et al., 2007).  
The selective inhibitor dorsomorphin is able to inhibit BMP-responsive SMAD 
phosphorylation (SMAD 1/5/8) and block the IL-6 mediated induction of hepcidin (Yu 
et al., 2008). Wang et al. reported that the inactivation of SMAD4 also inhibits the up-
regulation of hepcidin by IL-6 stimulation (Wang et al., 2005), thus suggesting that 
SMAD plays an important role in IL-6 regulation of hepcidin expression.   
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In conclusion, HFE, TfR2, HJV and STAT3 proteins appear to be upstream regulators of 
hepcidin production.  
 
1.4.  Hepcidin related disorders 
1.4.1. Hepcidin and Inflammation 
 
In humans, the liver is the central innate immune response site and is responsible for the 
increased synthesis of many acute-phase proteins, which are involved in host defense. 
Acute-phase response is a major pathophysiologic phenomenon that accompanies 
inflammation (Gabay and Kushner, 1999).  
Cytokines are a category of signaling proteins that are produced during inflammation. 
Pro-inflammatory cytokines interleukin-1α (IL-1α), IL-1β and IL-6 are able to up-
regulate hepcidin expression with interferon-β (IFN-β) inhibiting hepcidin transcription 
(Lee et al., 2004; Lee et al., 2005).  
During inflammatory conditions, iron absorption declines and iron is sequestered in 
macrophages. This leads to the decrease of plasma iron levels or hypoferremia (Rivera et 
al., 2005). Numerous studies have reported that hepcidin expression is also markedly 
increased during infection and inflammation (Ganz, 2002; Nicolas et al., 2002a; Nemeth 
et al., 2004a). Using both mice and human experimental models, Nemeth et al. have 
shown that IL-6 acts directly on hepatocytes to stimulate hepcidin production (Nemeth 
et al., 2004a). Hepcidin, in turn, acts as a negative regulator of intestinal iron absorption 
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and macrophage iron release. This results in hypoferremia and if the condition persists, it 
may lead to anemia of chronic disease (ACD) or anemia of chronic inflammation (refer 
to Figure 1-10) (Darshan and Anderson, 2009).  
 
Inflammation Æ Macrophage Æ Hepatocyte Æ  ↑Hepcidin Æ Hypoferremia Æ Anemia of inflammation
Macrophage iron release 
Intestinal iron absorption 
X
X
 
Figure 1-10: Regulation of hepcidin production during inflammation. Inflammation 
leads to macrophage stimulation of IL-6, which acts on hepatocytes to induce hepcidin 
production. Hepcidin in turn inhibits iron release in macrophages and inhibits intestinal 
iron absorption, leading to hypoferremia and anemia of chronic disease. 
 
Other inflammatory-induced models using turpentine (Nicolas et al., 2002a) or 
lipopolysacharide (LPS) (Kemna et al., 2005a; Nemeth et al., 2003a) report dramatic 
increases in hepcidin expression, leading to reduction of serum iron in mice. In another 
study by Nemeth et al., they reported that IL-6 is necessary for the induction of hepcidin 
and hypoferremia during inflammation, whereas in IL-6 knock-out mice, hepcidin 
mRNA was suppressed by other acute-phase cytokines such as tumor necrosis factor-α 
(TNF-α) (Nemeth et al., 2004a). These studies strongly suggest that hepcidin plays a key 
role in the dysregulation of iron homeostasis during inflammation. 
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1.4.2. Hepcidin, Anemia, Hypoxia and Erythropoiesis 
 
Most of the body’s iron is normally found in circulating red blood cells (RBCs) in the 
form of hemoglobin which is essential for oxygen transport in the body (Gasche et al., 
2004).  
Anemia may result from defects at any stage of red cell and hemoglobin production or 
when the rate of hemolysis exceeds the rate of erythropoiesis in the bone marrow (Di 
Santolo et al., 2008). Anemia and hypoxia decreases liver hepcidin expression (Nicolas 
et al., 2002a). Hepcidin expression is dramatically reduced in mice by acute anemia 
induced by hemolysis provoked by phenylhydrazine (PHZ) or repeated phlebotomy 
(Nicolas et al., 2002b). The same study also showed that hypoxia alone can cause a 
rapid decrease in hepcidin synthesis (Nicolas et al., 2002a). The results are rational as 
anemia is caused by the reduction in the amount of circulating hemoglobin which 
decreases the delivery of oxygen to the tissues, resulting in hypoxia. Hypoxia as 
described above can directly induce HIF-1α expression and interact with hepcidin 
expression via the von Hippel-Lindau/hypoxia-inducible transcription factor (VHL/HIF) 
pathway and interacts with the hypoxia responsive element in the hepcidin promoter 
(Peyssonnaux et al., 2007).  
 
Hypoxia has been identified as the primary signal regulating erythropoietin (EPO) 
production by the liver in the fetus and the kidneys in adults, where EPO in turn triggers 
erythropoiesis. However, the stimulation of erythropoiesis and iron supply to the plasma 
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led to the reduction of hepcidin expression (Nicolas et al., 2002b). Decreased liver 
hepcidin gene expression was observed when EPO was directly injected into C57BL/6 
mice for 3 days to mimic the effect of hypoxia as compared to saline-injected control 
mice (Nicolas et al., 2002b). Several studies have shown that EPO, via signaling through 
EPOR and the transcription factor C/EBPα, is able to modulate hepcidin expression 
(Eckardt and Kurtz, 2005; Lin et al., 2007; Pinto et al., 2008). This finding contrasts 
with that previously reported by Pak et al. which reported that hepcidin was not directly 
regulated by EPO, but by a signal downstream from EPO (Pak et al., 2006). Thus further 
investigation into the nature of the erythropoietic regulator of hepcidin is required.  
These findings also documented the possibility of using EPO on patients suffering from 
non-renal anemia (e.g. cancer or autoimmune diseases) to increase erythropoiesis and 
suppress hepcidin production to improve iron availability. 
 
1.4.3. Hepcidin and anemia of chronic disease/inflammation 
 
Anemia of chronic disease (ACD), also termed as anemia of inflammation, is primarily 
found in patients with diseases involving chronic immune activation and is the most 
commonly seen anemia in hospitalized patients (Weiss and Goodnough, 2005; Weiss, 
2008b). The frequency of ACD patients suffering from infections, malignancies and 
auto-immune disorder ranges from 8 to 95% (Weiss and Goodnough, 2005). A higher 
percentage of anemia has been associated with advanced age and cancer, with ACD as 
the underlying cause in up to 77% of these patients (Dunn et al., 2003) and the 
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prevalence of anemia was estimated between 20 and 80% in patients with auto-immune 
disorders such as rheumatoid arthritis or inflammatory bowel disease (Gasche et al., 
2004; Goyal et al., 2008; Zarychanski and Houston, 2008). 
Mixed forms of anemia may be seen in dialysis patients which arise from the classical 
features of renal anemia together with the pathophysiological changes induced with 
chronic inflammation due to the dialysis (Eschbach, 2002; Weiss, 2008b). In patients 
with ACD, anemia is generally mild (> 100g/L hemoglobin concentration) to moderate 
(85-100g/L hemoglobin concentration) (Zarychanski and Houston, 2008).  
Three major pathophysiological factors have been identified to underlie ACD;   
1) inflammation leading to iron retention within cells; 2) cytokines such as interferon-γ 
(IFN-γ), IFN-α, TNF-α and IL-1  and acute-phase proteins that suppress proliferation 
and differentiation of erythroid progenitor cells (Weiss et al., 1996); and 3) the down-
regulation of erythropoiesis further aggravating homeostasis and contributing to the 
development of ACD (Weiss, 2008b). IL-1 and TNF-α can induce the formation of toxic 
radicals which can damage erythropoietin-producing cells and inhibit erythropoietin 
formation (Jelkmann, 1998).  
At the molecular level of ACD, chronic inflammation leads to the continuous 
stimulation of IL-6 and hepcidin which binds to ferroportin and inhibits the efflux of 
iron (Raj, 2008a). This cascade of reactions prevents the release of iron from the cells 
into the plasma, thus inducing hypoferremia and limits the availability of iron for 
erythropoiesis as described above (refer to Figure 1-10). 
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1.4.4. Iron overload disorders (Hemochromatosis) 
 
At the end of the 19
th century, Dr von Recklinghausen introduced the term 
‘hemochromatosis’, which refers to the clinical disorder that results from excess of total 
body iron and organ failure due to iron toxicity. The disease manifestations include 
cirrhosis, diabetes mellitus and other endocrinopathies, cardiomyopathy, arthropathy, 
skin pigmentation and increased susceptibility to liver cancer in cirrhosis patients 
(Biasiotto et al., 2003; Camaschella, 2005). 
 
In hemochromatosis patients, iron is progressively stored in all tissues over a period of 
many years, especially in the liver and pancreas where iron concentration may reach 50-
100 times the normal level. Early symptoms of hemochromatosis include lethargy, 
abdominal pain, and arthralgia. Several organs that are affected by hemochromatosis are 
the liver, heart, pancreas, pituitary gland, thyroid gland, joints, and the skin 
(Camaschella, 2005). Regular treatment by phlebotomy can remove excessive iron 
stores which is an effective treatment for primary iron overload. However, toxic iron 
accumulation in secondary iron overload disorders resulting from repeated blood 
transfusion for treatment of genetic hemolytic anemia such as thalassemia or sickle cell 
diseases can only be targeted by iron-chelating drugs (Weiss, 2008a) 
Table 1-1 classifies several types and subtypes of hereditary hemochromatosis (HH);  
i) HH type 1 is caused by mutation in the HFE gene; ii) HH type 2A is caused by 
mutations in the HJV gene and HH type 2B is caused by mutations in the HAMP gene; 
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iii) HH type 3 is caused by mutations in the TFR2 gene, and iv) HH type 4 is caused by 
mutations in the ferroportin gene.  Other rare genetic iron overload disorders such as 
aceruploplasminemia (mutation in the Cp protein), atransferrinemia (lack of transferrin 
protein) and hereditary hyperferritemia (mutations in L-ferritin) have also been reported 
(Siah et al., 2005). 
 
Table 1-1: Classification of main genetic iron overload disorders. (Adapted from Brissot 
et al. 2008) 
Name Type 
Affected 
Chromosome 
Mutated 
Protein 
Mode of 
transmission
Hemochromatosis 1  6 HFE  Recessive 
Juvenile Hemochromatosis  2A 1  Hemojuvelin  Recessive 
Juvenile Hemochromatosis  2B  19  Hepcidin  Recessive 
Hemochromatosis 3  7 
Transferrin 
Receptor 2 
Recessive 
Ferroportin disease   4  2  Ferroportin  Dominant 
Aceruloplasminemia - 3  Ceruloplasmin  Recessive 
 
 
1.4.4.1.  HFE related hemochromatosis (Hemochromatosis Type 1) 
 
HH type 1 is the most prevalent form of iron overload disease caused by HFE mutation 
(Feder et al., 1996). In this autosomal recessive disease, excessive iron is found in the 
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parencymal cells of various tissues due to the increased iron absorption by the intestinal 
enterocytes. Hepcidin levels are also correspondingly low when HFE is dysfunctional 
(Olynyk et al., 2008).   
The major mutation of this gene is located on chromosome 6 or at the protein level is the 
C282Y mutation. This mutation is a G to A transition at nucleotide 845 of the open 
reading frame where cysteine is substituted by tyrosine at amino acid 282 (Feder et al., 
1996). C282Y mutation is most prevalent in Caucasian population and is almost absent 
in non-Caucasians (Cullen et al., 1998; Poddar, 2006; Dhillon et al., 2007). Another 
mutation, H63D, is a C-G transition at nucleotide 187 of the HFE gene which results in a 
histidine to aspartic acid substitution (Feder et al., 1996; Barton et al., 1997). Iron 
overload is also seen in patients with C282Y/H63D compound heterozygous genotype 
(Olynyk et al., 1999; Waalen et al., 2005). 
In Australia, HH affects about 1 in 200 individuals with an estimated carrier frequency 
of 1 in 10 for individuals of Northern European descent (Olynyk et al., 1999; Allen et al., 
2008). 
 
1.4.4.2.  Juvenile hemochromatosis (Hemochromatosis Type2) 
 
Juvenile hemochromatosis (JH) is a rare and particularly severe form of 
hemochromatosis affecting adolescents or young adults (<30 years old) causing cardiac 
and endocrine complications. Patients with JH often present with very high serum 
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ferritin levels, elevated transferrin saturation, hypogonadism, cardiomyopathy and 
diabetes (De Gobbi et al., 2002; Papanikolaou et al., 2005; Lee and Beutler, 2009).  
JH can be classified into 2 types (Type 2A and 2B). Type 2A is due to mutations in the 
HJV gene including a G320V mutation on chromosome 1 (Papanikolaou et al., 2004). 
Type 2B is due to mutations in the hepcidin gene (HAMP; OMIM 606464) on 
chromosome 19. A number of mutations have been identified including 93delG, 
166CÆT and C70R have been identified in the HAMP gene on chromosome 19q13 
(Roetto et al., 2003; Roetto et al., 2004). 
 
1.4.4.3.  Transferrin receptor-2 mutation (Hemochromatosis Type 3) 
 
Hemochromatosis type 3 which has a similar phenotype to hemochromatosis type 1 is 
due to mutations in transferrin receptor-2 (TfR2) gene on chromosome 7   
(OMIM 604720) (Roetto et al., 2003). TfR2 is 48% identical to TfR1 and has a lower 
binding affinity to diferric Tf. TfR2 stability is increased in the presence of diferric Tf 
which provides evidence that TfR2 protein may act as a sensor of iron status modulating 
iron absorption and macrophage iron recycling by regulating hepcidin expression (Robb 
and Wessling-Resnick, 2004; Pelucchi et al., 2009).  
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1.4.4.3.1.  The mechanism of hepcidin deficiency-iron overload 
 
In hemochromatosis type 1, 2 and 3, mutations in HFE, HJV, HAMP or TfR2 impair the 
signal cascade for hepcidin induction. As described above, this results in suppression of 
hepcidin peptide synthesis and secretion into the plasma resulting in decreased binding 
to ferroportin on the cell surface of the duodenal enterocytes, macrophages and 
hepatocytes, reducing the internalization and degradation of ferroportin. The increased 
levels of ferroportin increase iron export from the intestine elevating plasma and liver 
iron levels, resulting in iron overload (refer to Figure 1-11).   
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Figure 1-11: Quantitative defect in hepcidin-ferroportin interaction (Hemochromatosis 
type 1, 2 and 3). Suppressed hepcidin expression lead to decrease degradation of 
ferroportin. This results in the increased expression of ferroportin on the cell surface, 
thus leading to the increase export of iron to the blood. 
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1.4.4.4.  Ferroportin disease (Hemochromatosis Type 4) 
 
Ferroportin disease is due to mutations in the ferroportin (SLC40A1) gene located on 
chromosome 2 (OMIM 604353) and is the only autosomal dominant form of 
hemochromatosis reported (Pietrangelo, 2004; Wallace and Subramaniam, 2007). This 
disease usually exhibits the milder phenotype of hemochromatosis type 1 and has been 
reported in several countries (Montosi et al., 2001; Wallace et al., 2002; Beutler et al., 
2003; Koyama et al., 2005; Subramaniam et al., 2005). Most of the reported mutations 
such as V162del and A77D are restricted to single families (Wallace and Subramaniam, 
2007). 
 
This ferroportin disease can be classified into 2 subtypes. Subtype 4A, the most common 
form, is characterized phenotypically by either normal or low plasma transferrin 
saturation with increased iron deposition in the Kupffer cells of the liver. Iron overload 
associated with hemochromatosis type 4A is due to mutations in ferroportin which 
impair cellular iron export (De Domenico et al., 2006). 
In subtype 4B, the atypical phenotype resembles hemochromatosis type 1 with increased 
transferrin saturation and iron accumulation preferentially in the hepatocytes (Wallace 
and Subramaniam, 2007). This is due to the mutations in ferroportin that make it 
resistant to the actions of hepcidin preventing ferroportin degradation and increasing 
cellular iron export from intestine and macrophages as seen in hemochromatosis type 1, 
2 or 3 (Drakesmith et al., 2005).  
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1.4.4.5.  Aceruloplasminemia 
 
Hereditary aceruloplasminemia is a rare autosomal recessive iron overload disorder. It is 
caused by mutations in the ceruloplasmin gene resulting in the absence of serum 
ceruloplasmin. Ceruloplasmin has ferroxidase activity and is required for the oxidation 
of iron, which is necessary for the binding of iron by transferrin (refer to Figure 1-2). In 
the absence of ceruloplasmin, the export of iron from cells is impaired resulting in an 
increase in cellular iron levels particularly in the liver and brain (De Domenico et al., 
2007a; Guo et al., 2009). 
In summary, in hemochromatosis type 1, 2, 3 and 4B, cellular iron loading is caused by 
an increased deposition of iron in cells; predominantly parenchymal cells. Whereas in 
hemochromatosis type 4A and aceuruloplasminemia, cellular iron overload is caused by 
decreased iron egress from the cells 
 
1.4.5. Thalassemia  
 
Each RBC contains hemoglobin, a tetramer protein which consists of 2 pairs of globin 
chains (α, β, γ and δ) that is bound to the heme molecule. Hemoglobin (in adults) is 
composed of 2 α- and 2 non α-chains. Impaired production of any of these globin chains 
can reduce hemoglobin production, resulting in a hematologic disease known as 
thalassemia (Yuan et al., 1993; Rund and Rachmilewitz, 2005).  
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There are several types of thalassemia depending on the impaired globin chains, such as 
the impairment production of α-globin chain resulting in the disease known as   
α-thalassemia disease. β-thalassemia disease is due to the impaired synthesis of the β-
chain (Muncie and Campbell, 2009). Approximately 5% of the world’s population has a 
globin variant, with about 1.7% with β-thalassemia traits (Rund and Rachmilewitz, 
2005). 
Patients with β-thalassemia develop iron overload due to increased iron absorption 
which can lead to hepatic cirrhosis, cardiac failure and death (Modell et al., 2000; Tanno 
et al., 2007). Beta-thalassemia consists of 2 subtypes; 1) thalassemia intermediate (TI) 
and 2) thalassemia major (TM) (Origa et al., 2007; Camberlein et al., 2008).  
Patients with TM have more severe anemia than patients with TI, and require frequent 
blood transfusions (Camberlein et al., 2008), however, their iron burden is also further 
exacerbated by transfusion therapy (Origa et al., 2007). 
In β-thalassemia patients, serum growth differentiation factor 15 (GDF15) is elevated, 
which has been shown to suppress hepcidin expression (Tanno et al., 2007). It has been 
suggested that in thalassemia, tissue hypoxia, marrow expansion and erythroblast 
apoptosis caused by globin chain imbalances induce the up-regulation of GDF15. 
Increased GDF15 down-regulates hepcidin production which contributes to iron 
overload whereas tissue hypoxia and ineffective erythropoiesis results in anemia (refer 
to Figure 1-12) (Tanno et al., 2007). 
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Figure 1-12: Iron regulation in thalassemia patients. 
 
1.5.  Hepcidin measurement in human disorders 
 
There has been substantial interest in developing a reliable quantitative assay for 
hepcidin in biological fluids, such as urine and serum. Successful measurement of 
hepcidin will improve our understanding of iron diseases and also to develop an useful 
tool for the diagnosis and clinical management of these iron related disorders (Piperno et 
al., 2009). 
 
1.5.1. ELISA assay     
 
The first method for hepcidin quantification was developed by Nemeth et al. using 
immunodot assay. In this method, urinary hepcidin was first extracted with cation-
exchange chromatography, followed by chemiluminescence using rabbit anti-human 
hepcidin primary antibodies (Nemeth et al., 2004a). This method was further developed 
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and validated for both urinary and serum hepcidin by Ganz et al. with limit of detection 
at 5 ng/mL (Ganz et al., 2008). However, this method was laborious and only suitable 
for a relatively small series of patients (Piperno et al., 2009). The other disadvantage of 
using the immunodot technique is the difficulty of synthesizing anti-hepcidin antibodies 
due to its small size (25 amino acids) and compact structure with few antigenic epitopes 
(Park et al., 2001) . The presence of four disulfide bonds among the eight cysteine 
residues also hampered the production of synthetic hepcidin in its native conformation 
(Hunter et al., 2002). 
A commercial ELISA assay for the detection of serum pro-hepcidin was developed 
(Kulaksiz et al., 2004). However this assay was not used widely as no correlation 
between pro-hepcidin with iron status and/or iron absorption was reported (Hadley et al., 
2006; Roe et al., 2007). Therefore, a more sensitive and robust technique such as mass 
spectrometry, is required for accurate quantification and detection of endogenous 
hepcidin. 
 
1.5.2. Mass spectrometry-based assay 
 
There have been many studies demonstrating the usefulness of time-of-flight mass 
spectrometry based techniques for targeted peptide quantification (Griffin et al., 2001; 
Gelfanova et al., 2007; Amini and Nilsson, 2008; Rubakhin and Sweedler, 2008). In 
particular, the level of endogenous hepcidin was quantified using surface-enhanced laser 
desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) in several 
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studies (Tomosugi et al., 2006; Kemna et al., 2007; Swinkels et al., 2008; Ward et al., 
2008b; Altamura et al., 2009). The first MS method was developed by Kemna et al. 
where a direct on-spot method using a copper-loaded immobilized metal-affinity capture 
ProteinChip array (IMAC30-Cu
2+) was employed for the quantitation of hepcidin 
(Kemna et al., 2007). The above method was further developed by Swinkels et al. where 
an internal standard (hepcidin-24) was included in the assay to achieve better precision 
(Swinkels et al., 2008).  
Other hepcidin SELDI-TOF MS methods include that of Tomosugi and co-workers, who 
analyzes serum/urine hepcidin with a bioprocessor and using external hepcidin-25 
standards. The assay by Altramure et al. which is similar to the Tomosugi et al. assay, 
semi-quantitated urinary hepcidin using external references containing ACTH, bovine 
insulin and synthetic human hepcidin (Altamura et al., 2009). The hepcidin 
concentration was then normalized to urinary creatinine and urea levels in the body.  
Several publications have also utilized stable isotopes labeled hepcidin together with 
mass spectrometry techniques in their hepcidin assay. Ward et al. utilized a stable 
isotope labeled hepcidin internal standard in the SELDI assay (Ward et al., 2008b). 
Bansal et al. had employed weak cation-exchange (WCX) magnetic nanoparticles and 
MALDI-TOF MS for the quantification of urinary hepcidin using [
15N,
13C2]Gly
12,20-
hepcidin-25 as internal standard (Bansal et al., 2009a),  whereas Anderson and 
colleagues have used [
15N2,
13C6]2Lys-hepcidin-25 as internal standard and MALDI-
TOF/TOF MS for their quantification of urinary hepcidin (Anderson et al., 2010). 
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Recently, quantification of urinary endogenous hepcidin-25 using a standard addition 
method and MALDI-TOF MS has been reported (Gay et al., 2010).  
 
Three serum hepcidin quantitative methods using liquid chromatography tandem triple 
quadrupole mass spectrometry (LC-MS/MS) together with solid phase extraction (SPE) 
were published with Murphy et al. using 100 μL aliquot of plasma or serum and 
calcitonin gene-related peptide (CGRP) as internal standard (Murphy et al., 2007). 
Kobold et al. employed an isotope-dilution method and μHPLC-tandem MS for serum 
hepcidin analysis (Kobold et al., 2008) and Li et al.  used [
13C9,
15N1]-Phe
4-hepcidin as 
internal standard for the analysis of serum samples (Li et al., 2009).   Bansal et al. 
reported the first LC tandem ion trap MS method for the quantitation of urinary hepcidin 
using selected reaction monitoring (SRM) (Bansal et al., 2009a). Murao et al. employed 
peptide precipitation method using trichloroacetic acid LC-MS/MS for the quantification 
of plasma hepcidin (Murao et al., 2007).  
In summary, studies have utilized different external calibration standards (Tomosugi et 
al., 2006; Altamura et al., 2009), stable isotope labeled hepcidin (Murao et al., 2007; 
Ward et al., 2008b; Bansal et al., 2009a; Bansal et al., 2009b; Li et al., 2009; Anderson 
et al., 2010) and truncated hepcidin analogues (Kemna et al., 2005b; Swinkels et al., 
2008) as internal standards for the quantification of hepcidin. The use of external 
standards are only able to provide semi-quantiative hepcidin concentrations whereas the 
use of labeled hepcidin are costly and difficult to synthesize. However, an accurate and 
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cost effective assay has been achieved in the quantification of endogenous hepcidin 
using a standard addition method. 
 
The advantage of using MALDI-TOF MS based assays mentioned, is that they have the 
potential to simultaneously distinguish and quantify multiple isoforms/variants of 
hepcidin compared to most ELISA based assays (Tomosugi et al., 2006; Kemna et al., 
2007; Swinkels et al., 2008; Ward et al., 2008b; Altamura et al., 2009; Bansal et al., 
2009b). LC MS based assays required about 10 min for each analysis whilst the 
MALDI-TOF assay requires less than 1 min of analysis time (Bansal et al., 2009b). 
However, both techniques are complementary, and LC MS can be used to provide 
further structural confidence for hepcidin while MALDI-TOF MS is able to provide fast 
and accurate analysis. 
Numerous MS-based hepcidin assays have been developed by different research groups. 
In the first Round Robin in the quantification of hepcidin levels in different biofluids 
(urine and serum), hepcidin concentrations differing widely between the different 
methods were observed (Kroot et al., 2009b). Therefore, a more standardized method 
would be ideal to provide more accurate and useful data which can be compared among 
the groups. 
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1.6.  Conclusion 
 
The discovery of hepcidin has revolutionized the field of iron metabolism. Hepcidin 
expression is up regulated by inflammation and iron overload, whereas hypoxia, iron 
deficiency and erythropoiesis suppress hepcidin expression.  
The recent advances in identifying the different complex pathways (BMP/SMAD, 
JAK/STAT, ERK, HFE/TfR1 and TfR2) that regulate hepcidin expression have led to a 
better understanding of iron related diseases such as ACD, thalassemia and 
hemochromatosis.  Further studies investigating these regulatory pathway(s) (e.g. 
TMPRSS6) and the crosstalk between the pathways will provide invaluable insight into 
understanding the mechanisms of iron homeostasis.  
The development of diagnostic and therapeutic treatments including the use of 
antagonist or agonists to hepcidin and other regulators could prove useful for the 
treatment of iron related diseases in the near future. 
     Chapter 2 
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2.1.  Peptidomics 
 
Peptidomics is the detailed study of the role that peptides play in health and disease. The 
concept of peptidomics was first introduced in 2000 at the Association of Biomolecular 
Resource Facilities (ABRF) conference in Bellevue, USA (Soloviev et al., 2008). The 
aim of peptidomics is to simultaneously identify and/or visualize the ‘peptidome’, which 
consists of the whole peptide content of a cell, tissue or organism (Boonen et al., 2008). 
Several peptidomics studies involving the identification and quantification of targeted 
peptides have also been published in recent years (Yamaguchi et al., 2007; Lee et al., 
2008; Menschaert et al., 2009; Perroud et al., 2009). 
Peptides are produced and processed in a multitude of biological pathways and proteases 
are the driving force generating the peptide pool (refer to Figure 2-1). They are usually 
redistributed between compartments within an organism and various peptides are 
produced at a given time and at a given location. Peptide pools within an organism, 
including intracellular and extracellular peptides, and peptides in the blood or urine, are 
dynamically interconnected (Soloviev et al., 2008). Care should therefore be taken in 
peptidomic studies, as the type of peptides and their concentrations are constantly 
changing due to the activity status of proteases and protease inhibitors, whose activities 
are determined by the body and environmental conditions. Therefore it is essential that 
all processes are stopped or quenched immediately to obtain a ‘snapshot’ of the 
peptidome at that specific time-point.  
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Figure 2-1: The translation of genetic information into protein followed by subsequent 
proteolysis to peptides. In addition, the associated research approaches are indicated. 
(Modified from Soloviev et al., 2008) 
 
2.1.1. Biofluids for peptidomics studies 
 
Body fluids such as urine, blood, saliva and cerebrospinal fluid (CSF) are an important 
source for peptidomic studies. The study of polypeptides in body fluids provided a 
valuable insight of their functional roles during different physiological and 
pathophysiological conditions (Thongboonkerd et al., 2007). Body fluids are a very 
complex mixture of molecules with a wide range of polarity, hydrophobicity, and size 
(Soloviev et al., 2008). Biofluids contain a large array of different ions, lipids, 
50 
    Chapter 2 
carbohydrates, salts and other molecular species which can cause signal suppression and 
inhibit biofluids being analyzed in their native form in a mass spectrometer (Beavis and 
Chait, 1996; Wang and Fitzgerald, 2000; Annesley, 2003; Schlosser et al., 2005; 
Soloviev et al., 2008). Therefore pre-processing of raw samples using clean-up 
techniques such as liquid-liquid extraction (LLE), solid phase extraction (SPE) or 
molecular weight cut-off is critical before any MS analysis. 
Urine contains a myriad of polypeptides which are derived from a variety of sources 
relating to the functions of many internal organs including glomerular filtration of blood 
plasma, cell sloughing, apoptosis, proteolytic cleavage of cell surfaces and secretion of 
exosomes by epithelial cells (Pisitkun et al., 2006; Zimmerli et al., 2008). Mass 
spectrometry-based approaches to urinary peptidomic profiling can reveal changes in 
excretion of specific peptides that can indicate certain diseases. These can be used for 
early diagnosis, classification of the disease in therapeutic response to therapy, prognosis 
and monitoring of the disease and therapy (Pisitkun et al., 2006). The other advantages 
of using urine for peptidomic analysis are its non-invasiveness and ease of collection. 
Urinary peptidomics has been applied to disease detection for coronary artery disease 
(Zimmerli et al., 2008; Muhlen et al., 2009) and the immunoreactive brain natriuretic 
peptide in renal disease (Totsune et al., 1996)  
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2.1.2. Targeted peptidomics 
 
As mentioned, several hundreds to thousands of different peptides are present in body 
fluids (Schulz-Knappe et al., 2001; Baggerman et al., 2002; Skold et al., 2002). 
Recently, mass spectrometry-based techniques have been the driving force behind the 
advancement in peptidomics (Soloviev and Finch, 2005).  
Untargeted peptidomics involves the analysis of the whole peptidome in a biofluid, 
which often lead to very complex mass spectra (Soloviev and Finch, 2005). To 
circumvent this and depending on the complexity of the sample, a certain degree of 
sample clean-up and fractionation procedures are employed before any analysis (Immler 
et al., 2006; Wei and Li, 2009). When peptides of biological significance are identified 
from the untargeted peptidomics analysis, targeted peptidomics are then employed 
(Baggerman et al., 2004).     
 
Targeted peptidomics focuses on the selective identification and quantification of one or 
a few peptides of interest from an array of peptides (Pan et al., 2009). The use of 
targeted peptidomics in mass spectrometry-based assays results in a less complex 
spectrum with higher compound sensitivity (Ye et al., 2009). In addition, structural 
elucidation is achievable when the peptide is analyzed with a tandem mass spectrometer 
(Baggerman et al., 2004). Recently, MS-based quantification analysis has been 
applicable to targeted peptidomics using methods such as absolute quantification 
(AQUA) (Gerber et al., 2003; Anderson et al., 2004), stable isotopic-labeling of amino 
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acids (Barnidge et al., 2004; Ramstrom and Bergquist, 2004) and the use of isobaric/ 
non-isobaric chemical labeling (e.g. iTRAQ) (Yocum et al., 2008).  
Compared to enzyme-linked immunosorbent assay (ELISA), which is limited by the 
availability of high specificity antibodies, MS-based techniques are able to provide an 
alternative approach which can precisely detect and quantify single or several peptides 
with high mass accuracy and sensitivity (Baggerman et al., 2004; Putz et al., 2005; 
Perroud et al., 2009).  
 
One of the main objectives of developing MS-based quantification strategies is its 
clinical applications, which is to quantify candidate peptides in association with diseases 
such as diabetic-nephropathic disease (Lapolla et al., 2009a; Lapolla et al., 2009b) and 
iron related disease (Kemna et al., 2005b; Ganz et al., 2008; Li et al., 2009). 
This chapter will focus on using a specific sample preparation technique, solid phase 
extraction (SPE), and will discuss the various MS-based instruments used for targeted 
peptidomics studies. 
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2.2.  Solid phase extraction (SPE) 
2.2.1. Introduction  
 
SPE was introduced in the early 1970s to eliminate or reduce the problems encountered 
with liquid-liquid extraction (LLE). The use of large volumes of toxic organic solvents 
and glassware required in LLE made this method laborious and costly (Berrueta et al., 
1995; Thurman and Mills, 1998). SPE concentrates and purifies analytes from samples 
(in solution) by sorption onto a disposable solid phase cartridge, followed by elution of 
the analyte with a solvent appropriate for instrumental analysis (Thurman and Mills, 
1998; Bielicka-Daszkiewicz et al., 2005).   
 
A SPE cartridge usually consists of sorbent, which is packed into a small polypropylene 
or polyethylene disposable syringe barrel column or cartridge. The packing material for 
the sorbent bed is similar to those used in liquid chromatography columns employing 
different retention mechanisms such as normal phase, reverse phase, ion exchange and 
size exclusion. Sorbents with larger particle size are used in SPE, typically 30 to 100 μm, 
compared to HPLC columns with particle size of 1.5 to 5 μm.  The advantages of SPE 
over LLE include the use of smaller sample quantities, lower solvent volumes and 
shorter sample extraction time (Telepchak et al., 2004). Higher recoveries are also 
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observed in extractions using SPE compared to LLE. In addition, SPE can be automated 
(Telepchak et al., 2004). 
The advancement of SPE has proved to be very useful in the isolation, fractionation and 
purification of peptides from biological samples (Herraiz and Casal, 1995). Several 
studies have utilized SPE to desalt urine samples for biomarker discovery (Balog et al., 
2009) and to clean up tryptic digests of bovine serum albumin (BSA) samples 
(Rappsilber et al., 2003). SPE is also employed to remove by-products from tert-
butoxycarbonyl (Boc) solid-phase peptide synthesis (Hofmann et al., 2005). 
 
2.2.2. Extraction steps in SPE  
 
Normally, each SPE cartridge will need to be conditioned before use by passing an 
appropriate solvent through the sorbent to ‘wet’ the packing material and to solvate the 
functional groups of the sorbent (Berrueta et al., 1995). This also removes air that is 
present in the column by filling the void space with solvent. The most common 
conditioning solvent used is methanol, followed by water or an aqueous buffer that is 
similar in composition to the sample matrix, which equilibrates the sorbent for aqueous 
samples (refer to Figure 2-2-1) (Berrueta et al., 1995). Precautions are taken to prevent 
the drying out of the sorbent before the sample loading step, as poor sorption mechanism 
leading to low recoveries is observed in dried sorbents (Thurman and Mills, 1998; 
Telepchak et al., 2004). 
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Sample pre-treatment by the addition of acid, base or dilution may be necessary 
depending on column chemistry and analyte properties. Samples can be loaded directly 
onto the conditioned SPE cartridge either by gravity feed, pumping, aspiration by 
vacuum or using an automated system (Berrueta et al., 1995). The concentration of 
analytes on the column whilst removing interferences, such as salts or buffers, can be 
achieved during this step (refer to Figure 2-2-2) (Berrueta et al., 1995). An additional 
‘washing’ step is employed to ensure that these interferences are eluted from the sorbent 
while the target analytes are still retained (refer to Figure 2-2-3) (Thurman and Mills, 
1998). However, care must be taken to prevent the breakthrough of analytes, where the 
analytes are ineffectively retained on the sorbent, resulting in low recovery (Telepchak 
et al., 2004). Breakthrough can be due to; 1) improper conditioning step; 2) overloading 
of sample where the capacity of the sorbent bed is insufficient to bind to the analytes; 3) 
the flow rate when the sample is being introduced; and 4) inappropriate sorbent used for 
the retention of target analyte (Berrueta et al., 1995; Telepchak et al., 2004). 
In the final step (refer to Figure 2-2-4), the analyte is eluted from the sorbent with the  
appropriate buffered solvent that disrupts the analyte-sorbent interaction  (Telepchak et 
al., 2004). Concentration of target compounds can be achieved by eluting the analytes 
with a smaller volume of solvent. 
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Figure 2-2: General process of solid phase extraction. Refer to text for more details. 
 
2.2.3. Overview of the different types of sorbent phases in SPE 
 
The selection of the appropriate sorbent phases, which is dependent on the behavior of 
the target analytes, is critical. Several phase classes such as normal, reversed and ion 
exchange phases are currently available.  
In normal phase sorbents (e.g. cyano (CN), amino (NH2), silica gel and diol (COHCOH), 
the stationary phase is more polar than the solvent or sample matrix that is applied to the 
sorbent bed. This phase is normally used when the analyte of interest is readily dissolved 
in an organic solvent and/or is immiscible in water. The primary mechanisms for solute 
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retention in normal phase extraction consists of interactions such as hydrogen bonding 
and dipole-dipole interactions (Thurman and Mills, 1998).  
In reverse-phase extraction, the sorbent packing materials are commonly more 
hydrophobic than the samples, such as octadecyl (C-18), octyl (C-8), ethyl (C-2). This 
phase is used with aqueous samples where van der Waal’s forces are the primary 
interaction and secondary interactions include hydrogen bonding and dipole-dipole 
interactions (Thurman and Mills, 1998). 
Ion exchange sorbent isolates analytes based on their ionic state (either cationic or 
anionic), where the charged analyte exchanges for another charged species that is 
already sorbed onto the ion exchange resin. This is executed by modifying the pH and 
the organic solvents of the solutions passing through the SPE cartridge. Thus the 
interactions include van der Waal’s forces, dipole-dipole interactions, hydrogen bonding 
and cation and anion exchange (Thurman and Mills, 1998). Amino (NH2) groups, 
quaternary amines and carboxylic acids are also used in ion exchange sorbents 
(Telepchak et al., 2004).  
 
2.2.4. Advancements of SPE  
 
For many years, the majority of SPE bonded phases were silica based with particle sizes 
of about 40 to 60 μm and an average pore size of about 60Å.  Bonded silica sorbents in 
SPE possess the same disadvantages that are observed for HPLC, including limited pH 
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range (pH 2-9) and, even under appropriate pH conditions (about pKa of around 4.5- 4.7), 
the silanol groups become ionized and are negatively charged and will react with 
positively charged compounds (e.g. protonated amines), thus reducing analyte recovery 
efficiency (Thurman and Mills, 1998). 
The major advancement in SPE has been the introduction of polymeric sorbents. These 
sorbents can tolerate a wide pH range, and solvents and buffers that would otherwise 
destroy silica-based sorbents (Bielicka-Daszkiewicz et al., 2005). The spherical-shaped 
polymeric sorbent materials produce very homogenous packed beds with reproducible 
flow characteristics and minimal back pressure. A higher sample capacity is also 
achieved with polymeric-based sorbent compared to silica-based sorbent. Silica sorbents 
are sensitive to the drying-out of sorbent material, whereas polymeric sorbent is more 
tolerant to the drying-out process, thus maintaining retention and recovery efficiency 
(Bielicka-Daszkiewicz et al., 2005). 
Monoliths are macroporous polymers prepared by direct polymerization in situ in a mold 
(Svec, 2006). Each monolith consists of a single piece of separation media instead of a 
cluster of packed particles. Monoliths are characterized by their high permeability and 
low mass transfer resistance (Leinweber et al., 2003; Sandra et al., 2008). These 
macroporous polymers are suitable for retaining macromolecules of up to several 
thousand molecular weight, such as polypeptides and peptides, thus they are widely 
employed as stationary phase in SPE cartridges and LC columns (Xiong et al., 2004; 
Sandra et al., 2008). 
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2.2.5. SPE in a tip (μSPE) 
 
As research in the fields of proteomics, peptidomics and metabolomics expands, the 
demand increases for new SPE development where rapid and high recovery sample 
clean-up is necessary. As some compounds are difficult to obtain and/or are in low 
abundance and sample volumes may be limited, the new SPE needs to accommodate 
low sample volume and at the same time, be able to concentrate the analyte of interest 
(Miyazaki et al., 2004).  
 
Micro-extraction SPE or μSPE is the miniaturization of the traditional SPE cartridge, 
which consists of SPE sorbent packed into pipette tips. Instead of using a vacuum 
manifold as in traditional SPE extraction, a micro-pipettor is used in μSPE (Miyazaki et 
al., 2004; Hasegawa et al., 2006; Svec, 2006). μSPE has the added advantage of 
achieving economy, time efficiency and reducing solvent costs as well as meeting the 
low sample volume requirement. 
Currently, a variety of phases ranging from C4 to C18 and ion exchange phases are 
commercially available with volume capacities ranging from 200 μL down to 10 μL. 
The advantages of using micro-extraction techniques over traditional SPE are:   
1) reduction in the volume of solvent required compared to LLE and normal SPE; 2) 
small volume of sample required (~10 – 200 μL), which is especially useful for volume 
limited samples; and 3) small elution volume (~0.5 – 10 μL) with minimal dead-volume 
and the ability to spot directly onto MALDI plates for analysis (Svec, 2006). Overall, 
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this technique is able to provide reproducible and high analyte recoveries for 
concentrating and purifying femtomole levels of peptides (Svec, 2006).  
 
2.2.6. Applications of μSPE 
 
The μSPE tips are commonly used as a desalting and concentrating step for biofluids or 
enzyme-digested samples before mass spectrometry analysis. Proteins and some 
peptides are often digested with proteolytic enzymes such as trypsin, Lys-C or Glu-C for 
peptide mass mapping. Chemicals and enzymes used in peptidomic reactions such as 
reduction, alkylation and digestion (including in-gel digestion), can dilute the analytes 
and also introduce unwanted salts into the mixture which causes signal suppression 
(Hillenkamp and Peter-Katalinic, 2007; Tiss et al., 2007; Soloviev et al., 2008). As the 
volume is limited in these samples, the utilization of μSPE in sample preparation before 
analysis with the mass spectrometer is necessary to remove contaminants and at the 
same time concentrate the analytes.  
 
Numerous studies have incorporated μSPE into their extraction protocol. Palmbald and 
Vogel have employed various μSPE tips for the desalting of BSA and BSA tryptic digest 
(Palmbald and Vogel, 2004). Omix C18 tips have been employed as a clean-up step for 
the analysis of soybean perxoidase that underwent carboxyamidation and trypsin 
digestion (Gray and Montgomery, 2006). Omix C18 tips have also been used to clean-up 
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and concentrate tryptic-digested recombinant adenomatous polyposis coli protein 
(Findeisen et al., 2008). Similarly, the ZipTip and MALDI-TOF MS have been used to 
produce highly reproducible protein profiles from diluted human plasma and serum 
(Nelsestuen et al., 2005). An average variation of 10%, for both intra- and inter-run 
assay has been reported in various μSPE coated magnetic beads for spiked serum 
samples (Tiss et al., 2007). 
The extensive choices of sorbent beds, high extraction reproducibility, ease of operation 
and automation have transformed µSPE into a versatile sample preparation technique for 
peptidomics analysis. 
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2.3.  Mass Spectrometry 
2.3.1. Background and history of mass spectrometry  
 
Mass spectrometry (MS) measures the molecular mass of an ion (Sem, 2007). The first 
mass spectrometer can be dated back to Sir J. J. Thompson in 1912, with the first atomic 
weight measurement of chlorine, bromine and krypton in 1919 by Thomson’s student 
Francis William Aston (Davis and Falconer, 1997). By virtue of its sensitivity and speed, 
mass spectrometry has played a key role in a wide range of scientific and analytical 
applications (Glish and Vachet, 2003; Sem, 2007) 
The development of ‘soft’ ionization techniques such as the electrospray ionization (ESI) 
and the matrix-assisted laser desorption/ionization (MALDI) have enabled the use of 
mass spectrometry in the study of biomolecules (e.g. peptides, proteins etc). Compared 
to traditional methods such as Edman sequencing and gel electrophoresis, mass 
spectrometry is superior with higher sensitivity, speed and accuracy. Together with 
recent advances in the design of mass analyzers, ion optics and the coupling of 
chromatographic techniques to the mass spectrometer, mass spectrometry has become 
the preferred analytical method for peptidomics studies due to its extended capabilities.   
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2.3.2. The mass spectrometer  
 
A mass spectrometer consists of five basic parts: the vacuum system; a sample 
introduction device; the ionization source; a mass analyzer; and an ion detector as shown 
in Figure 2-3 below. 
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Figure 2-3: Schematic representation of the five basic parts of a mass spectrometer: a 
vacuum system, a sample introduction device, an ion source, a mass analyzer, and an ion 
detector.  
 
2.3.3. The Ion source  
 
The primary function of the ion source is to convert the analytes of interest into gas 
phase ions which enable them to be analyzed in the vacuum of the mass spectrometer 
(Glish and Vachet, 2003). The introduction of ‘soft’ ionization techniques such as ESI 
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and MALDI made mass spectrometry accessible for peptides and proteins (Boonen et al., 
2008; Soloviev et al., 2008).  
 
2.3.3.1.  Electrospray ionization (ESI) 
 
Electrospray ionization was developed by John Fenn and co-workers in the 1980s (Fenn 
et al., 1989), where ions were created by applying a strong electric field under 
atmospheric pressure to a liquid which is passed through a narrow-bore capillary needle 
at low flux (Hoffmann et al., 1996). The transfer of ions from solution to the gas phase 
is termed the desolvation process (Kebarle and Tang, 1993).  
 
As a potential difference is placed between the capillary tip and the counter-electrode 
(mass spectrometer), this causes excessive charges to accumulate near the end of the 
capillary and the emerging liquid which is attracted to the counter-electrode to form a 
dynamic cone of liquid referred to as a ‘Taylor cone’ at the exit of the ESI capillary 
(Cole, 2000). The additional flow of nebulizer gas (e.g. nitrogen) in an annular sheath 
surrounding the nebulizer needle is used to assist in droplet formation (Chapman, 1996) 
(refer to Figure 2-4). This fine mist of highly charged droplets that emerge from the apex 
of the Taylor cone is further desolvated with a stream of heated drying gas (usually 
nitrogen). This causes the charged droplets to evaporate and decrease in size until they 
are unstable and explode (Coulomb explosions). This process will continue until the 
formation of desolvated ions is obtained (Cole, 2000) (refer to Figure 2-5). Currently, 
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there are two major competing theories about the production of lone ions, the ‘charged 
residue model’ (CRM) and the ‘ion evaporation model’ (IEM).  
In the ‘charged residue model’, the charged droplet undergoes Coulomb explosions to 
produced smaller droplets until only a single molecule of analyte is present in them. As 
the smaller droplet evaporates completely, the charges on the droplet are transferred to 
the molecule (Dole et al., 1968). This model is preferred in the process of gas phase ion 
formation for high molecular weight molecules (Winger et al., 1993). 
In the ‘ion evaporation model’, the droplet, like in ‘CRM’, undergoes Coulomb 
explosions to form smaller droplets. However, when the droplets shrink to radii of less 
than 10 nm, ion emission from the droplets and into the gas phase will occur (Iribarne 
and Thomson, 1976). This model is well supported in relation to small (in)organic ions 
and does not apply for very large ions such as proteins (Kebarle and Verkerk, 2009). 
+
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Figure 2-4: Schematic of an electrospray ion source. Solvent flow and drying gas are 
indicated by red arrows (Adapted from Agilent, 2003). 
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B 
 
Figure 2-5: Diagram showing charged droplet exiting from tip of nebulizer needle and 
undergoing coulomb explosions to form smaller offspring droplets. A: The droplet size 
produced by a normal ESI and a nanoESI needle. B: ESI spectrum showing multiply 
charged of an intact protein (Adapted from Agilent, 2003). 
 
A particular feature of peptide ESI spectra is that the molecular ions recorded are 
multiply charged, (M+nH)
n+, in both positive and/or negative-ion mode, and cover  a 
range of charge states (refer to Figure 2-5B) (Krutchinsky et al., 1998a; Veenstra et al., 
1998; Watt et al., 2007). A mass spectrometer separates ions according to their mass-to-
charge (m/z) ratio, rather than their molecular mass.  Thus, for peptides with multiple 
charges, a ‘low-mass’ analyzer such as an ion trap can be used (Chapman, 1996). 
The ESI process can be disturbed by the presence of low concentrations of salts, buffers 
and detergents, which can form adducts with the analyte ions or suppress ion formation 
(Chapman, 1996; Cole, 2000). Therefore, a high performance liquid chromatography 
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(HPLC) is usually coupled to the ESI ion source, where a first dimension 
chromatography can help ‘clean-up’ the analytes. 
 
2.3.3.2.  Matrix-assisted laser desorption/ionization  
 
The other ‘soft’ ionization technique is the matrix-assisted laser desorption/ionization or 
MALDI. This technique was developed by two separate groups, Koichi Tanaka and co-
workers  (Tanaka et al., 1987), and Michael Karas and Franz Hillenkamp (Karas and 
Hillenkamp, 1988). MALDI is extensively used in peptidomics studies as it allows the 
sensitive detection of large, singly charged non-volatile and heat labile molecules by 
mass spectrometry (Hillenkamp and Peter-Katalinic, 2007; Garaguso and Borlak, 2008; 
Tammen et al., 2008).  
In MALDI, the analyte is first co-crystallized with a large molar excess of matrix 
compound (analyte to matrix ratio of about 10
-6:10
-2) such as 4-hydroxy-α-
cyanocinnamic acid (CHCA), sinapinic acid (SA) or 2,5-dihydroxybenzoic acid (DHB), 
which are usually UV-absorbing weak organic acids. A pulsed laser (usually a nitrogen 
laser of 337 nm) is then used to irradiate and sublimate the crystallized mixture, which 
in the process carries the analyte into the gas phase (Hillenkamp and Peter-Katalinic, 
2007). The key role of the matrix is to strongly absorb the laser energy and softly ‘lift’ 
the analyte species into the gas phase without destroying or fragmenting them. The other 
important role of the matrix is to act as a proton donor and acceptor to the analyte. 
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In MALDI, singly protonated ion species [M+H]
+ for peptides with molecular weight of 
500 – 5,000 are usually generated, unlike in ESI where multiply charged ion species are 
observed. For MALDI analysis of intact proteins with relative molecular weight of more 
than 8,000, singly-protonated [M+H]
+ and/or multiply-protonated [M+nH]
n+ ion species 
are observed (Sem, 2007). MALDI is usually coupled with a time-of-flight (TOF) mass 
spectrometer due to its ability to detect large ions (> 10,000 m/z) and  analyze pulses of 
ions (several nanoseconds wide) generated from the laser ablation, whereas trapping 
devices such as ion traps and Fourier transform ion cyclotron resonance-mass 
spectrometers (FTICR-MS) require ions to be in quasi-continuous mode (Hillenkamp 
and Peter-Katalinic, 2007). 
 
2.3.4. The mass analyzer  
 
The function of the mass analyzer is to separate ions (produced from the ion source) 
according to their mass-to-charge (m/z) ratio (Chapman, 1996). However, the real mass 
can only be calculated if the charge states of the peptides are determined (Soloviev et al., 
2008). Two mass analyzers described in this section are the ion trap mass spectrometer 
(IT MS) and the time-of-flight mass spectrometer (TOF MS). 
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2.3.4.1.  Ion trap mass spectrometer (IT MS) 
 
The quadrupole ion trap mass spectrometer (referred as ion trap MS ) functions as both 
ion storage, where gaseous ions are confined for a period of time, and as a mass analyzer 
of considerable mass range and mass resolution (March, 1997). The ion trap is made up 
of a rotationally symmetrical ring electrode of hyperbolic shape and two spherical end-
caps electrodes of the same cross-section (refer to Figure 2-6) (Hoffmann et al., 1996; 
Wong and Cooks, 1997). The ion trap can be imagined as a compressed ‘three 
dimensional quadrupole’ where ions are trapped, stabilized and ejected from the trap by 
electrical field and radio frequency (RF) (Hoffmann et al., 1996).  
The ability to trap ions allows this instrument to perform tandem mass spectrometry 
(MS
n). In MS
n function, the ions of interest are isolated from a mixture of ions and 
undergo collision-induced dissociation (CID), usually with helium buffer gas. The 
product ions, which are fragment ions derived from precursor ions, are analyzed. This 
process can be repeated several times with the isolation, fragmentation and analysis of 
the product ions (March, 1997; Wong and Cooks, 1997). The advantage of performing 
MS
n is the ability to reduce other matrix components or instrumental background 
(chemical noise), thus improving signal-to-noise (S/N) ratio. Complex structural 
elucidation and isomer distinction can also be achieved using the MS
n function (Wong 
and Cooks, 1997). 
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A significant weakness of IT MS is the poor dynamic range due to space charging 
effects, which is defined as changes in ion motion resulting from the interaction of ions 
in the trap, and its quantitative precision (Wong and Cooks, 1997). 
 
Figure  2-6:  The ion trap consists of three electrodes with hyperbolic surfaces - the 
central ring electrode, and two adjacent end-cap electrodes. (Adapted from Wong and 
Cooks, 1997) 
The coupling of liquid chromatography (LC) with an ESI ion source and the ion trap 
mass analyzer (LC-ESI-IT MS) is a powerful technique for the analysis of peptides and 
proteins. This method has also provided a more sensitive analysis technique for 
peptidomics and proteomics compared to traditional techniques such as gel 
electrophoresis.  More details on liquid chromatography are described in Section 2.3.5. 
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In Figure 2-7, the analyte of interest is eluted from the LC and is forced through the 
nebulizer needle where it is ionized, as described in Section 2.3.3.1, and transferred into 
the mass analyzer via the glass capillary. The functions of the two skimmers lenses, 
octopole and the lenses are to remove any contaminants and neutral species, and also to 
re-focus the ions entering into ion trap. 
 
 
Figure 2-7: Schematic of a LC-ESI-IT MS. (Adapted from Agilent, 2003)  
 
2.3.4.2.  Time-of-flight mass spectrometer (TOF MS) 
 
The time-of-flight mass spectrometer (TOF-MS), shown in Figure 2-8, is usually 
coupled with a MALDI source. The use of a pulsed-ion detector and high vacuum 
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‘flight-tube’ to separate the ions according to mass-to-charge ratio is ideal for the 
MALDI source, as the MALDI laser generates pulses of ions of several nanoseconds 
wide (Hillenkamp and Peter-Katalinic, 2007). In TOF analysis, ion m/z is determined by 
the ion drift time in high vacuum with all ion species of different masses having the 
same kinetic energy. Low molecular weight ions travels at a greater velocity through the 
TOF and reaches the detector first compared to larger ions. Therefore, different species 
of ions will reach the detector at different times due to their respective velocities (Brown 
and Lennon, 1995). 
Two different options are available for determining the distance the ions will travel in 
the ‘flight-tube’. In linear mode, the ions generated by the laser are extracted into the 
‘flight-tube’ (or free drift region) and travel towards the first detector (refer to Figure 2-8 
(blue arrow)). In reflectron mode, the reflector acts as an ion mirror. Thus ions from the 
first drift-free region are reflected by the ion mirror and travel along the second drift-free 
region, and into the second detector (refer to Figure 2-8 (red arrows)). This not only 
enlarges the flight tube, it also corrects for minor kinetic energy differences among ions 
of the same m/z value, thus improving mass resolution (>10,000 FWHM) and mass 
accuracy (~10 ppm) (Hillenkamp and Peter-Katalinic, 2007).  
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Figure  2-8:  Schematic of an axial MALDI-TOF MS with both linear (blue) and 
reflectron mode (red). Refer to texts for more detailed description. 
 
The sensitivity and mass range of MALDI-TOF MS are unsurpassed, however it is 
limited by mass measurement accuracy and resolution (Takach et al., 1997). The 
introduction of delayed extraction (DE) (Wiley and McLaren, 1955) in MALDI-TOF 
MS (Vestal et al., 1995; Whittal and Li, 1995) together with reflectron technology (as 
described above), has led to significant improvements in mass accuracy and resolution 
(Takach et al., 1997). In DE mode, the sample plate and ion extraction grid are at similar 
potentials during laser irradiation. A potential gradient is then applied to the plate and 
the grid after a time delay, where the delay allows transient ions to decompose, and the 
analytes are then projected into the ‘flight-tube’ (Haff et al., 1998).  
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As the extraction of ions are delayed until the flight-density plume (formed by ablated 
matrix and non-ionized sample) has expanded, this minimizes the collisional energy loss 
and also reduces the ion energy variation during the desorption/ionization process. Thus, 
ions produced by DE exhibit a narrower initial velocity distribution leading to better 
mass accuracy (Haff et al., 1998). 
 
2.3.4.3.  Orthogonal-time-of-flight mass spectrometer (O-TOF MS) 
 
The MALDI-O-TOF system employs an orthogonal time-of-flight (O-TOF) 
configuration (refer to Figure 2-9), compared to the usual axial TOF MS (refer to   
Figure 2-8). Similar to the axial MALDI source, a plume of ions are formed when the 
matrix is irradiated. The ions then enter the ion transfer optics which re-focuses and 
steers the ions into the TOF section.  A voltage pulse (ion modulator) is applied where 
the ions are deflected sideways such that the ion beam path is deflected perpendicular to 
the original direction of motion and into the field-free region (‘liner’ shield) of the TOF. 
Finally the ions are reflected by the dual-stage reflector and into the microchannel plates 
(MCP) detector (Loboda et al., 2003; Hillenkamp and Peter-Katalinic, 2007). Mass 
accuracy is improved by this perpendicular motion as it eliminates the high initial axial 
velocity distribution of the plume from the arrival times of the ions (Guilhaus et al., 
2000).  
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In conventional MALDI-TOF systems, the MALDI source is coupled with a TOF mass 
spectrometer, whereas in O-TOF instruments, the MALDI source and the transfer optics 
are decoupled from the TOF analyzer. This minimizes any discrepancies associated with 
the sample target and/or the ionization of the sample that can be carried into the detector 
thus affecting mass accuracy, resolution and sensitivity (Chernushevich et al., 2001; 
Loboda et al., 2003). The use of the dual-stage reflector also reduces peak broadening 
and higher peak resolution is obtained as compared to a single-stage reflector (Loboda et 
al., 2003).   
  Ion transfer 
optics 
 
Figure  2-9:  MALDI-O-TOF MS (prOTOF 2000) instrument configuration (Adapted 
from PerkinElmer) 
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In Figure 2-9, ‘collisional cooling’ (e.g. nitrogen gas) is applied in the MALDI ion 
source to reduce degradation and fragmentation of molecular ions (in-source decay) 
generated by laser irradiation. The cooling flow also helps in the re-focusing of the ions 
leaving the source into the ion transfer optics (Loboda et al., 2003). 
The ion transfer optics in the O-TOF instrument, which consists of the cone, the 
quadrupole, the rings, orifices and mesh, are operated at a pressure of around 8 mTorr. 
These optics provide both radial and axial collisional damping of ion motion 
(Chernushevich et al., 2001). The ions are also thermalized in collisions with neutral gas 
(e,g, nitrogen gas), similar to the ‘collisional cooling’ in the source. This reduces both 
the energy spread and the beam diameter, thus improving resolution (>10,000 FWHM) 
and accuracy (<10 ppm) (Chernushevich et al., 2001; Loboda et al., 2003; Hillenkamp 
and Peter-Katalinic, 2007). 
In the ion transfer optics, pulsed ions are converted into a quasi-continuous ion source 
where ions are continuously transferred into the pulser region of the TOF. The pusher 
(ion modulator) then injects them into the TOF section (reflectron) and into the MCP 
detectors. This design minimizes problems experienced in conventional MALDI-TOF 
systems such as complicated calibration procedures, and the associated requirement to 
optimize delayed extraction parameters and detector saturations (Krutchinsky et al., 
1998b; Chernushevich et al., 2001). This design also enables the coupling of a MALDI 
source to instruments such as an ion trap MS or a FTICR MS. 
However, there are some limitations to the O-TOF instrument. Firstly, ions drifting from 
the source to the pusher (ion modulator) will experience some TOF separation, therefore 
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it is critical that the pulser timing relative to the laser pulse be adjusted carefully 
(Hillenkamp and Peter-Katalinic, 2007). Secondly, ions pulsed out of the pusher must 
travel along the flight tube and into the detector to be detected as a signal. Any ions that 
are not in the pusher region at the time of pulsing will be lost (Guilhaus et al., 2000; 
Chernushevich et al., 2001). 
 
2.4.  High performance liquid chromatography (HPLC) 
 
High performance liquid chromatography (HPLC or LC) is often the method of choice 
for the analysis of biological samples, as it is able to handle very small amounts of 
material (Pramanik et al., 2002). Reversed phase liquid chromatography (RPLC) has 
become a major tool for peptide separations, where compounds are eluted from a 
reversed-phases (RP) column (stationary phase) by passing solvents (mobile phase) of 
increasing solvent strength (Mitulovic and Mechtler, 2006; Liu et al., 2007b). 
The mobile phases used in RPLC usually comprises of a combination of organic 
solvents (such as methanol or acetonitrile) and water with a low concentration of buffers 
(such as trifluoroacetic acid, formic acid or acetic acid) (Mann et al., 2001). As the 
solvent strength of the mobile phase is increased gradually by increasing the volume 
fraction of the organic solvent, the peptide mixture on a RP column will elute in order of 
increasing hydrophobicity (Jandera et al., 2004).  
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A wide variety of HPLC columns are available that differ in the type of stationary phase, 
pore size, column length and particle size. As mentioned, RP chromatography is widely 
use in peptidomics studies, where separation is based on the interaction of the 
hydrophobic peptides between the hydrophobic stationary phase and the polar 
hydrophilic mobile phase (Mitulovic and Mechtler, 2006). Other HPLC stationary 
phases such as normal and ion exchange phases are available. Their column chemistries 
are as described in Section 2.2.3. 
Due to the demand for greater sensitivity in peptidomics and proteomics analysis, 
capillary LC and smaller diameter columns have been developed (Mitulovic and 
Mechtler, 2006). Capillary LC employs flow rate of 1-20 μL/min with column ID of  
75-500 μm, which not only reduces solvent usage, but also improves the speed and 
sensitivity of the separation (Jandera et al., 2004; Liu et al., 2007b). The coupling of 
capillary LC to the ESI MS is ideally suited as the low volumes of the mobile phase 
introduced into the ion source are easily nebulized, to the stage of allowing the use of 
non-volatile mobile phase additives (Jandera et al., 2004). 
 
2.5.  Application of mass spectrometry in peptidomics 
 
Mass spectrometry has played an important role in the field of peptidomics as the high 
mass accuracy of these instruments is essential in the structural elucidation of proteins 
through peptide mass fingerprinting (PMF), where the larger protein is broken down into 
smaller peptides.  
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The introduction of mass spectrometry has revolutionized protein identification by 
reducing the analysis process from several hours to a few minutes and increasing 
sensitivity by several orders of magnitude (Soloviev and Finch, 2005; Soloviev et al., 
2008). Mass spectrometry has also revolutionized the detection of small native peptides 
which are essential in pathophysiological studies of diseases (Totsune et al., 1996; 
Petricoin III et al., 2002; Kim et al., 2003; Liu et al., 2007a; Tammen et al., 2008) and 
biomarker discovery (Zhu et al., 2003; Polito III et al., 2006; Zimmerli et al., 2008; 
Balog et al., 2009; Muhlen et al., 2009). An excellent review on the quantification of 
bioactive peptides using the multiple MS platforms, such as MALDI-TOF MS and ESI-
LC MS, has been written by Tamvakopoulos (Tamvakopoulos, 2007). 
Both the LC-ESI-IT MS and the MALDI-O-TOF MS are able to provide complementary 
data for peptidomics analysis (Bakhtiar and Nelson, 2001). In LC-ESI-IT MS, the HPLC 
is able to provide either a one- or two-dimensional separation of the complex sample 
mixture (e.g. urine), where salts, buffers and undesirable matrix components, which 
causes ion suppression, are removed (Pramanik et al., 2002). The peptide of interest is 
also concentrated on the LC column before being eluted from the column, ionized by the 
ESI source and introduced into the ion trap mass analyzer. Multiply-charged ions species 
are usually observed in the ESI-IT mass analyzer, whereas singly-charged ion species 
with high isotopic resolution are observed in MALDI-O-TOF MS. By using both 
instruments in a complementary fashion, the molecular mass of the unknown intact 
peptide can easily and accurately be determined, and structural elucidation can be 
carried out by using the MS
n functionality of the ESI-IT MS. 
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Several authors have used capillary LC-ESI-IT MS to separate and identify tryptic 
digested peptides (Davis and Lee, 1992; Premstaller et al., 2001; Walcher et al., 2002). 
Song  et al. (2005) have isolated and quantified γ-aminobutyric acid (GABA) from 
human cerebrospinal fluid and plasma using capillary LC MS. In contrast, Wu and 
colleagues employed targeted proteomics using LC-ESI-IT MS for profiling and 
quantitation of low level proteins, such as human growth hormone, in human plasma 
(Wu et al., 2002). 
 
The MALDI-TOF MS has generally been used as a qualitative tool for protein/peptide 
profiling (Albrethsen, 2007; Duncan et al., 2008). Recent improvements in 
instrumentation and automation have seen this analyzer being used for quantitative 
purposes such as the quantification of cyclotide kalata B1 in plasma (Colgrave et al., 
2005) and digested peptides from serum (Bublitz et al., 2006). An interesting article 
focusing on the characterization (both qualitative and quantitative) of small molecule 
analysis has been reviewed by Cohen and Gusev (2002). 
Several studies have also encompassed both techniques (LC MS and MALDI-TOF MS) 
in their analysis (Satterfield and Welch, 2005; Krokhin et al., 2006). Benkali and co-
workers have utilized nano-LC MS coupled off-line to MALDI-TOF/TOF for urinary 
biomarkers identification (Benkali et al., 2008), while Bansal and colleagues have 
quantified urinary hepcidin using both LC MS and MALDI-TOF MS (Bansal et al., 
2009a; Bansal et al., 2009b). 
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2.6.  Purpose of this study 
 
As mentioned in Chapter 1, extensive research is still required to understand the links 
between hepcidin and iron-related disorders. Thus, the quantification of hepcidin in 
biofluids will be of great importance. In the short period of time since hepcidin was first 
identified by Kraus et al. (2000) and Park et al. (2001), numerous groups have tried to 
isolate and quantify bioactive hepcidin-25 using mass spectrometry. The majority of 
publications detailing hepcidin quantification have only appeared within the last two 
years, where several authors have utilized external calibration standards (Tomosugi et al., 
2006; Altamura et al., 2009), stable isotope labeled hepcidin (Kobold et al., 2008; Ward 
et al., 2008b; Bansal et al., 2009a; Bansal et al., 2009b; Anderson et al., 2010) or 
truncated hepcidin analogue (Kemna et al., 2005b; Swinkels et al., 2008) as internal 
standards to quantify hepcidin. Only semi-quantitative hepcidin concentration can be 
achieved from the use of external standards whereas the use of labeled hepcidin internal 
standard is costly and is difficult to synthesize.  
Recent advancements using label-free quantification of peptides have achieved results 
comparable with data obtained from using stable isotopes (Bizzarri et al., 2008; 
Rubakhin and Sweedler, 2008; Wang et al., 2008; Winefield et al., 2009). Thus, the 
successful development of this label-free assay for the quantification of endogenous 
hepcidin will not only provide an accurate assay, but also a cost-effective one. 
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The main focus of this project is to develop a mass spectrometry-based diagnostic assay 
for the targeted quantification analysis of hepcidin in urine samples as it is a non-
invasive technique. This assay should be high-throughput and relatively easy to carry out 
with just a simple clean-up step of crude urine before analysis.  
Other stability issues (e.g. freeze-thaw, incubation duration) and the level of hepcidin in 
different sections of urine were investigated to obtain information on the properties of 
hepcidin during the whole sample handling process. 
    Chapter 3 
 
 
 
3.  Chapter 3 - 
Materials and Methods 
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3.1.  Reagents 
Compounds 
Peptide standards:  Synthetic hepcidin standard 
(DTHFPICIFCCGCCHRSKCGMCCKT, 2789.4 g/mol) was 
obtained from Peptide Institute Inc, Osaka, Japan.  
Adrenocorticotropic hormone (ACTH) fragment 18-39 
(RPVKVYPNGAEDESAEAFPLEF, 2464.2 g/mol) was obtained 
from Sigma-Aldrich, St. Louis, MO, USA. 
 
MALDI matrices:  Powdered  α-Cyano-4-hydroxycinnamic acid (CHCA) was 
obtained from Sigma-Aldrich, St. Louis, MO, USA. CHCA was 
re-crystallized with HPLC/ Spectrophotometric grade ethanol 
(Sigma-Aldrich, St. Louis, MO, USA) and stored in a desiccator. 
Sinapinic acid (SA) or 3,5-Dimethoxy-4-hydroxycinnamic acid 
was obtained from Fluka, Steinheim, Germany.  
 Both matrices (CHCA or SA) were made up to 10 mg/mL in 50% ACN/ H2O/ 0.1% 
TFA (v/v/v). The matrix solution was sonicated for 10 minutes and centrifuged at   
2000 rpm for 5 minutes. The supernatant was collected and used as the MALDI matrix 
solution. 
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Solvents/chemicals 
Methanol (MeOH) and acetonitrile (ACN) of HPLC grade were obtained from Burdick 
and Jackson Inc, Muskegon, MI, USA. Trifluoroacetic acid (TFA) was obtained from 
Sigma-Aldrich, St. Louis, MO, USA. Deionized (DI) water (resistivity 18 MΩ.cm) was 
obtained from an in-lab Milli-Q system. Analytical grade pyridine was obtained from 
UNIVAR, NSW, Australia and formic acid was obtained from Fluka, Steinheim, 
Germany. Creatine and creatinine standards were obtained from Fluka, Steinheim, 
Germany. 
 
3.2.  Sample collection 
 
Three sections (start-, mid- and end-stream) of the same urine sample were collected 
according to the following protocol: 
Start stream:   The first 5 seconds of urine is collected in a 50 mL sterile container. This 
is followed by 5 seconds of urine that is not collected.  
Mid stream:   The next 5 seconds of the urine is collected in another sterile container, 
followed by another 5 seconds of urine not collected. 
End stream:   The rest of the urine is collected in a sterile container.   
All individual urine sections were vortexed and immediately divided into 1 mL aliquots 
and stored at -80
oC. 
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Control urine samples were acquired from personnel in the laboratory. Mid-stream urine 
aliquots that had undergone only one freeze-thaw cycle were used in all method 
development/ analysis stages unless otherwise stated (Vanhoutte et al., 2007; Altamura 
et al., 2009; Bansal et al., 2009b). 
Mid-stream urine samples from hemochromatosis patients and patients with anemia of 
chronic disease (ACD) were collected in Fremantle Hospital according to the sample 
collection protocol in this section. 
 
3.3.  Method development of urinary hepcidin extraction using solid 
phase extraction (SPE) 
3.3.1. Selection of SPE phases 
 
A variety of sorbent phases, such as ion exchange and reversed phases were investigated. 
The cation exchange (CX) sorbent cartridges investigated in this experiment were the 
GracePure Cation-X 100 mg (Deerfield, IL, USA) and the Varian Omix strong cation 
exchange (SCX) tip (Lake Forest, CA, USA). The anion exchange (AX) sorbent 
cartridge investigated was the GracePure Anion-X 100 mg (Deerfield, IL, USA). 
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Reversed phased (RP) sorbent cartridges investigated were Phenomenex Strata-X 30 mg 
(Torrance, CA, USA), Varian Abs Elut Nexus 60 mg and Varian Bond Elut Plexa 60 mg 
(Lake Forest, CA, USA).  
The SPE cartridges evaluated for the extraction of urinary hepcidin and the conditions 
used are shown in Table 3-1. 
 
The extraction procedures, in this case using the GracePure Cation-X SPE, are stated 
below with references to the solvent compositions and volumes listed in Table 3-1. 
The GracePure Cation-X SPE was mounted onto a vacuum manifold (Grace, Deerfield, 
IL, USA) and was conditioned by passing 500 μL of MeOH followed by 500 μL of H2O 
through the cartridge. A milliliter of urine spiked with 100 nM of hepcidin was 
pretreated with 0.1% TFA and introduced onto the SPE bed. The sorbent bed was 
washed with 500 μL of H2O. The analyte was eluted with 500 μL of 80% ACN/ H2O/ 
0.1% TFA (v/v/v) (extract 1), followed by another 500 μL of 80% ACN/ H2O/ 5% 
NH4OH (v/v/v) (extract 2). The analysis was performed in triplicate. 
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Table 3-1: Extraction protocol of urinary hepcidin using different sorbent phases and brands of SPE. 
Sorbent Phase  Cation Exchange  Anion 
Exchange  Reversed Phase 
Brand  GracePure 
Cation-X  Omix SCX  GracePure 
Anion-X  Strata-X  Nexus  Plexa  Plexa 
Condition  500 μL MeOH  100 μL 50% 
MeOH/H2O  500 μL MeOH 
500 μL H2O 
1 mL MeOH  1 mL MeOH  1 mL MeOH  1 mL MeOH 
Equilibration  500 μL H2O  -  1 mL H2O  1 mL H2O  1 mL H2O  1 mL H2O 
Sample  1mL urine in 
0.1%TFA/H2O* 
100 μL urine 
in 0.1% 
TFA/H2O* 
1 mL urine in 
1% 
NH4OH/H2O
* 
2 mL urine in 
0.1%TFA/H2O* 
2 mL urine in 
0.1%TFA/H2O* 
1 mL urine in 
0.1%TFA/H2O* 
1 mL urine in 1% 
NH4OH/H2O* 
Wash  500 μL H2O 100  μL H2O 500  μL H2O  1 mL 5% 
MeOH/H2O*  1 mL H2O  500 μL 5% 
MeOH/H2O* 
500 μL 5% 
MeOH/H2O* 
Elution 1 
(extract 1) 
500 μL 80% 
ACN/H2O/ 0.1% 
TFA* 
50 μL 30% 
MeOH/H2O/ 
5% NH4OH* 
500 μL 80% 
ACN/H2O/ 
0.1% TFA* 
1 mL 100% 
ACN/0.1% 
TFA* 
1 mL 100% 
ACN/0.1% TFA* 
500 μL 100% 
ACN 
500 μL 100% 
ACN 
Elution 2 
(extract 2) 
500 μL 80% 
ACN/H2O/ 5% 
NH4OH* 
-  -  - - - - 
* All solvents are represented in v/v or v/v/v.
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3.3.1.1.  Preliminary analysis of hepcidin using the MALDI-O-TOF 
MS (prOTOF 2000) 
 
All hepcidin analysis in the method development stages were analyzed using the 
MALDI-O-TOF MS, prOTOF 2000 from PerkinElmer, herein referred to as MALDI-
TOF MS, unless otherwise stated. 
Each SPE extract was mixed with an equal volume of 10 mg/mL CHCA matrix solution. 
Five replicates of 1μL mixture were spotted onto a 384-well stainless steel MALDI plate 
and analyzed using MALDI-TOF MS.   The instrumental parameters are listed in   
Table 3-2 and Figure 3-1. Before the start of any analysis, the instrument is externally 
calibrated with ProXPRESSION PepMix 1 (PerkinElmer, Shelton, CT, USA) for 
improved mass accuracy.  
The monoisotopic peak areas of Hepc-25 (2788 to 2795 m/z) were used to determine the 
suitability of each variable, such as the type of SPE phase, solvent composition, matrix, 
for hepcidin-specific extraction.  
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Table 3-2: MALDI-O-TOF MS (prOTOF2000) acquisition and instrumental parameters. 
Acquisition method parameters 
Laser shots  100  Declustering  30 V 
Laser rate  100 Hz  Laser strength  70% 
Mass range  1000 – 3500 Da  Acquisition pattern  9 point circle 
Cooling flow  190 mL/min  Spectra collected per 
spot  2 
Focusing flow  210 mL/min 
 
Instrument settings 
Acceleration 
voltage  -16 kV  Steer 1  0 
Cone  36.6  Steer 2  0 
Quad Offset  29.6  Push  1490 
Ring  28.6  Pull  -1490 
Orifice  27.6  Pull offset  50 
Mesh  30.8  Detector Bias  2300 
Optics 1  0  Mirror Plate  2200 
Optics 2  0  Mirror Grid  -1485 
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A 
 
B   
 
Figure 3-1: Schematic diagrams of the acquisition (panel A) and instrumental 
parameters (panel B) of the MALDI-TOF MS used in the analysis of urinary hepcidin.  
 
3.3.2. Selection of reversed phase micro-SPE (μSPE) 
 
To achieve a more cost effective extraction, traditional SPE extraction was scaled down 
to ‘SPE in a pipette tip’ or μSPE (Hasegawa et al., 2006). As reversed-phase SPE had 
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shown in previous experiment to be the most effective in hepcidin extraction, three 
reversed phase μSPE tips were investigated. They are the Varian Omix C4 (100 μL tips) 
and C18 (100 μL tips) (Lake Forest, CA, USA) and the Millipore C18 Ziptip (10 μL tips) 
(Bedford, MA, USA). 
 
Urine sample was spiked Hepc-25 stock solution standard (100 μM) to give a final 
concentration of 100 nM. The Omix C4 tip was mounted onto a micropipette and 
conditioned, equilibrated, loaded, washed and eluted respectively as follows: 
 
Condition:  An aliquot of 50 μL 50% ACN/ H2O (v/v) was passed through the 
tip and the eluant was discarded. This was repeated with another 
lot of 50 μL of 50% ACN/ H2O (v/v), with the eluant again 
discarded. 
Equilibration:  An aliquot of 50 μL 1% TFA/ H2O (v/v) was passed through the 
tip, with the eluant discarded. This step was repeated with another 
volume of 50 μL 1% TFA/ H2O (v/v). 
Sample loading:  Two aliquots of 50 μL of urine were introduced into the tip. A 
constant flow rate (~100 μL/min) was maintained during 
aspiration and elution to ensure maximum interaction of analyte 
with the sorbent bed. 
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Washes:  Two aliquots of 50 μL 0.1% TFA/ H2O (v/v) were passed through 
the tip, maintaining a constant flow rate (~100 μL/min). 
Elution:  The target analyte (hepcidin) was eluted from the tip with two 
aliquots of 50μL 100% ACN/ 0.1% TFA (v/v) into a 
microcentrifuge tube. 
Special precautions were taken to prevent the introduction of air through the sorbent by 
keeping the plunger of the pipettor depressed to the first stop between the transitioning 
of different reagents.  
The analysis was performed in triplicate and the extracts were analyzed as mentioned in 
Section 3.3.1.1.  
μSPE sorbents were trialed according to the conditions shown in Table 3-3.  
Table 3-3: Extraction protocol of urinary hepcidin using reversed phase μSPE. 
Sorbent 
Phase  Reversed Phase 
μSPE  Ziptip C18
a  Omix C18
b  Omix C4
b 
Condition  2x 5 μL 50% 
ACN/H2O*  2x 50 μL 50% ACN/H2O* 
Equilibration  2x 5 μL 1% 
TFA/H2O*  2x 50 μL 1% TFA/H2O* 
Sample  2x 5μL urine in 0.1% 
TFA/H2O* 
2x 50 μL urine in 0.1% 
TFA/H2O* 
Wash  2x 5 μL 0.1% 
TFA/H2O*  2x 50 μL 0.1% TFA/H2O* 
Elution  2x 5 μL 100% 
ACN/0.1%TFA* 
2x 50 μL 100% 
ACN/0.1%TFA* 
a The Ziptip used is commercially packed in 10 μL tips. 
bThe Omix tips used are commercially packed in 100 μL tips. 
* All solvents are represented in v/v or v/v/v and according to manufacturer protocol. 
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3.3.3. Optimization of hepcidin extraction using Omix C4 
3.3.3.1.  Selection of washing and eluting solvents 
 
The Omix C4 tip was conditioned and equilibrated as stated in Section 3.3.2. An aliquot 
of 50 μL of urine sample (spiked with Hepc-25 standard to give a final concentration of 
100 nM) was passed through the C4 tip and the eluant was discarded. This step was 
repeated with another aliquot of 50 μL of spiked urine sample. The tip was then serially 
eluted with 50 μL aliquots of solvent mixture containing different concentrations of 
organic and aqueous reagent, first eluting the target analyte with 50 μL of 10% MeOH/ 
H2O/ 0.1% FA (v/v/v) into a microcentrifuge tube, followed by a 50 μL of 20% MeOH/ 
H2O/ 0.1% FA (v/v/v) into another microcentrifuge tube. This serial elution was 
continued until 100% MeOH/ H2O/ 0.1% FA (v/v/v) is achieved. The eluants were 
analyzed using the MALDI-TOF MS method as described in Section 3.3.1.1.   
 
The retention and elution of Hepc-25 on the C4 tip was carried out with a series of 
different solvent systems as listed in Table 3-4. Each mixture comprised different ratios 
of aqueous (H2O) and organic (ACN or MeOH) solvent and buffers (e.g. TFA, FA and 
NH4OH). An incremental ratio of 10% organic solvent was used in this experiment to 
serially elute hepcidin from the tip.  
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Table 3-4: Different composition of solvent mixtures trialed for hepcidin extraction. 
Solvent composition 
0 to 100% MeOH/ H2O/ 0.1% FA 
0 to 100% MeOH/ H2O/ 0.1% TFA 
0 to 100% ACN/ H2O/ 0.1% FA 
0 to 100% ACN/ H2O/ 0.1% TFA 
100% H2O (unbuffered) 
0 to 100% MeOH/ H2O pH10 (adjusted with ammonium hydroxide) 
 
3.3.3.2.  Pre-treatment of urine samples 
 
Urine samples used in this experiment were spiked with 100 nM of Hepc-25 standard. 
The spiked urine was further buffered with either 0.1% TFA (v/v) or 1% NH4OH (v/v), 
or left unbuffered.  
The spiked samples were then extracted with Omix C4 μSPE using the following solvent 
system listed in Table 3-5 and analyzed as described in Section 3.3.1.1. 
 
3.3.3.3.  Sample breakthrough analysis 
 
Different loading volumes (50, 100 and 150 μL) of urine were introduced into the C4 tip 
to determine the breakthrough volume. 
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A volume of 50, 100 or 150 μL of unbuffered urine was introduced into the C4 tip. 
Urinary hepcidin was extracted according to the parameters listed in Table 3-6. The 
flow-through, ‘wash’ layer and the eluant were analyzed for the presence of hepcidin as 
mentioned in Section 3.3.1.1. 
 
Table 3-5: Extraction protocol of urinary hepcidin using Omix C4 tip in urine with and 
without pre-treatments. 
Steps  Solvent compositions and volume 
Condition  2x 50 μL 50% ACN/ H2O 
Equilibration  2x 50 μL 1% TFA/ H2O 
Sample  2x 50 μL buffered or unbuffered urine 
Wash  2x 50 μL 30% MeOH/ H2O pH10 
Elution  2x 50 μL 80% ACN/ H2O/ 0.1%TFA 
 
Table 3-6: Urinary hepcidin extraction parameters using Omix C4 μSPE. 
Steps  μSPE solvent compositions and volume
Condition  2x 50 μL 50% ACN/ H2O 
Equilibration  2x 50 μL 1% TFA/ H2O 
Sample  urine (without pre-treatment) 
Wash  2x 50 μL 30% MeOH/ H2O pH10 
Elution  2x 10 μL 80% ACN/ H2O/ 0.1%TFA 
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3.3.4. Optimized extraction method for urinary hepcidin  
 
The parameters listed in Table 3-7 describe the optimized method for the extraction of 
urinary hepcidin using Omix C4 μSPE, which was used as the common extraction 
protocol unless otherwise stated. 
 
Table 3-7: Optimized method for the extraction of urinary hepcidin using Omix C4 
μSPE. 
Steps  μSPE solvent compositions and volume
Condition  2x 50 μL 50% ACN/ H2O 
Equilibration  2x 50 μL 1% TFA/ H2O 
Sample  2x 50 μL urine (without pre-treatment) 
Wash  2x 50 μL 30% MeOH/ H2O pH10 
Elution  2x 10 μL 80% ACN/ H2O/ 0.1%TFA 
 
3.4.  Method Development of MALDI-TOF MS for hepcidin analysis 
 
In this section, Hepc-25 standard and ACTH (fragment 18-39) in DI water were used for 
the optimization of the MALDI-TOF MS for the hepcidin analysis method.  
Hepc-25 standard (200 nM) and ACTH (100 nM) in DI water were mixed in a ratio of 
1:1. The standard mixture was then combined with an equal volume of matrix solution to 
give a final concentration of 50 nM of hepcidin and 25 nM of ACTH. Aliquots of 0.8 μL 
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of the mixture were spotted (in triplicate) onto a 384-well MALDIchip (PerkinElmer) 
and analyzed as mentioned in Section 3.3.1.1. 
This was the standard protocol used for combining samples/standards with MALDI 
matrix, followed by spotting onto the MALDIchip, unless otherwise stated. 
 
3.4.1. Comparison between CHCA and SA matrix 
 
Both CHCA and SA matrix were used to investigate the differences in urinary profile 
between the two matrices. 
Unbuffered urine sample was extracted according to Table 3-7. A microliter of the 
eluant was mixed with 1 μL of the MALDI matrix solution. Five replicates of 1 μL of 
the combined mixture were spotted onto a 384-well stainless steel MALDI plate and 
analyzed with the MALDI-TOF MS method as described in Section 3.3.1.1. For 
sinapinic acid, a laser intensity of 85% was used instead, whereas 70% laser intensity 
was used for CHCA matrix. 
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3.4.2. CHCA matrix optimization 
3.4.2.1.  Matrix solvent  
 
The recrystallized CHCA matrix (10 mg) was dissolved in 1 mL of 50% ACN/ H2O/ 0.1% 
TFA (v/v/v), to give a concentration of 10 mg/mL of CHCA solution. The mixture was 
sonicated for 10 minutes and centrifuged at 2000 rpm for 5 minutes. The supernatant 
was used as the MALDI matrix solution. 
The CHCA solutions were prepared/spotted and analyzed according to Section 3.4 and 
Section 3.3.1.1 respectively. 
Several preparations of CHCA varying in aqueous-organic ratio and buffers, shown in 
Table 3-8, were prepared according to literature reports (Qiagen Mass Spec Focus Chip 
Handbook; Smirnov et al., 2004; Stapels et al., 2004; Zabet-Moghaddam et al., 2006; 
Fukuyama et al., 2009). 
Table 3-8: Different CHCA preparations used in literatures.    
Matrix solvent investigated  References 
50% ACN/ H2O/ 0.1% TFA (v/v/v)  Smirnov et al. (2004) 
Stapels et al. (2004) 
36% MeOH/ 56% ACN/ 8% H2O/ 0.1% 
TFA (v/v/v/v) 
Qiagen Mass spec  focus chip handbook, 
Valencia, CA 
100% MeOH/ 0.1% TFA (v/v)  Hewlett Packard (Agilent) 
0.05mmol (9.5 mg) CHCA in 2:1 ACN/ 
H2O/ 0.1% TFA + 0.05mmol Py in 2:1 
ACN/ H2O/ 0.1%TFA 
Zabet-Moghaddam et al. (2006) 
3AQ/ CHCA  Fuyuyama et al. (2009) 
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3.4.2.2.  Influence of pH modifiers in crystal formation of CHCA  
 
Two acids commonly used in MALDI-TOF mass spectrometry are TFA and FA (Cohen 
and Chait, 1996; Colgrave et al., 2005). To investigate the influence the acids have on 
matrix crystallization, different concentrations of acid were added to the CHCA matrix.  
CHCA (10 mg/mL) was dissolved in 36% MeOH/ 56% ACN/ 8% DI H2O (v/v/v) 
followed by the addition of 0.5% pyridine (v/v). The concentrations of TFA or FA added 
to the matrix solution were 0.1%, 0.5%, 1.0%, 2.0% and 3.0% (v/v). The CHCA solution 
with pH modifiers were sonicated and centrifuged at 2000 rpm for 10 and 5 minutes 
respectively. 
The respective CHCA matrix was combined with 25 nM of Hepc-25 and 50 nM of 
ACTH standards. The combined mixture was spotted in triplicate and analyzed 
according to Section 3.4 and Section 3.3.1.1 respectively. 
 
3.4.2.3.  Analyte-to-matrix ratio 
 
The influence of analyte-to-matrix ratio in relation to signal intensities was investigated. 
Hepc-25 and ACTH (fragment 18-39) standards were prepared according to Section 3.4. 
Analyte-to-matrix ratio of 1:1, 1:10, 1:100 were investigated, where in 10:1 ratio, 9 μL 
of CHCA solution was mixed with 1 μL of the standard mix solution. Triplicate spotting 
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of 0.8 μL of the combined mixture was analyzed using the 384-well MALDIchip plate 
according to the procedure listed in Section 3.3.1.1. 
 
3.4.3. MALDI plates, acquisition patterns and spotting techniques 
3.4.3.1.  Spotting techniques  
 
Two different brands of CHCA matrices were used in this experiment which was the in-
solution CHCA matrix obtained from Hewlett Packard (Wilmington, Delaware, USA) 
which contained 10 mg/mL of CHCA in MeOH solution. The other brand is the   
re-crystallized CHCA from Sigma-Aldrich (St. Louis, MO, USA) dissolved in 36% 
MeOH/ 56% ACN/ 8% H2O/ 0.1% TFA/ 0.5% pyridine (v/v/v/v/v) to give a 
concentration of 10 and 23 mg of CHCA/mL respectively.  
Four different spotting techniques were investigated where signal intensity and 
reproducibility are the main criteria for the quantification of Hepc-25.  
The various techniques investigated in this experiment were (refer to Figure 3-2 for 
illustration): 
1.  Dried droplet method – 1 μL of extract was mixed with 1 μL of CHCA matrix 
in a microcentrifuge tube. 1 μL of the combined mixture was spotted onto each 
well and allowed to air dry at room temperature for 30 mins. 
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2.  Vacuum drying method – This method is similar to the dried droplet method 
except that the spots were dried in a vacuum manifold at 60 kPa. 
3.  Overlay method – 0.5 μL of CHCA matrix was spotted onto the well and 
allowed to air dry (~5 mins). 1 μL of the analyte-matrix mixture (as prepared 
using the dried droplet method) was spotted on top of the pre-spotted well and 
allowed to dry at room temperature for 30 mins. 
4.  Sandwich method – 1 μL of the matrix was spotted onto the well followed by 1 
μL of the extract. Another 1 μL of matrix layer was then spotted onto the same 
well. Each layer was allowed to air dry before the application of the next layer. 
Matrix 
Analyte  Vacuum 
Dried Droplet 
method 
Vacuum Drying 
method 
Overlay 
method 
Sandwich 
method 
 
Figure 3-2: Illustration of the various spotting techniques employed for the optimization 
of the hepcidin assay. 
 
Urinary hepcidin was extracted according to Section 3.3.4. The analyte-matrix solution 
was prepared according to the various techniques described above. A total of 4 replicates 
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were spotted onto a 384-well stainless steel MALDI plate and analyzed as mentioned in 
Section 3.3.1.1. 
 
3.4.3.2.  Sample spot washing 
 
Urinary hepcidin was extracted according to Section 3.3.4. 0.8 μL aliquots of the extract 
was then spotted onto the 384-well MALDIchip and allowed to air day at room 
temperature for 30 mins. 
The spots were then washed once with 1 μL of cold H2O and allowed to incubate for 5 
seconds. The washing buffer (cold H2O) was then blown off using pressurized air and 
was allowed to air dry at room temperature for 30 mins. The spot is then analyzed 
according to Section 3.3.1.1. 
Two other washing buffers (cold H2O with 0.1% TFA and cold H2O buffered to pH 8.6 
with ammonium hydroxide) were investigated and compared with spots that did not 
undergo any washing. All respective washes were performed in triplicate. 
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3.4.3.3.  Selection of MALDI plates 
 
Three different MALDI plates were investigated in this analysis. They were the 96-well 
stainless steel MALDI plate, the 96-well MALDIchip plate, and the 384-well 
MALDIchip plate. 
Hepc-25 standard was diluted to concentrations of 16, 31, 63 and 130 nM with 50% 
ACN/H2O. The standard solutions were then mixed with CHCA matrix in 36% MeOH/ 
56% ACN/ 8% H2O/ 0.1% TFA/ 0.5% pyridine (v/v/v/v/v). The dried droplet technique 
was used as described in Section 3.4.3.1 with triplicate spotting of 0.8 μL of the mixture 
onto each plate. The plates were analyzed as mentioned in Section 3.3.1.1. 
 
3.4.3.4.  Acquisition pattern 
 
The same preparation protocol was carried out as listed in Section 3.4.3.2 with Hepc-25 
standards spotted onto the 384-well MALDIchip plate. 
The set of standards were acquired with the parameters outlined in Section 3.3.1.1. 
Another set of standards were acquired with the same parameters except a ‘Z-mode’ 
acquisition pattern (22 acquisition spots) was used instead of a ‘9 point circle’   
(10 acquisition spots).  
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3.4.3.5.  Spotting/pipetting technique 
 
Two pipetting methods, traditional and reverse pipetting, were investigated during the 
optimization of the spotting step and are described below:  
Traditional Pipetting (Forward pipetting) – The operating button of the pipette was 
depressed to the first stop. The tip on the pipette was lowered into the solution and the 
operating button slowly released. The liquid was dispensed by depressing the operating 
button to the second stop. 
Reverse Pipetting - The operating button of the pipette was depressed to the second 
stop. The tip on the pipette was lowered into the solution and the operating button 
slowly released. The liquid was dispensed by depressing the operating button to the first 
stop. 
 
Hepc-25 standard was diluted to concentrations of 16, 31, 63 and 130 nM with 50% 
ACN/H2O. An equal volume of ACTH (1μM) as internal standard was added to the 
Hepc-25 standard solutions. The standards mixtures were then mixed with equal 
volumes of CHCA matrix in 36% MeOH/ 56% ACN/ 8% H2O/ 0.1% TFA/ 0.5% 
pyridine (v/v/v/v/v). The ratio of Hepc-25 standard to ACTH internal standard to CHCA 
matrix were 1: 1: 2 respectively. All the above mentioned procedures were executed 
using the traditional pipetting technique. 
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An aliquot of 0.8 μL of the mixture was spotted (using reverse pipetting technique) onto 
384-well MALDIchip and analyzed as described in Section 3.3.1.1.  Five replicates were 
spotted for each concentration. 
 
3.4.4. Optimized MALDI matrix and spotting technique 
 
For the optimized MALDI method, 10 mg/mL of re-crystallized CHCA matrix was 
dissolved in 36% MeOH/ 56% ACN/ 8% DI H2O (v/v/v) followed by the addition of 0.5% 
pyridine (v/v). The mixture is then acidified with 1% TFA (v/v) followed by sonication 
and centrifugation at 2000 rpm for 10 and 5 minutes respectively. 
The dried droplet method with an analyte-to-matrix ratio of 1:1 (v/v) was employed.  
0.8 μL aliqouts of the mixture were reversed pipette onto a 384-well MALDIchip plate. 
 
3.5.  Instrumental optimization 
3.5.1. MALDI-O-TOF MS tuning 
 
The instrument optics were first optimized using ProXPRESSION PepMix 1 containing 
the following peptides with their final concentration in brackets, Angiotensin II (0.8 nM), 
Angiotensin I (1.2 nM), Neurotensin (0.8 nM), ACTH clip 1-17 (1.5 nM) and ACTH 
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clip 18-39 (1.25 nM). Several parameters such as detector bias, detector distribution, 
sensitivity, resolution and the alignment of the detectors were optimized.  
Further optimization of the instrument specific to Hepc-25 analysis was performed using 
1 nM of ACTH clip 18-39 and 6 nM of Hepc-25 standard mixtures prepared and spotted 
according to the instructions in Section 3.4.4.  
Parameters such as signal intensity, signal-to-noise ratio and peak resolution of Hepc-25 
standard (2788 to 2795 m/z) and internal standard ACTH (2465 to 2468 m/z) were 
monitored during the optimization process. A compromised setting between maximum 
sensitivity and resolution were chosen to achieve lower limits of detection with 
monoisotopic resolution. 
The optimized instrument parameters for hepcidin analysis are as listed in Table 3-9. 
The acquisition parameters used in the analysis of urinary hepcidin are shown in   
Figure 3-3A. Figure 3-3B shows the schematic diagram of the MALDI-TOF MS ion 
optics and the voltages applied for hepcidin analysis.  
Parameters highlighted in red (in Figure 3-3) represent the optimized settings that are 
different from the original setting illustrated in Figure 3-1. 
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Table 3-9: Optimized MALDI-O-TOF MS acquisition and instrumental parameters. 
Acquisition method parameters 
Laser shots  100  Declustering  35 V 
Laser rate  100 Hz  Laser strength  70% 
Mass range  700 – 5000 Da  Acquisition pattern  9 point circle 
Cooling flow  190 mL/min  Spectra collected per 
spot  2 
Focusing flow  212.1 mL/min 
 
Instrument settings 
Acceleration 
voltage  -16 kV  Steer 1  0 
Cone  39.0  Steer 2  0 
Quad Offset  33.4  Steer 2  0 
Ring  31.0  Push  1500 
Orifice  30.0  Pull  -1500 
Mesh  29.5  Pull offset  94 
Optics 1  0.1  Detector Bias  2406 
Optics 2  -0.7  Mirror plate  2202 
Steer 1  0  Mirror Grid  -1496 
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A 
 
 
 
B 
 
Figure 3-3: Schematic diagrams of the optimized acquisition (panel A) and 
instrumental parameters (panel B) of the MALDI-TOF MS used in the analysis of 
urinary hepcidin.  Parameters that are different from the original settings (refer to   
Table 3-1) are highlighted in red. 
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3.6.  Quantification of Hepc-25 using standard addition method 
3.6.1. Hepc-25 standard preparation of Hepc-25 and ACTH 
 
Stock solution of 2 μM Hepc-25 was diluted with 50% ACN/H2O (v/v) to make final 
concentrations of 20, 50, 200 or 500 nM. 
Stock solution of 10 μM ACTH was diluted to 100 nM with 50% ACN/ H2O (v/v). 
 
3.6.2. Standard addition procedure 
 
One part of the internal standard ACTH was mixed with one part of 20 nM, 50 nM, 200 
nM or 500 nM Hepc-25 standard to give a final concentration of 50 nM ACTH and 
hepcidin standard of 10 nM, 25 nM, 100 nM and 250 nM respectively. For ‘blank’ 
samples, one part of ACTH was mixed with one part of 50% ACN/ H2O (v/v). 
Urinary hepcidin extracted with the Omix C4 μSPE, as described in section 3.3.4, was 
mixed with the prepared standards mixture (Hepc-25/ACTH standards) and CHCA 
matrix (as described in Section 3.4.4) in a ratio of 1:1:2 (extract: standards mix: CHCA). 
The mixture was vortexed for 10 seconds and the dried droplet method (refer to   
Section 3.4.3.1) was utilized, where 0.8 μL of the mixture was reverse pipetted onto a 
384-well MALDIchip and allowed to dry in ambient temperature. Five replicates were 
spotted for each concentration onto the MALDIchip. 
111 
    Chapter 3 
The analysis was carried out with the MALDI-TOF MS with instrument parameters 
listed in Table 3-9. Mass accuracy was externally calibrated with ProXPRESSION 
PepMix 1 at the beginning of every analysis. 
 
3.6.3. Data analysis 
 
All data acquired by the MALDI-TOF MS were exported and analyzed using Data 
Explorer Version 4.0.0.0 (Applied Biosystems). Baseline correction and noise filter with 
correlation factor of 1 were applied to the raw mass spectra using the Data Explorer 
software. The summed peak area of Hepc-25 (2788 to 2795 m/z) and ACTH (2465 to 
2468 m/z) was used to plot a calibration curve. All S/N and resolution values were 
derived using the data analysis software. 
Calibration curves were constructed with the summed peak area ratio of Hepc-25 to 
ACTH versus theoretical concentrations. A linear equation (y=mx+b) was derived from 
the calibration curve, where y is the relative area (analyte/IS) and x is the standard 
addition concentration of analyte. Unknown endogenous Hepc-25 concentrations were 
calculated using the equation x=-(-b/m). 
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3.7.  Extraction recovery of Hepcidin-25 
3.7.1. ‘Blank’ urine sample 
 
Two reversed phased SPE cartridges (Phenomenex Strata-X and Varian Nexus SPE) 
were used to clean-up the urine sample to ensure complete removal of hepcidin from the 
sample. 
Both the Strata-X and Nexus SPE were conditioned and equilibrated as stated in   
Table 3-1. 2 mL of urine sample was passed through the Strata-X SPE and the eluant 
was collected. The eluant was further re-extracted with a Nexus SPE and the eluant was 
again collected.  
The eluant was then extracted with an Omix C4 μSPE using the extraction protocol 
(refer to Section 3.3.4) and analyzed using the MALDI-TOF MS (refer to Section 3.4.4) 
to ensure that hepcidin was not present in the starting eluant. 
 
3.7.2. Hepc-25 standard spiked in water 
 
Hepc-25 standard was spiked in water to give a final concentration of 50 nM. The spiked 
sample was extracted as stated in Section 3.3.4, to give a final concentration of 250 nM, 
based on a hypothetical extraction recovery of 100%. This is labeled as ‘extracted’ 
sample. 
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In another sample containing 80% ACN/ H2O/ 1.0 %TFA (v/v/v), Hepc-25 standard was 
added to give a final concentration of 250 nM. This is labeled as ‘blank’ sample. 
Both samples, with a final on-spot Hepc-25 concentration of 100 fmole, were then 
analyzed using MALDI-TOF MS as listed in Section 3.4.4.  
Summed peak areas of Hepc-25 standard (2788 to 2795 m/z) from both samples were 
compared using the following equation: 
 
Summed peak area of Hepc25 in ‘extracted’ sample
Summed peak area of Hepc25 in ‘blank’ sample
    100% 
 
3.7.3. Hepc-25 standard spiked in ‘blank’ urine 
 
Control urine sample was first extracted as stated in Section 3.7.1 and divided into two  
1 mL aliquots.  
In one of the aliquots, the ‘blank’ urine sample was then spiked with Hepc-25 standard 
to give a final concentration of 50 nM. The spiked urine was extracted according to the 
procedure listed in Section 3.3.4 and labeled as ‘extracted’ urine sample. 
In another aliquot, the same ‘blank’ urine sample was extracted according to the 
procedure listed in Section 3.3.4. The extract was then spiked with Hepc-25 standard to 
give a final concentration of 250 nM and labeled as ‘blank’ urine sample. 
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Both samples, with a final on-spot Hepc-25 concentration of 100 fmole, were then 
analyzed using MALDI-TOF MS as listed in Section 3.4.4.  
Summed peak areas of Hepc-25 standard (2788 to 2795 m/z) from both aliquots were 
compared using the following equation: 
 
Summed peak area of Hepc25 in ‘extracted’ sample
Summed peak area of Hepc25 in ‘blank’ sample
    100% 
 
3.8.  Ion suppression study 
 
A ‘blank’ urine sample was derived using the method listed in Section 3.7.1 and 
extracted according to the method in Section 3.3.4.  
The extract sample was spiked with 50 nM of Hepc-25 standard. Another aliquot of 
Hepc-25 standard (50 nM) was spiked into a solvent containing 80% ACN/H2O/ 1% 
TFA (v/v/v). 
Both aliquots were then analyzed using the MALDI-TOF MS method (refer to   
Section 3.4.4). Each concentration was spotted in triplicate.  
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3.9.  Limit of detection 
 
A ‘blank’ urine sample was derived using the method listed in Section 3.7.1 and 
extracted according to the method in Section 3.3.4.  
The extract sample was spiked with different concentrations of Hepc-25 standard (10, 5, 
2.5, 1.3, 0.7, 0.4 nM) and analyzed using the MALDI-TOF MS method (refer to   
Section 3.4.4). Each concentration was spotted in triplicate.  
 
3.10.  Hepcidin levels in different sections of urine 
 
Three sections (start-, mid- and end-stream) of the same control urine sample were 
collected according to the procedures listed in Section 3.2. Each phase was extracted 
with the Omix C4 tips, as described in Section 3.3.4, and analyzed using standard 
addition method as described in Section 3.6. 
 
3.11.  Stability of hepcidin in simulated environment  
 
A single batch of ‘mid-stream’ control urine sample that had not undergone any freeze-
thaw cycle was divided and stored in microcentrifuge tubes (1 mL aliquot). Two normal 
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‘analysis’ environments were simulated as i) normal lab conditions of 30
oC using a 
thermomixer (Eppendorf) with moderate vortex of 500 RPM; and ii) in ice-box 
environment of 4
oC using crushed ice.  
The samples were extracted at the specific time intervals of 1, 3, 5, 7, 24, 48 and 72 
hours for the 30
oC condition and 1, 3, 5 and 7 hours for the 4
oC simulation. Sample 
extraction and analysis procedures were as described in Section 3.3.4 and 3.6. 
 
3.12.  Freeze-thaw cycles 
 
A single batch of ‘mid-stream’ control urine samples prior to undergoing any freeze-
thaw cycle was divided into 1 mL aliquots. The samples were exposed to several freeze-
thaw cycles where each aliquot was thawed in a thermomixer at 30
oC, 500 RPM for  
1 hour before analysis. The rest were returned to a -80
oC freezer and allowed to freeze 
for at least 2 hours before undergoing the next cycle. A total of 4 freeze-thaw cycles 
were investigated and compared to sample that did not undergo any freeze-thaw cycles.  
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3.13.  Precision assay 
3.13.1.  Spot-to-spot reproducibility 
 
Spot-to-spot reproducibility was determined by replicate spotting (n=5) of extracted 
urine samples with different concentrations of added Hepc-25 together with IS and 
compared with different sets (n=15). Sample extraction and analysis procedures were as 
described in Section 3.3.4 and 3.6. 
 
3.13.2.  Inter- and intra-day precision assay 
 
Intra- and inter day reproducibility was determined using a single control urine sample 
that had been aliquoted into smaller tubes and freeze-thawed only once. For the intra-
day precision study, a set of 5 replicates was performed using the optimized extraction 
method mentioned in Section 3.3.4 and the samples were analyzed as described in 
Section 3.4. This was repeated on 3 separate days for the assessment of inter-day 
precision.  
All precision measurements (coefficient of variation) were expressed as the percentage 
relative standard deviation (% RSD).  
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3.14.  Hepcidin analysis using LC MS 
3.14.1.  Infusion mass spectrometry 
 
A classical ion trap MS (Bruker-Daltonik, Bremen, Germany) was optimized for   
Hepc-25 analysis. The instrument was first calibrated via direct infusion (Kd Scientific 
Inc., MA, USA) at 5 μL/min with Agilent ESI tuning mix (G2421-60001) diluted in a 
1:1 ratio (tuning mix:ACN; v/v). The ion trap was controlled by MSD Trap Control 
(version 5.1) from Bruker-Daltonik, Bremen, Germany. 
 
Hepc-25 stock solution (100 μM) was diluted to 50 nM with 30% ACN/0.1% FA H2O 
(v/v). The diluted Hepc-25 standard was directly infused using a syringe pump at   
5 μL/min into the ion trap MS. The ion optics of the spectrometer such as capillary, 
skimmers, lenses and octopole voltages were optimized to 698.8 m/z which is the 
[M+4H]
4+ of Hepc-25 peptide. 
The optimized ion trap settings for direct infusion are listed in Figure 3-4. 
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A
B 
Figure 3-4: Optimized instrumental parameters of ion trap MS used in the direct 
infusion analysis of Hepc-25. A: Optimized nebulizer pressure, drying gas and 
temperature used. B: The ion optics voltages used in the analysis.   
 
3.14.2.  Capillary LC-ESI-IT MS 
 
An Agilent 1100 Series capillary HPLC (Agilent Technologies Ltd., Alpharetta, GA, 
USA) was used for hepcidin analysis. The capillary LC consists of an Agilent 1100 
series; micro vacuum degasser, micro auto sampler, thermostat column compartment 
and binary pumps configured to operate at a maximum flow rate of 20 μL/min. The LC 
was connected to a classical ion trap MS (Bruker-Daltonik, Bremen, Germany) with an 
ESI source. The LC was controlled by Chemstation rev. A.09.03 (Agilent Technologies 
Ltd.). All tubing was of fused-silica with a PEEK protection layer, with an internal 
diameter of 50 μm. 
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An analytical column, ProteCol C18 (0.3 x 150 mm) with 3 μm particles and 300 Å pore 
size (SGE, Australia) was used. The column was maintained at a constant temperature of 
50
oC with a flow rate of 5 μL/min. Mobile phase A consisted of LCMS grade water with 
0.1% formic acid (v/v) and mobile phase B consisted of ACN with 0.1% formic   
acid (v/v), a gradient program holding at 10% B for 1 min followed by ramping to 80% 
B in 7 mins. The gradient was held at 80% B for another 7 mins (refer to Table 3-10). A 
post time of 20 mins was included after each analysis to ensure that the column was 
equilibrated for the next analysis. An injection volume of 3 μL was used. 
The LC method was further optimized to provide a cleaner baseline. Mobile phase A and 
B remained the same, with mobile phase A consisting of water with 0.1% formic   
acid (v/v) and mobile phase B with ACN with 0.1% formic acid (v/v). The LC gradient 
program is as listed in Table 3-11. Other parameters optimized include nebulizer 
pressure, drying gas temperature and drying gas flow. 
 
Table 3-10: LC gradient program for hepcidin analysis. 
Time (min)  % B 
0 10 
1 10 
8 80 
15 80 
16 10 
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Table 3-11: Optimized LC gradient program for hepcidin analysis. 
Time (min)  % B 
0 10 
5 10 
20 95 
25 95 
26 10 
 
3.14.2.1.  Pre-treatment of urinary hepcidin 
 
As urinary hepcidin was extracted in 80% ACN/ H2O/ 1% TFA (v/v/v), several pre-
treatment techniques prior to LC analysis were investigated. 
Dilution method 
Urinary hepcidin extract (10 μL) was diluted (10X) with DI H2O to give a final solvent 
concentration of 8% ACN/ H2O/ 0.1%TFA (v/v/v).   
Speed Vac method 
Urinary hepcidin extract (10 μL) was dried in a Speed Vac (Eppendorf) until dryness. 
The pellet was reconstituted in 100 μL of 8% ACN/ H2O/ 0.1%TFA (v/v/v) buffer. 
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Both samples were then analyzed in triplicate using the optimized LC MS method in 
Section 3.14.2. 
 
3.14.2.2.  Limit of Detection 
 
A ‘blank’ urine sample was derived using the method listed in Section 3.7.1 and 
extracted according to the method listed in Section 3.3.4.  
The extracted sample was diluted using the dilution method (refer to Section 3.14.3) and 
then spiked with different concentrations of Hepc-25 standard (50, 25, 13, 7, 4, 2 and  
1 nM) and analyzed using the optimized LC MS method (refer to Section 3.14.2). Each 
concentration was analyzed in triplicate.  
 
3.14.2.3.  Quantification of Hepc-25 using LC MS 
 
A ‘mid-stream’ control urine sample that underwent a single freeze-thaw cycle was used 
in this analysis. The sample was thawed in a thermomixer at 30
oC, 500 RPM for 1 hour 
before analysis. The sample was extracted according to the protocol listed in   
Section 3.3.4. The extract was then diluted using the dilution method as mentioned in 
Section 3.14.3. 
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The urinary Hepc-25 concentration was then externally quantified using ‘blank’ urine 
extract spiked with Hepc-25 standards (10, 50, 100, 500 and 1000 nM). All 
samples/standards were analyzed in triplicate using the LC MS method listed in   
Section 3.14.2. 
 
3.15.  Hepc-25 quantification using MALDI-TOF MS and   
LC-ESI-IT MS 
 
 A ‘mid-stream’ control urine sample that underwent a single freeze-thaw cycle was 
used in this analysis. The sample was thawed in a thermomixer at 30
oC, 500 RPM for  
1 hour before analysis. The sample was extracted according to the protocol listed in 
Section 3.3.4.  
The urinary extract was then analyzed using both the optimized method for MALDI-
TOF MS and LC-ESI-IT MS as listed in Section 3.4.4 and 3.15 respectively. 
 
3.16.  Creatinine analysis 
 
Creatine and creatinine standards were diluted to a concentration range of   
52 to 846 μg/mL with 10.8 mM ammonium acetate solution (Univar, NSW). Urine 
samples were diluted 10 times with 10.8 mM ammonium acetate solution prior to 
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analysis. Standards and samples were injected (1 μL) into an Agilent 1100 series HPLC 
(Agilent Technologies, Palo Alto, CA, USA) with a 150mm x 2.0 mm x 3 μm Pursuit 
XRs diphenyl column (Varian Inc.). The column was maintained at a constant 
temperature of 25
oC with a flow rate of 0.2 mL/min. Mobile phase A consisted of   
10.8 mM ammonium acetate solution and mobile phase B consisted of ACN with   
0.1% formic acid (v/v), a gradient program holding at 0% B for 10 mins followed by 
ramping to 100% B at 20% B/min. The eluant was monitored at wavelengths 210 nm 
and 236 nm with a diode array detector (Agilent Technologies, Palo Alto, CA, USA). 
 
3.17.  Urinary Hepc-25 analysis in hemochromatosis patients and 
control subjects 
 
‘Mid stream’ urine samples from hemochromatosis patients and control subjects were 
collected as indicated in Section 3.2. All samples used in this analysis only underwent a 
single freeze-thaw cycle. The sample was thawed in a thermomixer at 30
oC, 500 RPM 
for 1 hour and was extracted according to the protocol listed in Section 3.3.4.  
Hepcidin analysis in all extract samples were performed using the standard addition 
method as listed in Section 3.6 and analyzed according to the MALDI-TOF MS method 
stated in Section 3.4.4.  
Creatinine analysis was performed according to the method listed in Section 3.16. 
    Chapter 4 
 
 
 
 
 
 
4.  Chapter 4 - 
Results and Discussion 
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4.1.  Extraction of urinary hepcidin 
4.1.1. Solid phase extraction 
 
All 3 isoforms of hepcidin, Hepc-20, -22 and -25, are found in urine with average 
molecular masses of 2192, 2436 and 2790 m/z respectively, when measured using 
SELDI-TOF MS (Park et al., 2001; Kemna et al., 2005b; Altamura et al., 2009). 
Hepcidin was reported to be a cationic peptide by Ganz et al. and Tomosugi et al. (Ganz, 
2003; Tomosugi et al., 2006). Thus several different types of sorbents were trialed for 
effective extraction of urinary hepcidin. 
In the isolation of urinary hepcidin using anion (GracePure anion) and cation (GracePure 
cation) exchange SPE, hepcidin was not observed in either phase. The packing materials 
of the Omix SCX tip become clogged after 2 aspirations of the urine sample. Therefore 
ion exchange methods were not selected for the isolation of hepcidin.  
Several C18 sorbents such as the Varian Abs Elut Nexus and Phenomenex Strata-X were 
able to isolate urinary hepcidin. However, the Varian Bond Elut Plexa was unsuccessful 
in isolating any hepcidin.  
Control urine extracted with the Nexus SPE showed all 3 isoforms of hepcidin in the 
elution fraction with 100% ACN/0.1% TFA (v/v), with molecular masses [M+H]
+ of 
2191, 2435 and 2790 m/z which equate to Hepc-20, -22 and -25 respectively (refer to 
Figure 4-1A). Hepcidin was not observed in the wash fraction indicating that hepcidin 
was not washed off the sorbent during the washing step (refer to Figure 4-1B). Further 
127 
    Chapter 4 
additional of 100% ACN/ 0.1% TFA revealed no sign of hepcidin, indicating that the 
peptide was totally eluted from the sorbent. 
Several identical peaks especially in the lower mass region (for example 1219, 1912, 
1756, 2050, 2251, 2379, 2566 and 2712 m/z) were observed in the same urine sample 
(control) extracted with Strata-X SPE (refer to Figure 4-2), but only Hepc-20 (2194 m/z) 
was isolated. This could be due to the pore size of the polymeric sorbents as the Bond 
Elut Nexus is 100 Å whereas the Strata-X is only 85 Å. Thus Hepc-25 would be too 
large to fit into the 85 Å pores and therefore is not bound onto the sorbent. The peak at 
1912 m/z represents uromodulin which is further discussed in Section 4.10. 
Hepcidin was not observed in the extraction with Plexa SPE. This is because the 
polymeric sorbent has hydrophilic exterior surfaces while the cavities or pores have 
hydrophobic surfaces as shown in Figure 4-3. Thus, the large molecular structure of 
hepcidin is not able to bind to the surface of the polymer or access the hydrophobic pore 
structure and is not retained by the sorbent.  
Sample preparation for hepcidin analysis is critical due to the low concentration of 
urinary hepcidin (< 1 nmol/mmol creatinine in hereditary hemochromatosis patients 
(Bansal et al., 2009a)) and the presence of salts in urine which can affect matrix crystal 
formation (Cohen and Chait, 1996) and cause signal suppression (Hillenkamp et al., 
1991; Mock et al., 1992; Garden et al., 1996; Mims and Hercules, 2003; Lastovickova et 
al., 2009). As shown in Figure 4-4, distinct peaks such as m/z 1912, 1218 and all 3 
isoforms of hepcidin are suppressed by salts and contaminants present in urine that was 
not treated using solid phase extraction. 
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Figure 4-1: Urinary profile of healthy volunteer (control) extracted with Varian Bond 
Elut Nexus SPE. A: Mass spectrum of the elute fraction. B: Mass spectrum of the wash 
fraction. Arrows indicate Hepc-20, -22 and -25. 
A
B 
Hepc-20  Hepc-25 
Hepc-22 
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Hepc-20 
Figure 4-2: Mass spectrum of the elute fraction of urine (control) extracted with 
Phenomenex Strata-X. 
Pores with 
hydrophobic 
surface 
Hydrophilic 
surface 
Hepcidin is not able to 
bind to the polymer 
surface or access the 
pore structure 
 
Figure 4-3: Polymer architecture of Varian Bond Elut Plexa (adapted from Varian, Inc.). 
   
Figure 4-4: Mass spectrum of neat urine without any sample preparation. 
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4.1.2. Extraction using μSPE 
 
Micro-extraction consists of a scaled down version of traditional solid phase extraction 
(Shen et al., 2006). In traditional SPE, sorbents such as C18 or SCX are packed into a 
syringe barrel, whereas in micro-solid phase extraction (μSPE), sorbents are packed into 
a pipette tip. The use of μSPE tips not only reduced the usage of solvents but also 
dramatically reduced sample loading volume. In this study, only 0.1 mL of urine sample 
was required for each analysis using the μSPE compared to the loading of 1 mL of 
sample with traditional SPE.  
The mass spectra obtained from the eluted fraction extracted with Omix C4 and C18 
shown in Figure 4-5 A and B respectively, were very similar to the spectra observed in 
Figure 4-1A and 4-2. All three isoforms of hepcidin were observed in the urine sample 
extracted with the Omix tips and only Hepc-25 was observed in the extraction with 
Millipore C18 Ziptip (refer to Figure 4-5C). Table 4-1 represents the signal intensities, 
signal-to-noise ratio and peak resolution of Hepc-20 and -25 for both Omix extractions 
(C4 and C18). Higher intensity Hepc-20 and -25 signals, better signal-to-noise ratio and 
cleaner baseline were achieved with C4 extraction compared to the C18 extraction. 
Resolutions of more than 10,000 FWHM were observed for both Hepc-20 and -25 
extractions in the C4 extraction.  
 
In most published literature, hepcidin measurements were performed using SELDI-TOF 
MS (Kemna et al., 2005b; Tomosugi et al., 2006; Swinkels et al., 2008; Ward et al., 
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2008b; Altamura et al., 2009). The low resolution mass spectra obtained by the SELDI-
TOF MS are due to the linear TOF configuration of the instrument, where monoisotopic 
resolution of hepcidin is not observed. The MALDI-TOF MS employed in this study has 
an orthogonal ion extraction design coupled with reflectron capabilities and is able to 
provide improved mass accuracy and produce monoisotopic resolutions for Hepc-20, 
Hepc-25 and even the low level compound, such as Hepc-22 (refer to Figure 4-6). 
 
The monoisotopic masses observed in the control urine sample were 2190.79, 2434.95 
and 2788.05 m/z which correlate to Hepc-20, -22 and -25 respectively (refer to Figure  
4-6). These masses correlated well with the findings by Schranz and colleagues with 
monoisotopic masses of 2190.89 m/z (Hepc-20), 2435.17 m/z (Hep-22) and 2788.36 m/z 
(Hepc-25) (Schranz et al., 2009).  
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Hepc-22 
Hepc-25 
 
 
 
Figure 4-5: Mass spectra of urine (control) extracted with µSPE A: Omix C4, B: Omix 
C18, and C: Millipore C18 Ziptip. 
B 
C
Hepc-25  Hepc-20  Hepc-22 
Hepc-25 
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Table 4-1: Average signal intensity, signal-to-noise ratio and resolution of urinary 
Hepc-20 and -25 extracted with Omix C4 and C18 μSPE. 
 
Hepc-20 (2191 m/z) Hepc-25  (2790  m/z) 
Signal 
intensity 
S/N  Resolution 
Signal 
intensity 
S/N  Resolution 
C4  14212.3 100.5  10572.2  22137.4 153.7  10673.7 
C18  7296.4 64.0  7795.4 15660.2  102.1  10731.3 
 
 
     
Hepc-20         Hepc-22         Hepc-25 
 
Figure 4-6: Zoom-in view of hepcidin of urine extracted with Omix C4 μSPE adapted 
from Figure 4-5A. High resolution mass spectra of Hepc-20, -22 and -25 are observed 
with monoisotopic masses of 2190.8, 2435.0 and 2788.1 m/z respectively. 
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4.1.3. Optimization of hepcidin extraction using Omix C4 
4.1.3.1.  Pre-treatment of sample 
 
In this experiment, similar peak areas were observed in both spiked urine buffered with 
0.1% TFA and unbuffered urine. However, a much lower amount of hepcidin was 
observed when the spiked urine was buffered with 1% NH4OH (refer to Figure 4-7).  
Unbuffered urine was selected for the extraction of hepcidin since better extraction 
recovery was achieved, as shown by a larger average peak area (refer to Figure 4-7).   
 
Figure 4-7: Mass spectra of extracted control urine samples (spiked with 100 nM 
hepcidin) buffered with either 0.1% TFA or 1% NH4OH and unbuffered sample. 
  
135 
    Chapter 4 
4.1.3.2.  Washing solvent 
 
Several different solvent compositions (such as ACN/H2O and MeOH/H2O) with 
different acidic modifiers (such as TFA and FA) were trialed.  
After extraction of urine samples using the C4 μSPE, the sorbent was washed with 
solvent containing acidic modifiers. Analysis with MALDI-TOF MS showed that 
hepcidin was observed in the washing phase. Thus hepcidin was not readily retained in 
the sorbent when acidified solvents were passed through.  
When unbuffered H2O was used in the washing phase, a low level of hepcidin was 
observed in the washing phase. However, a noisier baseline and ion suppressed hepcidin 
peaks were observed in the elution phase. In this case, the cause of ion suppression was 
that the elution strength of water alone and was insufficient to dislodge these 
contaminants such as buffers and salts, from the sorbent bed. Thus the addition of small 
amounts of organic solvents are required, such that it is strong enough to remove 
contaminants from the sorbent but is not strong enough to elute hepcidin from the 
sorbent bed. 
 
Li and co-workers (2009) employed a solvent composition (e.g. MeOH) containing basic 
modifiers (e.g. NaOH) in the washing step for hepcidin extraction. Better hepcidin 
recovery was observed when the extract was washed with 30% MeOH/H2O (v/v) 
buffered to pH 10 with NH4OH as compared to washes containing 30% MeOH/H2O/ 0.1% 
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TFA (v/v/v) (refer to Figure 4-8). This wash solvent buffer, 30% MeOH/H2O (v/v) 
buffered to pH 10 with NH4OH, is also able to retain hepcidin on the sorbent and 
produced a cleaner extract (lower background noise) when compared with washes using 
only H2O. 
 
Figure 4-8: MS spectra of the eluant phase of urinary Hepc-25 extracted using C4 μSPE 
and washed with solvent containing either NH4OH or TFA. 
 
4.1.3.3.  Eluting solvent 
 
Hepc-25 was first extracted with the Omix C4 μSPE and serially eluted with solvent 
mixture containing various concentration of ACN/H2O/0.1% TFA (v/v/v) (refer to 
Figure 4-9). In Figure 4-9A, it was observed that the majority of hepcidin was eluted 
from the C4 tip with 50% ACN/H2O/0.1% TFA (v/v/v). A small Hepc-25 peak was 
observed when the tip was further eluted with 70% ACN/H2O/0.1% TFA (v/v/v), as 
shown in Figure 4-9B. Further elution with 80% ACN/H2O/0.1% TFA (v/v/v) showed 
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no sign of Hepc-25 peak (refer to Figure 4-9C). A higher concentration of methanol was 
required to elute Hepc-25 where the majority of hepcidin was eluted with 60% 
MeOH/H2O/0.1% TFA (v/v/v). A solvent mixture of 90% MeOH/H2O/0.1% TFA (v/v/v) 
was required to completely elute hepcidin from the μSPE tip. However, a nosier baseline 
was also observed when methanol was used as extraction solvent when compared to 
acetonitrile.  
Thus an elution solvent composition of 80% ACN/H2O/0.1% TFA (v/v/v) was employed 
in all subsequent urinary hepcidin extractions using the C4 tip to ensure complete elution 
of hepcidin from the sorbent bed.  
 
4.1.3.4.  Breakthrough analysis 
 
For breakthrough analysis, hepcidin was not observed in the flow-through fraction for 
both a loading volume of 50 and 100 μL (as shown in Figure 4-10), whereas hepcidin 
was observed in the flow-through fraction with a loading volume of 150 μL. Thus a 
maximum loading volume of 100 μL of urine sample was used for each Omix C4 μSPE 
extraction in order to achieve maximum retention of analytes and improve sensitivity. 
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Figure 4-9: Serial elution of 100nM of hepcidin-25 standard extracted with C4 μSPE. 
The μSPE was serially eluted with 50 μL of A: 50% ACN/H2O/0.1% TFA (v/v/v), B: 70% 
ACN/H2O/0.1% TFA (v/v/v) and C: 80% ACN/H2O/0.1% TFA (v/v/v). 
Small Hepc-25 signal 
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Figure 4-10: Mass spectrum of the flow-through fraction after passing 100 μL of urine 
through the C4 μSPE.  
 
4.2.  MALDI-TOF MS analysis of hepcidin 
4.2.1. MALDI matrices 
 
The two most commonly used MALDI matrices for proteomic and peptidomic analysis 
are α-Cyano-4-hydroxycinnamic acid (CHCA) and sinapinic acid. CHCA is the first 
choice for use with protein and peptides of less than 5 kDa whilst sinapinic acid is used 
for proteins with molecular weight greater than 5 kDa (Gonnet et al., 2003; 
Lastovickova et al., 2009). 
In many hepcidin analysis studies, sinapinic acid was selected as the matrix for SELDI-
TOF MS analysis (Kemna et al., 2005b; Kemna et al., 2007; Ward et al., 2008a; 
Altamura et al., 2009). Recently, the use of CHCA matrix for hepcidin analysis was 
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reported by Bansal et al. (2009) and Tomosugi et al. (2006) for MALDI- and SELDI-
TOF MS analysis respectively.  
Two very different urine extract profiles were observed when either sinapinic acid or 
CHCA was used as the MALDI matrix (refer to Figure 4-11). Three isoforms of 
hepcidin (Hepc-20, -22 and -25) were observed with monoisotopic peaks of 2191, 2436 
and 2788 m/z respectively when sinapinic acid matrix was used with the extracted urine 
(refer to Figure 4-11A). When CHCA matrix was used, a different profile was observed, 
as shown in Figure 4-11B. Similar to the mass spectra observed with sinapinic acid 
(refer to Figure 4-11A), all 3 isoforms of hepcidin can also be distinguished from the 
spectra, as indicated in Figure 4-11B. However, instead of only identifying hepcidin (as 
with sinapinic acid), several other compounds, such as 1912, 2711 and 3203 m/z, were 
also observed when CHCA matrix was used.  
Although sinapinic acid gave good indication of the 3 isoforms of hepcidin, the signal 
intensities and resolution observed at 2789 m/z were only 462 counts and 12,000 
respectively. Higher hepcidin signal intensities and similar resolution of 3789 counts and 
11,000 respectively were observed with CHCA. This equates to an 8-fold increase in 
hepcidin signal intensity with comparable resolution from using CHCA matrix 
compared to sinapinic acid. A less noisy MS baseline was also observed with using 
CHCA where matrix clusters are observed to be in the 700 to 1300 m/z region. Higher 
laser intensity (85%) was also necessary to ablate analyte from the sinapinic acid matrix 
compared to the laser intensity (70%) used with CHCA, which is able to produce higher 
signal intensities and signal-to-noise ratio. The use of lower laser energy can also 
prolong the life-span of the N2 laser. 
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A
B 
 
Figure 4-11: Mass spectrum profile of extracted urine in either A: sinapinic acid matrix 
(ACN/H2O/TFA (50%/50%/0.1%, v/v/v), or B: CHCA matrix (ACN/H2O/TFA 
(50%/50%/0.1%, v/v/v)). 
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4.2.2. Influence of solvent compositions and concentrations on crystal 
formation 
 
Ionic matrices (IM) or ionic liquid matrices (ILM) which consist of equimolar mixtures 
of conventional MALDI matrices such as CHCA, SA or DHB, together with organic 
bases such as pyridine (Py) or tributylamine (TBA) (Tholey and Heinzle, 2006) have 
been introduced as a potential alternative to conventional crystalline matrices 
(Armstrong et al., 2001). 
Recent advancement in the use of ILM has seen better homogeneity between sample and 
matrix leading to better spot-to-spot reproducibility, higher signal intensity and also 
lower detection limits to attomol levels when compared to conventional MALDI 
matrices (Tholey and Heinzle, 2006; Fukuyama et al., 2008; Fukuyama et al., 2009). 
 
In the analysis using liquid matrix 3-aminoquinoline/CHCA (3AQ/CHCA), the matrix 
did not crystallize upon drying. Good signal intensities of hepcidin and ACTH standards 
were observed when analyzed using MALDI-TOF MS. However when urinary extract 
with 3AQ/CHCA matrix was used, hepcidin was not observed in the mass spectrum. 
This could be due to ion suppression from salts present in the urine extract similar to 
those observed in conventional matrix (Smirnov et al., 2004). Further investigations are 
required in order to utilize this liquid matrix for hepcidin analysis. 
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When organic matrix such as CHCA in 50% ACN/H2O /0.1% TFA was spotted onto a 
MALDIchip plate, the spots tended to re-locate and dry at the side of the well. Large 
crystal formation was also observed when this matrix was employed, thus leading to 
high variability between spots. Similar observations where the matrix re-locate and dry 
at the side of the well was observed when HP CHCA was used. However, smaller crystal 
formation was observed when this matrix (HP CHCA) is used. 
When a matrix composition of MeOH/ACN/H2O/TFA (36%/56%/8%/0.1%, v/v/v/v) 
(Qiagen Mass Spec Focus Chip Handbook) was spotted onto the MALDIchip, small 
crystals were observed and these crystals were well spread around the inside of the well. 
In the findings by Zabet-Moghaddam et al. (2006), better S/N ratios, reduction of 
chemical noise and matrix clusters were observed when pyridine was added into CHCA 
matrix. When compared to the Qiagen method, better S/N ratio was observed among the 
hepcidin peaks. However, matrix crystallization around the well was not as homogenous 
as observed in the Qiagen method. With the addition of equimolar pyridine added into 
the Qiagen solvent concoction, a more homogenous matrix crystallization with improved 
S/N ratio was observed. 
 
4.2.3. Influence of acidic modifiers and crystal formation 
 
The ability to produce fine homogenous crystals is essential in producing spot-to-spot 
and shot-to-shot reproducibility for hepcidin quantitation. In Figure 4-12 and 4-13, it is 
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observed that the type of acid modifier and its concentrations were able to influence the 
crystallization process of CHCA matrix (Cohen and Chait, 1996). 
To produce large singular crystals, a minimum concentration of 0.5% TFA was required 
(refer to Figure 4-12). However, a more homogenous crystal formation was observed in 
CHCA with 1% TFA. This concentration (1% TFA) also produced the highest signal 
intensity among the different TFA concentrations tested (refer to Figure 4-12). The 
matrix crystallization observed in both 1% and 2% TFA in Figure 4-12 were quite 
similar with homogenous spread of small crystals, but the matrix with 1% TFA was able 
to produce hepcidin peak area of 26% better than that of 2% TFA. It was also observed 
that in 3% TFA, crystal formation becomes less homogenous and signal intensity started 
to decline by 6% compared to 2% TFA. 
A higher concentration of formic acid (more than 2%) was required to stimulate 
individual crystal formation and to produce a substantial signal intensity of more than 
S/N ratio of 10 for Hepc-25 quantification (refer to Figure 4-13). However, the peak area 
of Hepc-25 observed in 1% TFA was 2.7 fold higher than the Hepc-25 peak observed in 
2% formic acid. 
Overall comparison between formic acid and TFA in matrix showed that TFA was able 
to promote smaller homogenous crystallization and better hepcidin signal intensities. 
CHCA with 1% TFA was selected, as this concentration produced the best crystal 
homogeneity and Hepc-25 signal intensity combination. 
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Figure 4-12: MS spectra and crystals formation of 50 fmol of ACTH (2466 m/z) and  
25 fmol of hepcidin (2790 m/z) standards in CHCA matrix with different concentration 
of TFA. The MS spectra in [1] showed CHCA matrix spiked with A: 0.1%, B: 0.5%, C: 
1%, D: 2% and E: 3% TFA. The images in [2] showed the crystallization of CHCA 
matrix at different TFA concentrations where A: 0.1%, B: 0.5%, C: 1%, D: 2% and  
E: 3% TFA.  
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Figure 4-13: MS spectra and crystals formation of 50 fmol of ACTH (2466 m/z) and  
25 fmol of hepcidin (2790 m/z) standards in CHCA matrix with different concentration 
of FA. The MS spectra in [1] showed CHCA matrix spiked with A: 0.1%, B: 0.5%, C: 
1%, D: 2% and E: 3% FA. The images in [2] showed the crystallization of CHCA 
matrix at different FA concentrations where A: 0.1%, B: 0.5%, C: 1%, D: 2% and E: 3% 
FA.  
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4.2.4. Analyte-to-matrix ratio  
 
In MALDI analysis, signal distribution of the mass spectra is dependent on the analyte to 
matrix ratio (concentration of analyte/concentration of matrix) (Schlosser et al., 2005; 
Hillenkamp and Peter-Katalinic, 2007). However in this analysis, the actual analyte 
(Hepc-25) concentration was unknown. Thus, the analyte/matrix ratio using volume (μL) 
was used instead of concentration. 
In Table 4-2, the signal intensity, S/N ratio and resolution for a 1:1 (analyte: matrix) 
ratio was higher compared to a 1:10 ratio. No hepcidin was observed in the 1:100 ratio. 
Thus. 1:1 a ratio was used in subsequent hepcidin analysis as sufficient signal intensities, 
S/N ratios and resolutions were observed. 
 
Table 4-2: Influence of matrix-to-analyte ratio on signal intensity, S/N and resolution of 
Hepc-25. 
Analyte: Matrix 
ratio 
Average hepc-25 
signal intensity* 
S/N Resolution 
1:1 10144 426 14401 
1:10 4581 136 12548 
1:100 ND  ND  ND 
* n=3 
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4.2.5. Spotting techniques 
 
As demonstrated by Cohen and Chait (1996), sample-matrix preparations greatly 
influence the quality of the MALDI mass spectra of proteins and peptides. Several 
different spotting methods, different brands of CHCA matrix (Hewlett Packard (HP) 
CHCA and Sigma-Aldrich (S-A) CHCA) and different CHCA concentrations (10 and  
23 mg of S-A CHCA /mL of solvent mixture) were tested for reproducibility in the 
quantification of Hepc-25. The average peak area and RSD for the different spotting 
techniques and matrices are reported in Table 4-3.  
 
Table 4-3: Average peak area and % RSD (in brackets) of urinary Hepc-25 using 
various spotting techniques, different CHCA matrices and concentrations. 
Spotting 
techniques* 
CHCA Matrix 
HP  S-A (10 mg/mL)  S-A (23 mg/mL) 
Dried Droplet  20479.5 (60.1%)  175812.8 (9.4%)  135144.3 (68.9%) 
Vacuum drying  15125 (60.8%)  89904.5 (21.8%)  110976.5 (41.5%) 
Overlay  19697 (16.0%)  262852.5 (27.6%)  206355.8 (9.3%) 
Sandwich  1012630 (46.5%)  1161280 (8.5%)  1213182 (7.3%) 
*n=4 replicates for each technique and matrix 
 
In the dried droplet technique, good signal intensities were observed in all three matrices 
and concentrations. The other advantages of the dried droplet method is the ease of 
preparation and plate spotting, such as the mixing of matrix with sample in a 
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microcentrifuge tube and the need to only spot the combined mixture onto the MALDI 
plate once, with spots being left to air-dry at atmospheric conditions. When compared to 
other methods, such as vacuum drying, overlay and sandwich, where more tedious 
preparation is required.  
 
For the dried droplet techniques investigated, the best signal intensity (175813) with an 
RSD of 9.4% was observed with the S-A CHCA (10 mg/mL). Lower signal intensities 
were observed in both S-A CHCA (23 mg/mL) and HP CHCA with intensities of 
135144 and 20480 respectively and the RSD observed for both matrices were more than 
60%.  
For the vacuum drying method, lower signal intensities with RSD ranging from 22% to 
61% were observed with all 3 different matrices when compared to the dried droplet 
method. The use of vacuum in the drying process may result in the removal of volatile 
acidic modifier (e.g. TFA) from the matrix, which is essential in the ionization of 
hepcidin. 
In the overlay technique, high hepcidin intensities were observed in the S-A matrices. 
The signal intensity and RSD observed in CHCA (23 mg/mL) were 206356 counts and 
9.3% respectively which is comparable to the values observed in CHCA (10 mg/mL) 
using the dried droplet method (9.4% RSD). The highest signal intensity was observed 
in the sandwich method which is due to the loading of 1 μL of extract onto each spot 
compared with the application of 0.5 μL of extract for the rest of the techniques. The 
150 
    Chapter 4 
sandwich method using CHCA of 10 and 23 mg/mL also achieved excellent RSD of 8.5% 
and 7.3% respectively.  
The drawback of the overlay and sandwich methods are the numerous steps involved in 
the spotting of different layers (matrix and/or extract) onto each well (refer to Figure 3-2) 
which leads to increased spotting time, spotting variability and precision errors in larger 
sample sets. Increased hepcidin oxidation with monoisotopic peak of 2805 m/z was 
observed in the sandwich method, as this technique requires longer preparation time 
with the application of a matrix layer on top of the air-dried extract fraction, which 
exposes hepcidin to prolonged atmospheric conditions. 
 
The dried droplet method using 10 mg/mL CHCA was chosen, as the sample-matrix 
preparation together with plate spotting can be readily carried out, with less than   
2 minutes required to execute the dried droplet spotting, compared with more than   
5 minutes needed for the sandwich method. Good signal intensity with high 
reproducibility was also achieved using this technique.  
The application of the dried droplet or sandwich method together with the automation of 
a liquid handler greatly reduced application (spotting) time which in turn minimized 
hepcidin oxidation, reduced spotting variables and greatly increased sample throughput.  
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4.2.6. Sample spot washing 
 
Higher signal intensities were observed in all samples that had undergone extra washing 
with cold H2O, cold H2O with 0.1% TFA or cold H2O buffered to pH 8.6, compared to 
sample wells that were not washed (refer to Table 4-4). As contaminants, such as trace 
metal salts, buffers and surfactants were removed with well washing, improved signal 
intensity and sensitivity were observed (Smirnov et al., 2004).  
The highest S/N ratio (649 S/N) was observed in the wells treated with a cold H2O wash, 
followed by cold H2O wash at pH 8.6 with S/N ratio of 494, and S/N ratio of 426 was 
achieved for wells without any washes. The lowest S/N ratio of 357 was observed in the 
wells that were treated with cold H2O containing 0.1% TFA (refer to Table 4-4). Even 
though intensity and some resolution was increased after the well washing step, peak 
resolution remained relatively constant within the range of 14,000 to 15,100 FWHM.  
However, the variability between wells of more than 15% was observed in wells that had 
undergone washing. RSD of 15.2%, 16.9% and 18.0% were observed in wells that were 
washed with cold H2O, cold H2O (0.1% TFA) and cold H2O (pH 8.6) respectively, 
compared to 7.6% observed in the initial wells (without any wash) as shown in Table 4-4. 
A sample washing step was not included in this assay since washing of the wells did not 
improve Hepc-25 intensity and S/N ratio, but significantly increased the % RSD by 
greater than 2-fold or greater (refer to Table 4-4).   
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Table 4-4: Influence of sample spot washing on signal intensity, S/N, resolution and % 
RSD of Hepc-25. 
 
Average Hepc-25 
signal intensity* 
S/N  Resolution  %RSD 
w/o wash  10144  426  14401  7.6 
Cold H2O 16304  649  13973  15.2 
Cold H2O + 
0.1% TFA 
15801 357  15129  16.9 
Cold H2O 
(pH 8.6) 
12955 494  14777  18.0 
* n=3 
 
4.2.7. The influence of MALDI plates, acquisition patterns and 
pipetting techniques on the reproducibility of hepcidin 
quantification 
4.2.7.1.  MALDI plates 
 
Three types of MALDI plates, the 96-well stainless steel and the 96- and 384-well 
MALDIchip plates were investigated. The stainless steel plates are re-usable and it is 
easier to see crystallization of matrix on this surface. However, there is always the 
possibility for cross contamination due to incomplete washing of the plate. High organic 
solvents are also not able to be remain in the centre of the well of these stainless steel 
plates and tend to spread to the outside of the well, resulting in the loss of sample.  
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The MALDIchip plates, on the other hand, has a hydrophobic barrier surrounding each 
well which concentrates the sample into the centre of each spot, increasing the 
sensitivity for low level analyte detection. These plates are also disposable, thus 
eliminating the chance of cross-contamination.  
 
From Table 4-5, the comparison between the 96-well stainless steel plate and the 96-
well MALDIchip plates showed little variation between the percentage RSD and 
correlation coefficient (R
2). When compared with the 384-well MALDIchip, better RSD 
and R
2 were observed especially at lower Hepc-25 concentration (15.6 - 62.5 nM). A 
coefficient of 0.997 was also achieved using the 384-well MALDIchip compared to the 
R
2 observed in the 96-well stainless steel and 96-well MALDIchip of 0.985 and 0.977 
respectively.  
 
Overall, better RSD, especially at the lower hepcidin concentration, and improved R
2 
coefficient was observed with the 384-well MALDIchip compared to the two other 
plates (96-well stainless steel plate and 96-well MALDIchip). High-density plates such 
as the 384-well plates will increase analysis throughput and also reduce the cost for each 
sample analysis as more samples can be analyzed in a single plate compared to a 96-well 
plate. 
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Table 4-5: Comparison of Hepc-25 quantification using different target plates.  
Plate type 
96-well         
stainless steel 
96-well 
MALDIchip 
384-well 
MALDIchip 
 
Peak 
area* 
% RSD 
Peak 
area* 
% RSD 
Peak 
area* 
% RSD 
H
e
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(
n
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)
  125 452149 13.0 295596 18.6 320689 29.1 
62.5  267702 9.0 179992 8.5 168270 5.1 
31.3  112159  11.4  68856 5.7 74512 2.6 
15.6  50482 29.1 27308 24.4 29916  9.2 
 R
2 0.985  0.977  0.997 
* Averaged area of 3 replicates/concentration. 
 
4.2.7.2.  Acquisition patterns and pipetting techniques 
 
Different pipetting techniques and acquisition patterns using the 384-well MALDIchip 
were investigated for spot-to-spot reproducibility and maximum sensitivity (using peak 
intensity).  
Two acquisition patterns, the Z-mode and the 9-point circle (9-pc), were investigated. 
The Z-mode consists of 22 acquisition spots with 2 spectra collected at each pattern, thus 
a total of 44 spectra were collected. In the 9-pc mode, a total of 20 spectra were 
collected which consist of 10 acquisition spots with 2 spectra collected at each pattern. 
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In Table 4-6, similar variations were observed in the percentage RSD between the 2 
modes using the same pipetting technique. However, a 2-fold increase in peak area was 
observed when the sample was acquired using the Z-mode compared with the 9-pc. This 
is due to the doubling in the number of spectra collected (44 spectra collected in Z-mode 
compared to 20 spectra in 9-pc mode). However, this also resulted in a much longer 
acquisition time as 88 seconds were required for each Z-mode acquisition compared to 
40 seconds using the 9-pc mode.  
 
Using the normal pipetting technique, the RSDs observed were between 13.4 and 17.5% 
with an average of 15.8% (Z-mode) and 14.4% (9-pc) (refer to Table 4-6). Using the 
reverse pipetting technique, the observed RSD was between 2.7% and 15.5% with an 
average of 9% for Z-mode and 7.3% for 9-pc. While both pipetting techniques and 
acquisition patterns yielded excellent linearity (R
2 = >0.99), reverse pipetting using 9-pc 
mode was selected for its shorter acquisition time. A higher throughput with RSDs of 
less than 10% can be achieved. 
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  Table 4-6: Comparison of Hepc-25 quantification with different pipetting techniques on a 384-well MALDIchip.  
 
Pipetting method  Normal Pipetting  Reverse Pipetting 
Acquisition pattern  Z-mode 9-pc Z-mode 9-pc 
 
Peak 
area* 
% RSD 
Peak 
area* 
% RSD 
Peak 
area* 
% RSD 
Peak 
area* 
% RSD 
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(
n
M
)
 
25.0  1049072 13.7 560109 13.4  1008562 7.0  582238  8.1 
12.5  490956 16.3 247237 13.4 486566  4.5  282270  2.7 
6.3 294270 17.5 163704 16.5 271089 15.5 164777 11.1 
R
2  0.994 0.999 0.998 0.997 
* Averaged area of 5 replicates/concentration. 
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4.3.  MALDI-TOF MS optimization 
 
Instrumental parameters were first tuned with PepMix 1 which contains 5 peptides 
followed by further optimization with ACTH clip 18-39 and Hepc-25 standards. The list 
of peptides and their final concentration are listed in Section 3.5.1. The ramping controls 
provided in the TOFworks software was used to assist in the optimization process. 
 
The detector bias and detector distribution were first optimized. In a single channel MCP 
(microchannel plate) detector, only the first ion that strikes the detector is detected in a 
given dead time of approximately 20 nsec. The multichannel MCP detector used in the 
MALDI-TOF MS, as shown in Figure 4-14, consists of 4 channels. Thus achieving 
greater accuracy and sensitivity in the ion count by compensating for the dead time 
associated with a single channel as up to four ions can be detected at any one time. The 
detectors were first aligned and the percentage distribution observed between these 
channels using the peptide mix standards were 1: 75%, 2: 100%, 3: 98% and 4: 71%. 
 
The instrument was then tuned for sensitivity using ACTH and Hepc-25 standards. The 
ion optics involved are the cone, mesh and the DC lens which consists of optics 1 & 2 
and steer 1 & 2 (refer to Figure 4-15A). The cooling and focusing gas (nitrogen gas) 
were optimized to prevent undesirable fragmentation and improve transmission of ions 
from the sample plate through to the quadrupole (Krutchinsky et al., 1998a). 
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Figure 4-14: Schematic of a MCP detector with 4 channels. 
  
 
Figure 4-15:  Ion optics in the MALDI-O-TOF MS. A: ion transmission section,   
B: TOF chamber ion path and assemblies (Adapted from PerkinElmer, 2004). 
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For the optimization of resolution, the voltages in the accelerator (push, pull optics), 
dual stage reflector (mirror grid and plate) and pull offset were fine-tuned (refer to 
Figure 4-15B). The ion reflector consists of a series of plates and grids that acts as an 
electromagnetic ion mirror. This ion reflector also compensates for the spread in kinetic 
energies of the ions as they enter the drift region (Krutchinsky et al., 1998a) and, 
together with the use of a two-stage ion reflector which allows finer control of ion 
reflection, peak resolution of more than 15,000 was achieved. 
However, with the improvement of resolution, signal intensity was reduced. Therefore, 
the instrument was re-tuned where a compromise between resolution and signal intensity 
was observed. In the final optimization, hepcidin peak resolution of at least 12,000 was 
observed with an increased signal intensity of 9-fold compared to the initial (not 
optimized) settings (refer to Figure 4-16). The optimized MALDI-TOF MS parameters 
are listed in Figure 3-3. 
 
4.4.  Extraction recovery of Hepc-25 
 
In this experiment, extraction recovery of more than 98% was achieved when Hepc-25 
standard was spiked into DI water (pH 7). When Hepc-25 standard (250 nM) was spiked 
in urine samples that had been pre-extracted using the method mentioned in   
Section 3.7.3, extraction recovery greater than 70% was achieved (refer to Table 4-7).  
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Figure 4-16: Comparison of Hepc-25 peak (4.8 fmol on spot) A: before, and B: after 
optimization.  
Table 4-7: Extraction recovery of Hepc-25 spiked in urine sample. 
 
Average Peak 
Area* 
Standard 
Deviation 
% RSD 
Urine spiked after 
extraction 
73837 5729  7.8  % 
Urine spiked 
before extraction 
58963 4904  8.3  % 
 Recovery  79.9 % 
* n=3 
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Murao  et al. (2007)  reported a 34% recovery for hepcidin employing protein 
precipitation method using trichloroacetic acid. Using a two-step extraction process 
involving protein precipitation and HLB μElution SPE, Murphy et al. (2007) reported an 
improved recovery of 59.2%, whereas Li at al. (2009) reported recoveries of greater 
than 60.4% using only the HLB μElution SPE. 
The only published urinary hepcidin recovery of 79% was observed by Bansal and 
colleagues (2009). Bansal et al. (2009) employed weak cation exchange (WCX) 
magnetic nanoparticles in the extraction of urinary hepcidin from 200 µL of urine. Thus, 
the extraction recovery achieved in this experiment is comparable to the method 
employed by Bansal et al. (2009). 
For the analysis using ELISA, urinary hepcidin recovery of greater than 90% was 
observed by Papanikolaou et al. (2005) using carboxymethyl ion exchange matrix (CM) 
extractions. However in this assay, high intra-precision assay variations of 5-19% were 
observed (Ganz et al., 2008).  
 
4.5.  Limit of detection and ion suppression 
 
The detection limit of hepcidin was determined by spiking hepcidin standard into 
extracted urine containing no hepcidin and analyzed using MALDI-TOF MS. The 
detection limits for Hepc-25 of 1 fmol (on-spot concentration) with S/N ratio of 50 was 
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achieved (refer to Figure 4-17). Further analysis with lower concentration of Hepc-25 
resulted in the loss of the peptide isotopic patterns.   
 
Ion suppression analysis was carried out by spiking Hepc-25 standard (50 nM) into both 
blank urine extract in 80% ACN/ H2O/ 1% TFA (v/v/v) and solvent containing   
80% ACN/H2O/ 1% TFA (v/v/v). From Table 4-8, ion suppression of 17.6% was 
observed between the two solvents. van Hout et al. (2000) observed up to 70% ion 
suppression from the extraction of clenbuterol in urine (van Hout et al., 2000). Ion 
suppression is due to the presence of matrix compounds such as urinary salts and buffers 
remaining in the μSPE sorbent (Annesley, 2003; Mims and Hercules, 2003). 
 
 
Figure 4-17: Detection limit of Hepc-25. Mass spectrum showing on-spot concentration 
of 1 fmol and 10 fmol of Hepc-25 and ACTH standards respectively.   
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Table 4-8: Average peak area of 50 nM hepcidin-25 standard spiked in blank urine 
extract and in solvent blank. 
 
Spiked in blank urine 
extract* 
Spiked in solvent blank* 
Average peak area  225963  274063 
* n=3 
 
4.6.  Stability of urinary hepcidin 
 
Careful consideration is often paid to the development of a mass spectrometry protocol 
and analysis of the mass spectrometry data.  Most studies in the literature have not 
considered how the handling of the samples prior to mass spectrometry analysis could 
affect the study results (Mitchell et al., 2005). 
Improper sample handling, such as sample collection and storage, can lead to 
degradation of urinary protein and peptides (< 10 kDa) resulting in inconsistent findings 
(Pisitkun et al., 2006). Urinary peptides also undergo degradation during the freeze-thaw 
process (Schaub et al., 2004). However, not all urinary peptides are similarly sensitive to 
these processes (Klasen et al., 1999; Schaub et al., 2004). Thus, it is critical to 
understand the behavior of hepcidin during these processes.  
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4.6.1. Hepcidin concentration in different urine sections 
 
Hepcidin levels in different urine sections have not been previously investigated. Thus in 
this section, different sections of urine (e.g. start-, mid- and end-stream) were 
investigated for any variation in Hepc-25 level. 
The variation in hepcidin concentration between the start- and mid-stream was minimal 
with average concentrations of 23.1 and 22.6 nM respectively (refer to Figure 4-18). 
However, the hepcidin levels was significantly lower in the end-stream section, with an 
average concentration of 19.4 nM (refer to Figure 4-18).   
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Figure 4-18: Hepcidin levels in different urine sections. 
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4.6.2. Incubation of hepcidin at 4
oC and 30
oC 
 
Larger variation in signal intensity was observed in urine incubated at 4
oC as compared 
to 30
oC incubation (refer to Figure 4-19). This was achieved by comparing the largest 
variation point, which is at the 3 hour time-point, to the initial hepcidin level (at 0 hour), 
where variations of 21% and 12% were observed for 4
oC and 30
oC incubation 
respectively.  
Urinary Hepc-25 was observed to be stable at 30
oC over a period of 7 hours before 
starting to degrade (refer to Figure 4-20). Thus, it is recommended that urinary hepcidin 
be extracted within 3 hours after thawing, which gave a 0.5 ppb variation. The linear 
regression and RSD achieved from all the data sets were more than 0.99 and under 9.1% 
respectively. 
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Figure 4-19: Variation of hepcidin levels in urine incubated at 4
oC and 30
oC. 
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Figure 4-20: Time course stability of hepcidin in urine incubated at 30
oC. 
 
It was observed that several peptides undergo degradation such as uromodulin (1912 
m/z), unknown peptide (2041m/z), Hepc-20 (2192 m/z) and Hepc-25 (2790 m/z) after 
prolonged incubation at 30
oC (refer to Figure 4-21). 
Methionine oxidation of Hepc-25 is due to the interaction of the methionine residue with 
ambient ozone to give a molecular mass of 2805 m/z (Cohen, 2006; Swinkels et al., 
2008). Urinary hepcidin-25 also undergoes degradation upon prolonged incubation at 
30
oC (refer to Figure 4-22).  
In this preliminary study (refer to Figure 4-22), no increase in peak area of oxidized 
Hepc-25 was observed between the 0 and 5 hour time points. A decrease in peak area of 
the monoisotopic unoxidized Hepc-25, at 2788 m/z, was observed in the same incubation 
period (Figure 4-22). A further decrease in Hepc-25 was observed in the 72 hour 
incubation sample with no further increase in oxidized hepcidin, thus indicating that 
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Hepc-25 is undergoing degradation during incubation at 30
oC. The use of the μSPE 
extraction method described above together with the rapid analysis using the MALDI-
TOF MS also minimizes oxidation of hepcidin.  
The degradation of uromodulin precursor at 1912 m/z was also observed after 24 hours 
and it was totally degraded after 48 hours after incubation at 30
oC (refer to Figure 4-21). 
Further discussion of uromodulin can be found in Section 4-10. 
 
C
B 
A
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Figure 4-21: MS profile of extracted control urine samples that underwent A: 0 hours, B: 
5 hours, and C: 72 hours of incubation at 30
oC.  
168 
    Chapter 4 
 
5 hours 
Start (0 hour) 
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Figure 4-22: Degradation of urinary Hepc-25 that underwent incubation at 30
oC. 
 
4.6.3. Freeze-thaw cycle 
 
In the freeze-thaw cycle analysis, Hepc-25 levels were relatively stable with an average 
concentration of 25.9 ± 2.6 nM (refer to Figure 4-23). It was also observed that the 
Hepc-25 level was highest (28.8 nM) when the sample underwent one freeze-thaw cycle 
compared to samples that underwent two freeze-thaw cycles and without any freeze-
thaw cycle, with Hepc-25 levels of 25.3 and 23.1 nM respectively (refer to Figure 4-23). 
This increase of hepcidin could be due to the loss of water thus concentrating hepcidin in 
the sample. This finding correlated with the results of Kemna et al., where Hepc-25 level 
was the highest in samples that underwent only one freeze-thaw cycle (Kemna et al., 
2007). In our data set, urinary hepcidin was stable throughout the cycles with a slight 
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decline in Hepc-25 levels. However in the findings by Kemna et al., Hepc-25 levels 
were inconsistent throughout the different thaw cycles (second to fourth thaw cycles).   
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Figure 4-23: Stability of Hepc-25 undergoing freeze-thaw cycles. 
 
4.7.  Precision assay of urinary Hepc-25 
 
The general application of MALDI-TOF MS for quantification was initially rejected due 
to a number of factors, such as significant variations in the signal intensity resulting 
from consecutive laser shots at different positions on a given spot (known as ‘shot-to-
shot’ reproducibility), along with differences observed between sample spots (‘spot-to-
spot’ reproducibility) (Colgrave et al., 2005). 
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These variations could be due to several reasons such as inhomogeneous   
co-crystallization of the matrix and sample molecules, fluctuations in laser intensity, 
and/or changes in detector response (Horak et al., 2001; Cohen and Gusev, 2002). Other 
factors such as sample matrix effects, analyte-to-matrix ratio and random fluctuations 
can also contribute to these variations (Gusev et al., 1995; Knochenmuss et al., 1996). 
Thus it is necessary to investigate the potential of the MALDI-TOF MS used in this 
project for accurate, precise and reproducible quantification of urinary hepcidin-25. 
 
4.7.1. Spot to Spot reproducibility, intra- and inter precision assay 
 
The employment of standardized sample preparation steps and the addition of internal 
standards can minimize interference factors while matrix effects, which affect the 
sensitivity of the analysis, can be reduced by the addition of standard of the analyte to 
the sample (also known as standard addition method) (Duncan et al., 2008).  
Spot-to-spot reproducibility of spiked urine with different concentrations of Hepc-25 
was performed. Hepc-25 concentrations of 2.5 to 62.5 fmol/μL were spiked into an 
extracted urine sample together with 12.5 fmol/μL of internal standard (ACTH). The 
percentage variation range and averages for 62.5, 25, 6.25, 2.5 fmol/μL of Hepc-25 
spiked urine and unspiked urine are shown in Table 4-9. The spot-to-spot reproducibility 
percentage RSD was pooled from all the data from the intra- and inter-day analyses. 
These results showed that variations between spots with the same concentrations were 
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below 6.5% with an overall average variation of less than or equal to 3.4% throughout 
the whole set. The set of urine samples with no spiking of Hepc-25 gave an average 
variation of only 3.1% (refer to Table 4-9). 
 
Table 4-9: Spot-to-spot reproducibility of extracted urine sample spiked with different 
concentrations of Hepc-25. 
Spiked sample 
(fmol of Hepc-25/μL) 
RSD range (%) 
(n=15)  Average RSD (%) 
62.5 0.7-6.4  3.4 
25.0 0.8-6.5  3.3 
6.25 1.0-5.5  2.8 
2.50 0.5-6.2  2.8 
0 1.1-5.1  3.1 
 
 
The endogenous Hepc-25 concentration between sets ranged from 40.2 to 56.2 fmol/μL 
of urine (refer to Table 4-10). In Table 4-10, a RSD of less than 10% was observed in all 
data sets for the intra-day precision assay.  
For inter-day precision assay, a RSD of 7.9% and 1.6% was observed for Hepc-25 and 
creatinine respectively (refer to Table 4-11). When endogenous Hepc-25 was normalized 
with urinary creatine, an inter-day RSD of 9.4% was observed with normalized ranges of 
2.3 to 2.7 nmol of Hepc-25/ mmol of creatinine in the same batch of control urine (refer 
172 
    Chapter 4 
to Table 4-11). Urinary creatinine was analyzed using HPLC with a UV/Vis detector 
(refer to Section 4.11). 
 
In conclusion, a validated quantification of urinary hepcidin using MALDI-TOF MS has 
been achieved. Various parameters such as matrix and solvent compositions, acquisition 
patterns and spotting techniques had been investigated in the MALDI-TOF MS analysis 
of hepcidin. 
Using standard addition method together with MALDI-TOF MS for the quantitative 
analysis of unlabeled hepcidin, intra- and inter-precisions of less than 9.5% RSD were 
achieved, and LOD and LOQ of 1.25 nM and 2.5 nM respectively were also determined. 
Several stability experiments such as incubation temperatures and freeze-thaw cycles 
were also carried out, which provided valuable information of urinary hepcidin prior to 
μSPE extraction. 
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Table 4-10: Intra-precision assay of urinary Hepc-25. 
 
Hepc-25/IS ratio (nM) 
Day 1  Day 2  Day 3 
Set  1  49.0 44.5 40.1 
Set  2  43.8 54.2 40.6 
Set  3  41.7 51.6 49.7 
Set  4  40.2 49.0 45.8 
Set  5  48.7 56.2 47.5 
Mean  44.7  51.1  44.7 
Standard Deviation  4.0  4.6  4.2 
RSD  9.0%  9.0%  9.5% 
 
 
Table 4-11: Inter-precision assay and normalization of Hepc-25 to creatinine in urine.  
 
Hepc-25/IS 
ratio (nM) 
Creatinine 
(mM) 
Normalization           
(nmol Hepc-25 to mmol 
creatinine) 
Day 1  44.7  15.3  2.3 
Day 2  51.1  15.0  2.7 
Day 3  44.7  15.5  2.3 
Mean  47.9  15.3  2.5 
Standard Deviation  4.5  0.3  0.2 
RSD  7.9  1.6  9.4 
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4.8.  LC MS analysis 
4.8.1. Infusion mass spectrometry 
 
The mass spectrometric parameters were first optimized using the ‘smart parameters’ 
function, available in the MSD Trap Control software. Direct infusion of 50 nM of 
Hepc-25 standard in positive mode was used in the optimization process. From the mass 
spectra, multiple charge states of the Hepc-25 peptide were observed with m/z 932.2, 
698.8 and 558.9, which correspond to charge state of [M+3H]
3+, [M+4H]
4+ and 
[M+5H]
5+ respectively and this is similar to those observed by Bansal et al. (2009) and 
Li et al. (2009) (refer to Figure 4-24). 
 
 
Figure 4-24: ESI-MS spectrum of hepcidin-25 standard (50 nM) using direct infusion 
method.  
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The most abundant ion observed for Hepc-25 was the quadruply charged molecular ion 
([M+4H]
4+), followed by the [M+5H]
5+ charge state (refer to Figure 4-24). Both 
precursor ions (558.9 and 698.8 m/z) yield multiple product ions when dissociated. 
However, none of these product ions were of sufficient intensity for further MS/MS 
analysis (refer to Figure 4-25B and C). Similar observations of low intensity product 
ions have been reported by Bansal et al. (2009a). 
Figure 4-25A shows the hepcidin sequence and the corresponding collision-induced 
dissociation (CID) product ions observed from the fragmentation of [M+4H]
4+ and 
[M+5H]
5+ with precursor ions of 698.8 and 558.9 m/z respectively. 
From the MS/MS of the precursor ion (698.8 m/z) using fragmentation amplitude of 1.12, 
the product ions observed were similar to those observed by Li et al. (2009), which 
consists of both large y- ions and both large and small b- ions (refer to Figure 4-25B). 
The most abundant product ion observed from the MS/MS of [M+4H]
4+ is 694.1 m/z 
which represent the y19
3+ product ion of Hepc-25. Efficient losses of product ions such 
as b3 (354.4 m/z) yield y22
3+, which is due to cleavage after the amino acid histidine at 
the N-terminal. Other losses due to cleavages after the proline (b4 ions) and 
phenylalanine (b5 ions) residues at the N-terminal yield y21
3+ and y20
3+ respectively 
(refer to Figure 4-25A). 
However, when 558.9 m/z was dissociated with a fragmentation amplitude of 1.27V, the 
most abundant product ion was 555.3 m/z which represents the b20
4+ fragment ion of 
Hepc-25. The remaining product ions observed are all y- ions (refer to Figure 4-25C).  
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Neither histidine or phenylalanine immonium ions at 110 and 120 m/z were observed in 
the MS/MS experiments (precursor ions of 558.9 and 698.8 m/z), in contrast to other 
publications (Murao et al., 2007; Li et al., 2009).  
 
A
B 
C
 
Figure 4-25: ESI-MS spectra and amino acid sequence of hepcidin. A: Hepc-25 
sequence and corresponding CID product ions. B: Fragmentation of precursor ion at 
698.8 m/z. C: Fragmentation of precursor ion at 558.9 m/z. 
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4.8.2. LC ESI-IT MS 
4.8.2.1.  Sample preparation of hepcidin extract for LC MS analysis 
 
Since hepcidin is extracted in 80% ACN/H2O/ 1% TFA (v/v/v), it is necessary to employ 
some form of sample preparation, such as drying or dilution, to formulate a final solvent 
(with hepcidin dissolved in) with organic-aqueous ratio similar to the starting LC mobile 
phase. This is to ensure that hepcidin will be able to interact and bind to the C18 column, 
while other salts and buffers which are unretained in the column are eluted. This also 
acts as a secondary clean-up step for urinary hepcidin. 
It is also necessary to remove or reduce the concentration of TFA in the solution as this 
acidic modifier can cause ion suppression (Annesley, 2003; Mallet et al., 2004). 
 
To develop a preferred method for preparing the extract for LC MS analysis, a control 
urine extract was either diluted 10X with DI H2O to give a final solvent ratio of   
8% ACN/H2O/ 0.1%TFA (v/v/v), or spun down to dryness using a Speed Vac. The 
pellet was then reconstituted with 8% ACN/H2O/ 0.1%TFA (v/v/v). 
Higher peak area was observed when the urine extract was processed by dilution 
compared to drying down (refer to Figure 4-26). This is due to the loss of analyte during 
the drying process, such as the hepcidin degradation due to increase in temperature 
generated during the spinning process and the adherence of the peptide to the walls of 
the microcentrifuge tube (Swinkels et al., 2008). The dilution of the urine extract will 
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also dilute interfering matrix components present in the extract, thus reducing ion 
suppression (Wang et al., 2007). 
 
 
Figure 4-26: Recovery of extracted Hepc-25. Extracted urinary Hepc-25 from normal 
subject was diluted 10X with H2O to give a final mobile phase of 8% ACN/ H2O/ 0.1% 
TFA (v/v/v) (red chromatogram). The same batch of extracted Hepc-25 was dried down 
in a SpeedyVac and reconstitute in 8% ACN/ H2O/ 0.1% TFA (v/v/v), shown with blue 
chromatogram. Hepc-25 standard (10 nM) in 8% ACN/ H2O/ 0.1% TFA (v/v/v) is 
shown with black chromatogram. 
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4.8.2.2.  MS of hepcidin 
 
The full scan of the extracted urine is observed in Figure 4-27A which shows the 
presence of other urinary compounds and the most abundant peak is uromodulin, which 
will be discussed in the Section 4.10. The Hepc-25 peak, indicated by a red arrow, has a 
retention time of 13.0 min and the MS spectrum of the peak can be observed in   
Figure 4-27B with [M+4H]
4+ (698.8 m/z) as the most abundant ion.  
 
The LC method was further optimized to produce a cleaner baseline without the loss of 
hepcidin intensity (refer to Figure 4-28). However, a slightly longer analysis time of  
26.0 min with Hepc-25 eluting at 18.5 min, compared to the analysis time of 16.0 min 
with hepcidin eluting at 13.0 min from the initial method.  
 
Other parameters such as the nebulizer pressure, drying gas and drying temperature were 
further optimized to achieve better sensitivity. 
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A
 
Figure 4-27: Chromatogram of extracted urine sample. A: Profile of urine extracted 
with C4 μSPE. Hepc-25 is indicated with a red arrow. B: MS spectra of Hepc-25 at 
retention time of 13.0 min. 
 
Figure 4-28: Comparison between two LC methods. The method listed in Table 3-10 
and 3-11 are indicated by red and black chromatogram respectively 
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4.8.2.3.  MS/MS of hepcidin 
 
The MS/MS of the [M+5H]
5+ (558.9 m/z)  precursor ion using a fragmentation 
amplitude of 1.27V, showed the y19
2+ ion with m/z 694.4 as the most abundant product 
ion (refer to Figure 4-29A). Initial MS/MS acquisition using precursor ion 558.9 m/z 
followed by fragmentation and isolation of 694.4 m/z (558.9 Æ 694.4 m/z) with averages 
of 2, ion accumulation time of 100 msec and a scan range of 500 – 700 m/z gave an 
average of 8 scan points (refer to Figure 4-29B). The reduction in total accumulation 
time resulted in a loss of sensitivity and increase in spectral averaging to 1 and 3 results 
in average scan points of 9 and 3 respectively. Similar observations in the low amount of 
scan points were also seen in the MS/MS of 698.8 Æ 694.1 m/z using a fragmentation 
amplitude of 1.12V.  
 
The ion trap analytical cycle in MS/MS mode refers to the time required when an ion 
enters the trap (filling the trap), undergoes isolation, fragmentation and is ejected from 
the trap (Wong and Cooks, 1997). The reproducibility of the Hepc-25 peak area in both 
urine samples and also in Hepc-25 standards analysis was poor. This could be due to 
several variables, such as the rate of ions entering the trap (ion injection time) and the 
ion trap being in different stages of the analytical cycle when Hepc-25 is being eluted, 
thus preventing the target analyte from entering the trap and being detected by the 
detector.  
 
182 
    Chapter 4 
Further optimization of the quadrupole ion trap will be required to achieve a faster 
analytical cycle for more reproducible analysis. Other faster scanning mass 
spectrometers such as the triple quadrupole MS (QQQ MS) and linear ion trap MS can 
also be utilized in the quantification of hepcidin (Krutchinsky et al., 2007; Murao et al., 
2007; Murphy et al., 2007; Kobold et al., 2008; Li et al., 2009).   
 
The MS/MS of precursor ions (698.8 m/z) followed by scanning of all ions in the range 
of 100 to 1500 m/z was employed for future LC runs, as the 698.8 m/z ion is more 
abundant than the 558.9 m/z ion, and a lower limit of detection can be achieved. 
Furthermore, structural elucidation and identification of Hepc-25 can also be achieved 
using this method compared to using selected-ion monitoring (SIM), whereby only a 
specific ion is selected and monitored. 
 
Using the above mentioned method, similar MS/MS spectra were observed in both the 
urine extract and Hepc-25 standard when the samples were separated using LC with CID 
of the [M+4H]
4+ ion in the ion trap (refer to Figure 4-30A and B). Thus, by using the 
retention time of Hepc-25 (18.5 min) together with its MS/MS spectra, a powerful 
technique of isolating and identifying Hepc-25 in clinical samples was achieved.  
 
183 
    Chapter 4 
 
A
B 
Figure 4-29: MS/MS of precursor ion (558.9 m/z) of extracted urine sample. A: MS/MS 
spectra of 558.9 m/z with 694.4 m/z as the most abundant product ion. B: MS/MS of 
558.9 Æ 694.4 m/z. 
 
 
Figure 4-30: Comparison of MS/MS spectra using precursor ion 698.8 m/z of A: 10 nM 
of hepc-25 standard and B: extracted control urine sample. 
A
B 
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4.8.2.4.  Limits of detection and quantification of Hepc-25  
 
In Figure 4-31, different concentrations of hepcidin standard spiked into blank urine to 
determine the limit of detection are shown. The on-column concentrations of Hepc-25 
standard are listed in Figure 4-31, where a limit of detection of 5 fmol of Hepc-25  
on-column or 1 nM was achieved. The limit of quantitation for Hepc-25 was set at  
50 fmol (10 nM) where a S/N ratio of more than 5 was observed.  
 
 
Figure 4-31: Overlays of hepcidin chromatograms containing different concentration of 
Hepc-25 standards. On-column concentrations are as stated. 
 
 
185 
    Chapter 4 
4.8.2.5.  Reproducibility of hepcidin-25 using the LC MS method 
 
In Table 4-12, the RSD observed in all standards and samples are presented and appear 
to be relatively high (16 – 28.9%). As in this experiment, no internal standard was used 
and the injection reproducibility was based on triplicate injections. A correlation 
coefficient (R
2) of 0.96 was observed in this experiment. Both RSD and R
2 could be 
further improved with the addition of an internal standard, such as ACTH (clip 18-39) or 
an analogue of hepcidin-25 (Swinkels et al., 2008).  
 
Table 4-12: LC MS reproducibility analysis of hepcidin standards (5 – 100 nM) and 
urine extracts (control subjects). The observed RSD are reported as percentage. 
 
Hepcidin standard (nM)  Control samples 
5 10  25  100  A B 
% RSD  27.5 26.4 19.8 16.0 18.9 28.9 
n= 3 
 
4.8.2.6.  Preliminary study using ACTH as internal standard for 
LC MS analysis 
 
Preliminary analysis using ACTH (clip 18-39) as the internal standard spiked in urine 
extracts showed that ACTH elutes at 13.5 min, whereas hepcidin-25 elutes at 13.0 min 
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and tails to 13.5 min (refer to Figure 4-32A). As the ion trap employed in this 
experiment was not fast enough to switch from MS/MS used in Hepc-25 analysis   
(698.8 m/z) to MS/MS for ACTH analysis (622.9 m/z), further optimization such as 
modifying the LC parameters to further separate these 2 compounds was used. 
Employing a higher duty cycle instrument such as a triple quadrupole MS or a hybrid 
quadrupole/linear ion trap MS could also be used to resolve this issue (Hager and Le 
Blanc, 2003; Shipkova et al., 2008). 
The most abundant ion observed for ACTH was the triply charged molecular ion 
([M+3H]
3+), followed by the doubly charged state ([M+2H]
2+) with m/z of 822.9 and 
1233.6 respectively (refer to Figure 4-32B). Future analysis involves optimizing the 
parameters for the MS/MS of the [M+3H]
3+ ion, in order  to quantify ACTH and to 
achieve better RSD for hepcidin quantification. 
 
4.9.  Hepcidin quantification using both MALDI-TOF MS and LC 
ESI-IT MS 
 
Two control urine samples were extracted and analyzed concurrently using both the  
LC MS and the MALDI-TOF MS method. Table 4-13 shows the concentration of 
urinary Hepc-25 from 2 healthy subjects (Sample A and B) analyzed using both methods 
(LC and MALDI-TOF method).  
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In sample A, urinary Hepc-25 concentrations of 22.25 and 22.57 nM were observed 
when analyzed with the LC MS and MALDI-TOF MS methods respectively. In   
sample B, the analysis using LC MS and MALDI-TOF MS method gave Hepc-25 
concentrations of 22.65 and 23.77 nM respectively. The differences in Hepc-25 
concentration between these two methods are less than 5% (1.4 – 4.9%). This shows that 
these 2 techniques are complementary to each other and can be used to countercheck or 
validate the accuracy and precision of the analysis periodically.  
 
Figure 4-32: Preliminary analysis using ACTH (clip 18-39) as internal standard.   
A: Overlay MS spectra of ACTH (50 nM) spiked in extracted urine in scan mode 
(purple chromatogram) and MS/MS 698.8 m/z of Hepc-25 (blue chromatogram). B: MS 
spectrum of ACTH (clip 18-39) showing the doubly ([M+2H]
2+) and triply ([M+3H]
3+) 
charged ions. 
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Table 4-13: Comparison of hepcidin-25 concentration in two control urine extracts 
using the LC MS and MALDI-TOF MS method.  
  Sample A  Sample B 
LC MS  MALDI-TOF 
MS  LC MS  MALDI-TOF 
MS 
Hepcidin-25 
concentration (nM)  22.25 22.57 22.65 23.77 
 
 
In conclusion, multiple charge states ([M+3H]
3+, [M+4H]
4+ and [M+5H]
5+) of urinary 
Hepc-25 were observed in LC MS analysis. Preliminary analysis showed the potential of 
using this technique in the semi-quantification of hepcidin by employing MS/MS of the 
[M+4H]
4+ ion and qualitative analysis can be achieved by using the retention time of 
Hepc-25, and LOD and LOQ of 1 nM and 10 nM respectively have also been 
determined However, high RSD were observed between replicates, which is due to the 
absence of an internal standard. Thus future work includes the selection of a suitable 
internal standard to reduce instrumental variability and the validation of the LC MS 
method for hepcidin analysis. 
Comparison using both MALDI-TOF MS and LC MS showed variability of less than 5% 
in the concentration of urinary Hepc-25. Thus, indicating that both instruments are 
complementary and can be use in the validation of the hepcidin assay. 
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4.10.  Uromodulin 
4.10.1.  Introduction 
 
Uromodulin (or Tamm-Horsfall protein) is the most abundant protein in human urine 
under physiological conditions (Serafini-Cessi et al., 2003). It is found in urine as a high 
molecular weight polymer that can be dissociated into monomers. (Santambrogio et al., 
2008). Uromodulin is expressed by the epithelial cells of the thick ascending limb of the 
loop of Henle and of the distal convoluted tubule, where it is shed from the apical 
plasma membrance into the tubule lumen (Santambrogio et al., 2008). 
Research in a mouse model showed that uromodulin plays a protective role against 
urinary tract infections and urothelial damage induced by calcium oxalate crystals (Bates 
et al., 2004; Mo et al., 2004).  It has also been proposed to play a role in renal immune 
response by acting as both an adjuvant and an auto-antigen (Saemann et al., 2005).  
Mutation in the uromodulin gene (UMOD) has been linked to Medullary Cystic Kidney 
Disease type 2 (MCKD2) and Familial Juvenile Hyperuricemic Nephropathy (FJHN) 
(Hart et al., 2002; Lapolla et al., 2009b). Recently, uromodulin has been identified as 
one of the predictive biomarkers for the diagnosis of kidney chronic allograph 
dysfunction (Quintana et al., 2009). 
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4.10.2.  MS of uromodulin precursor 
 
In all urinary profile spectra using MALDI-TOF MS, the most abundant peak observed 
is at 1912 m/z (refer to Figure 4-33A). Further investigation using MALDI TOF/TOF 
was carried out to determine the sequence of this peptide, and m/z 1912 was found to be 
the precursor fragment 549 – 606 of uromodulin. The sequence and MS/MS fragments 
of uromodulin precursor can be observed in Figure 4-33B, which corresponds with the 
findings by Lapolla et al. (2009). 
Similar to the MALDI-TOF analysis, when the same urine sample was analyzed using 
the LC MS method, the most abundant peak observed at 12.7 min represented 
uromodulin precursor (refer to Figure 4-26A). Multiple charge states of uromodulin 
were observed with m/z 957.1 and 638.4 corresponding to charge states of [M+2H]
2+ and 
[M+3H]
3+ respectively (refer to Figure 4-33C). These results are similar to the findings 
by Quintana et al. (2009). 
Uromodulin precursor (1912 m/z) has been found to be the most abundant peak in 
healthy subjects and in diabetic patients. However, this precursor is under-expressed in 
nephropathic and diabetic-nephropathic patients (Lapolla et al., 2009a; Lapolla et al., 
2009b). Thus, using the assay method for urinary hepcidin, in addition to providing non-
invasive quantification of hepcidin, the incorporation of biomarkers such as uromodulin 
precursor can be used in the screening for other renal disorders. 
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Figure 4-33: MS spectra of uromodulin precursor in extracted control urine. A: Urine 
analyzed using MALDI-TOF MS, B: Urine analyzed using LC-MS at retention time of 
12.7 min, and C: MALDI-TOF/TOF of uromodulin precursor (1912 m/z). Uromodulin 
precursor sequence and corresponding CID product ions (insert). 
A
B 
C
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4.11.  Creatinine Analysis 
 
Creatinine is produced when creatine and phosphocreatine are excreted from the body 
(Hoberman et al., 1948). As creatinine content of urine remains relatively constant for 
an individual, urinary creatinine has been analyzed for many years as an indicator of 
glomerular filtration rate and often used as a normalization factor when measuring other 
urinary components (Allison et al., 1966; Stokes and O'Connor, 2003). 
As cited in the review by Smith-Palmer (2002), several authors have employed creatine 
and creatinine normalization using HPLC with either reversed-phase columns (Yang, 
1998), porous graphitic columns (Gu and Lim, 1990; Inamoto et al., 1998) or ion pairing 
chromatography (Dunnett et al., 1991; Yokoyama et al., 2000). Among these 
approaches, baseline separation of both creatine and creatinine was only achieved with 
porous graphitic columns, which requires a more tedious sample preparation, such as 
pre-treatment of urine sample with C8 SPE cartridge, and a longer analysis time (Smith-
Palmer, 2002). 
In this study, baseline separations of both polar creatine and creatinine have been 
achieved as shown in Figure 4-34A and C. The diphenyl column used for this analysis 
separates analytes primarily based on differences in their π-electron structure. The main 
advantages of this method are the short analysis time (< 15min) and minimal sample 
preparation. The only sample preparation required is the dilution of the urine sample 
with mobile phase buffer (10.8mM ammonium acetate buffer). Using a diode array 
detector, creatine can be monitored at 210 nm with a retention time of 2.9 min, whereas 
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creatinine can be monitored at both 210 and 236 nm with a retention time of 4.8 min 
(refer to Figure 4-34A and B). The UV spectra in Figure 4-35A show the absorption 
peaks of urinary creatinine with λmax at 210 and 236 nm. These observations correlate 
with the wavelength reported in several publications (Yang, 1998; Jen et al., 2002; 
Smith-Palmer, 2002; Tsikas et al., 2004). The unknown compound with retention time 
of 3.2 min (refer to Figure 4-35B) is uric acid which is also present in urine (Werner et 
al., 1990), and shows the characteristic absorption peaks at 210, 236 and 293 nm (refer 
to Figure 4-35B), similar to the findings by Jen et al. (2002). 
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Figure 4-34: Chromatogram of urine sample diluted 1:10 with ammonium acetate (A 
and B) and creatine and creatinine standards (C). Chromatogram of urine sample in 
panel A is measured at 210 nm and at 236 nm in panel B. Chromatogram of standards 
mixture in panel C are measured in both 210 nm (red) and 236 nm (blue). Peaks: (1) 
unknown; (2) creatine; (3) uric acid; (4) creatinine. 
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Figure 4-35: The UV spectra of creatinine and uric acid in urine sample. A: UV spectra 
of creatinine with λmax of 210 and 236 nm. B: UV spectra of uric acid with λmax of 210, 
236 and 293 nm. 
 
External creatinine standards were used in the quantitation of urinary creatinine. An 
average RSD of 0.67% (0.43 – 1.28%) was observed in creatinine standards as shown in 
Table 4-14, with a minimum correlation coefficient of 0.99 (refer to Figure 4-36). In the 
quantitation of creatinine concentration in human urine samples, an average RSD of  
4.44% (0.47 – 22.68%) was observed (refer to Table 4-15), with the exception of   
1 outlier with an RSD of 22.68%. It is unclear as to the cause of the high %RSD as the 
clinical histories of these samples were not provided during the analysis.  
The urinary creatinine observed among all our subjects was between 86.7 and   
249.8 μg/ mL of urine. 
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Table 4-14: Concentration of creatinine standards used and the observed RSD. 
Creatinine standards 
(μg/ mL) 
% RSD (n=3) 
52.9 0.59 
105.8 1.28 
211.5 0.57 
423.0 0.46 
846.0 0.43 
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Figure 4-36: Creatinine standard curve. 
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Table 4-15: Creatinine concentration and RSD observed in healthy and hereditary 
hemochromatosis subjects. 
 Sample  no. 
Creatinine 
concentration 
(μg/mL) 
% RSD 
(n=3) 
H
e
m
o
c
h
r
o
m
a
t
o
s
i
s
 
1 164.3  3.92 
2 86.7  2.11 
3 178.1  0.58 
4 123.4  0.51 
5 249.8  22.78 
H
e
a
l
t
h
y
  A 148.0  0.86 
B 218.8  0.47 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.12.  Hepcidin levels in control subjects and hemochromatosis patients 
 
From Table 4-16, it is observed that the normalized urinary Hepc-25 in 
hemochromatosis patients (0.95-1.46 nmol/ mmol creatinine) is lower than in healthy 
subjects (1.64-1.82 nmol/ mmol creatinine). Among the 5 hemochromatosis patients 
analyzed in this experiment, 2 patients (Subject 3 and 5) have Hepc-25/creatinine ratio 
of less than 1 nmol Hepc-25/ mmol creatinine and 1 patient (Subject 1) has   
Hepc-25/creatinine ratio below the detection limit.  
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These results correlate with the finding by Swinkels et al. with control urinary Hepc-25 
levels of 0.21 to 2.14 nmol/ mmol creatinine (n=5) using the SELDI method, and by 
Nemeth et al. with urinary Hepc-25 levels of 0.43 to 8.54 nmol/ mmol creatinine (n=4) 
using the less accurate immunodot assay (Nemeth et al., 2005; Swinkels et al., 2008). 
Bansal and colleagues observed an average urinary hepcidin concentration of   
10.1±2.9 nmol/ mmol creatinine (n=5) in their control samples (Bansal et al., 2009b). 
However, Bansal et al. observed a urinary hepcidin level of 1.31±0.42 nmol/ mmol 
creatinine in hemochromatosis patients. These results correlated well with the findings 
by other authors where the level of urinary hepcidin is lower in hemochromatosis 
patients compared to healthy subjects (Kemna et al., 2005b; Nemeth et al., 2005; 
Bozzini et al., 2008; Bansal et al., 2009a; Bansal et al., 2009b). 
 
From this preliminary study, Subjects 1, 3 and 5 should develop iron overload disease 
faster than Subjects 2 and 5, especially in Subject 1, as Hepc-25 was below the detection 
limit, therefore the subject will not be able to negatively regulate iron absorption and 
will be more prone to iron overload disease compared to Subject; 3 and 5. However, 
various environmental and dietary aspects will also affect the rate of iron absorption and 
storage.  
As only 7 samples, consisting of 5 hemochromatosis samples and 2 control samples, 
were used in this study, a larger sample number is therefore required to obtain more 
statistically significant data, which will be essential in providing a diagnostic and 
monitoring assay for iron related disorders.  
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Table 4-16: Urinary Hepc-25 to creatinine ratio in healthy and hereditary 
hemochromatosis subjects.  
 
Subject
Creatinine 
(Cr) (nmol/L) 
Hepcidin-25 
(Hepc-25) 
(nmol/L) 
Hepc-25/Cr ratio 
(nmol Hepc/mmol Cr) 
H
e
m
o
c
h
r
o
m
a
t
o
s
i
s
 
1  14.53  < 1.25 nmol/L  NA 
2 7.66  11.19  1.46 
3 15.75  15.06  0.96 
4 11.08  12.82  1.16 
5 22.08  20.97  0.95 
H
e
a
l
t
h
y
  A 19.34  31.64  1.64 
B 13.08  23.77  1.82 
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In recent years, numerous published methods using MALDI/SELDI-TOF MS with 
stable isotopes (Ward et al., 2008b; Bansal et al., 2009b; Anderson et al., 2010) and 
hepcidin analogues (Kemna et al., 2005b; Swinkels et al., 2008) have been used in the 
quantification of hepcidin. Several other authors have also employed various MS-based 
techniques, such as ion trap MS in hepcidin quantification (Murphy et al., 2007; Kobold 
et al., 2008; Bansal et al., 2009a; Li et al., 2009). Here, we report the first standard 
addition method for the quantification of label-free endogenous hepcidin using MALDI-
TOF MS (Gay et al., 2010). 
In the analysis of urinary hepcidin using MALDI-TOF MS, all three isoforms of 
hepcidin (Hepc-20, -22 and -25) were detected, which correlates with findings in the 
literature (Swinkels et al., 2008; Bansal et al., 2009b; Anderson et al., 2010) . The 
advantages of using urine samples are that they are non-invasive, readily available and 
less complex compared to serum samples (Bramham et al., 2009). In this study, several 
different SPE stationary phases employed by other authors such as WCX (Altamura et 
al., 2009; Bansal et al., 2009a; Bansal et al., 2009b) and reversed phase (Li et al., 2007; 
Murphy et al., 2007) sorbent were investigated. It was observed that reversed phase SPE 
was able to retain hepcidin better than the WCX SPE. Further scaling-down of the 
extraction procedure lead to the utilization of Omix C4 μSPE, where the whole 
extraction procedure can be performed using only a micropipetter. In this extraction, 
only 100 μL of urine sample was required for each extraction which is comparable to 
other methods, where 50 to 200 μL of sample was required for the extraction (Bansal et 
al., 2009b; Anderson et al., 2010). Other advantages of this extraction method are that 
pre-treatment of the urine sample is not required and the extraction time for each sample 
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is less than 5 minutes. A recovery of more than 70% was also achieved which is 
comparable if not better than previous studies (Murphy et al., 2007; Bansal et al., 2009b; 
Li et al., 2009). 
 
High resolution with accurate mass MALDI-TOF MS was used in this analysis. 
Molecular ions, [M+H]
+, of Hepc-20, -22 and -25, with monoisotopic m/z of 2190.8, 
2435.0 and 2788.1 respectively, were observed in the mass spectra. The MALDI-TOF 
MS system was optimized to achieve a detection limit of 1.25 nM (1 fmole on-spot), 
which is comparable to the methods by Swinkels et al. (2008) and Murphy et al. (2007) 
(refer to Table 5-1). As numerous samples (up to 25 samples) can be spotted onto a  
384-well MALDIchip plate and the analysis for each spot is less than 40 sec, a high 
throughput analysis is achieved compared to SELDI-TOF methods, where only 8 wells 
are available on each plate. The other drawback of using the SELDI system is the 
observation of low resolution mass spectra due to its linear TOF configuration, as this 
system is designed for protein profiling. Thus they do not possess either the reflectron or 
pulsed ion extraction found in current MALDI-TOF MS system (Bansal et al., 2009b). 
 
Numerous groups have developed various TOF-based methods in the quantification of 
hepcidin (Kemna et al., 2007; Swinkels et al., 2008; Bansal et al., 2009b; Anderson et 
al., 2010). In this study, using the standard addition method and MALDI-TOF MS, a 
LOQ of 2.5 nM was achieved. This is comparable to the findings by Anderson et al. 
(2010) and Bansal et al. (2009), using labeled Hepc-25 with LOQ of 2.5 and 5 nM 
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respectively (refer to Table 5-1). Li et al. (2009) was able to obtain a lower LOQ   
(0.9 nM) using a LC triple-quadrupole MS. However, a high average relative error of 15% 
was also observed.  
 
MALDI-TOF MS is generally not employed in quantification for peptidomic analysis. 
This is because variables such as ‘shot-to-shot’ and ‘spot-to-spot’ variation due to 
inhomogeneous crystallization, fluctuation in laser intensity and changes in detector 
response can cause significant variation and unreliable data (Colgrave et al., 2005). 
However, the use of standard addition (Hepc-25) and internal standard (ACTH) can 
minimize interferences such as matrix effects and instrumental fluctuations. 
In this assay, a RSD of less than 10% was observed in both intra- and inter-day precision 
assays. An average RSD of 3.4% was also observed for the spot-to-spot reproducibility 
assay. In the intra-day assay, a RSD of 9.0-9.5% with a variation of 0.5% was observed. 
This compares with other studies in Table 5-1, where a large variation range (1.2% to 
14%) was observed. The method developed in this study was superior with an intra-day 
assay of 9.4%, compared to other studies where intra-day assays of more than 10% were 
observed (refer to Table 5-1). 
In Table 5-1, the inter-day precision assays reported in the literature are more than 10% 
except for Li et al. (2009) who reported precision of 5.1-13.4%. For this inter-day assay, 
precision of 9.4% was observed using the developed method, which is better than those 
reported previously. 
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The inclusion of the ACTH internal standard not only minimizes instrumental 
fluctuation, it is also ideally positioned between Hepc-20 and Hepc-25 in the mass 
spectrum, and does not overlap with the Hepc-22 peak. The hampering effect of the 
matrix on sensitivity of this analysis is also further minimized by the addition of analyte 
(standard) to the sample (standard addition method). The drawback of using labeled 
hepcidin are its high cost and difficult synthesis, compared to using both ACTH and 
hepcidin standards which are readily available and can be purchased commercially.   
 
Currently, there is limited information on the stability of hepcidin in urine (Kemna et al., 
2007) compared to serum (Tomosugi et al., 2006; Murphy et al., 2007; Li et al., 2009). 
Thus it is of great importance to investigate the integrity of hepcidin in urine samples 
with respect to sample handling procedures. All urine samples were advised to be stored 
at -80
oC until further analysis so as to prevent peptide degradation (Thongboonkerd, 
2007; Petri et al., 2008; Altamura et al., 2009; Kroot et al., 2009a). In the freeze-thaw 
stability experiment, urinary Hepc-25 was relatively stable (average concentration of 
25.9 ± 2.6 nM). However, an elevated Hepc-25 level was observed when the sample 
underwent one freeze-thaw cycle. This finding was also observed by Kemna and 
colleagues (2007), and it could be due to the loss of water, concentrating hepcidin in the 
sample.  
In the hepcidin incubation study (4
oC vs 30
oC), Hepc-25 variation of 0.5 ppb was 
observed in the 30
oC incubation. Thus, it is recommended that urinary extraction be 
carried out within 3 hours of thawing as Hepc-25 was observed to undergo degradation 
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(refer to Figure 4-22). From the urinary profiles, several other peptides, such as 
uromodulin and Hepc-20, were also observed to undergo degradation during the 30
oC 
incubation, where an almost complete degradation of urinary peptides was observed 
after 72 hours (refer to Figure 4-21).  
Current preliminary studies on the stability of urinary hepcidin are based on the pre-
extraction of urine samples. Further investigation on the behavior of urinary hepcidin 
post-extraction, will be essential to determine the degree of degradation and the 
reliability of the analysis. Parallel stability analysis of both serum and urine biofluids 
will also provide comparable insights into the behavior of hepcidin both pre- and post-
extraction. 
 
In the current literature, the concentration of hepcidin in different urine sections (start-, 
mid- and end-stream) has not been investigated. In this study, different concentrations of 
urinary Hepc-25 were observed in different urine sections. Similar Hepc-25 
concentrations were observed in both start- and mid-stream, however a decline in   
Hepc-25 level was observed in the end-stream. 
These analyses provided a valuable insight into the stability of hepcidin and highlighted 
the importance of sample handling procedures. As large variations were observed when 
urine samples underwent different handling processes, a standardized collection, 
handling and extraction procedures was implemented to ensure accuracy and 
comparable data among the samples. 
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Multiple charge states ([M+3H]
3+, [M+4H]
4+ and [M+5H]
5+) of urinary Hepc-25 were 
observed in LC-ESI-IT MS analysis, which correlates with the finding of Bansal et al. 
(2009) and Li et al. (2009). In the quantitative analysis of hepcidin, Bansal et al. (2009) 
and Li et al. (2009) performed MS/MS on the [M+3H]
3+ and [M+4H]
4+ charge states 
respectively. Contrary to their findings, the MS/MS experiments performed on the 
different charge states in this study did not yield product ions of sufficient intensity for 
further isolation. Therefore, an alternative semi-quantitative method was employed 
where the precursor ion (698.8 m/z) was fragmented and all its product ions collected. 
With this method, the identification of Hepc-25 can be achieved from the formation of 
product ions generating a fingerprint of Hepc-25. The use of the HPLC elution time of 
Hepc-25, which provides a secondary qualitative check, together with the ion trap MS 
method, a powerful diagnostic assay of Hepc-25 using LC-ESI-IT MS has been achieved. 
However, this LC MS method is still in its preliminary stages where the addition of a 
suitable internal standard to reduce instrumental and sample variability is required.  
 
Urinary Hepc-25 concentration variation of less than 5% was achieved when the same 
sample was analyzed in both instruments (MALDI-TOF MS and LC MS). These 
findings correlate with the results reported by Bansal et al. with a 39% difference 
between the two instruments (Bansal et al., 2009a; Bansal et al., 2009b). One limitation 
of the MALDI-TOF analysis proposed by Bansal et al. is the physical properties of the 
sample. In the MALDI-TOF analysis, the sample is not in solution and thus is not 
homogeneous as compared to LC analysis (Bansal et al., 2009b). However from these 
206 
    Chapter 5 
studies, it shows that both techniques are complementary and can be employed in the 
counter-validation of both instruments.  
The main limitation of this clinical study between hemochromatosis patients and healthy 
subjects was the availability of samples. Only a total of 7 urine samples   
(5 hemochromatosis and 2 control samples) were analyzed using the developed MALDI-
TOF method. Hepc-25 levels in hemochromatosis patients (0.95-1.46 nmol/ mmol 
Creatinine; with 1 sample having Hepc-25 levels below the LOD) were lower than those 
in healthy subjects (1.64-1.82 nmol/ mmol Creatinine), which correlated with findings 
by several authors (Nemeth et al., 2005; Swinkels et al., 2008; Bansal et al., 2009b). 
However, the Hepc-25 levels reported in these studies range widely (0.21 to 13.1 nmol/ 
mmol Creatinine). In the first international round robin carried out by Swinkels and 
colleagues, high variability in Hepc-25 levels between different methods was observed 
(Kroot et al., 2009b). Thus, it is of great importance that standardized collection and 
analysis methods, which correlate between different groups be employed, to ensure 
comparable results between the groups. 
 
Future development of this project would be to finalize and validate the LC MS method 
for the analysis of Hepc-25. Another key milestone would be to translate the urinary 
hepcidin extraction method for the extraction of serum samples, as a lower overall 
(pre)analytical variability between subjects was observed in serum samples when 
compared to urine samples (Kroot et al., 2009a). However, low variability in urinary 
Hepc-25 between fasted subjects was also observed by the same authors in samples 
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collected in the morning (6-11am) (Kroot et al., 2009a). Thus the development of both 
urinary and serum methods will allow the analysis of hepcidin in both biofluids and also 
provide an insight into the relationship between the two matrices. Further automation 
with a sample preparation instrument will also greatly reduce extraction and spotting 
variability, thus increasing the accuracy and precision of the data. 
MALDI-TOF MS has been widely used in biomarker discovery such as in ovarian 
cancer (Lopez et al., 2007; Ziganshin et al., 2008), colorectal cancer (Ward et al., 2006; 
Alexandrov et al., 2009) and in renal diseases (Lapolla et al., 2009a; Wai-Hoe et al., 
2009). This platform can be employed in future studies to identify potential biomarkers 
between healthy subjects and in patients with iron-related diseases, providing an 
invaluable primary diagnostic assay.  
 
Since the isolation of hepcidin by Krause et al. (2000) and Park et al. (2001), a vast 
amount of research has been undertaken to decipher this key iron regulator. In terms of 
molecular biology, current research focusing on the signaling and regulatory pathways 
of hepcidin is being carried out by numerous groups. On the other hand, several groups 
have succeeded in isolating and quantifying hepcidin. However, extensive work is still 
required to achieve a standardized collection and analysis method between different 
research groups, which would be beneficial in providing an all-rounded assay in both 
clinical and research-based environments. 
With increased understanding of the regulatory behavior of hepcidin and the 
development of hepcidin diagnostic assays, the use of hepcidin in targeted therapeutics 
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for iron-related diseases will be essential in providing treatment for these disorders. 
Although there are no hepcidin therapies currently available, several candidates are 
currently being investigated (Nemeth, 2010). The development of hepcidin agonists 
would be useful in the treatment of iron overload disorders such as in β-thalassemia, 
iron-loading anemia and in hemochromatosis, whereas the use of hepcidin antagonists 
would be useful for treating patients with hepcidin overload, such as anemia of chronic 
disease. Apart from applying direct influences to hepcidin activity, as in agonists and 
antagonists, other agents targeting the pathways regulating hepcidin expression, such as 
sHJV and anti IL-6 antibody, should also be investigated (Babitt et al., 2007; Kawabata 
et al., 2007).  
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Table 5-1: Comparison of hepcidin results with recent studies. 
Method  SELDI  SELDI  SELDI  Immunodot LC/MSMS  LC/MSMS MALDI  MALDI  MALDI 
References  Tomosugi 
et al., 2006 
Swinkels  
et al., 2008 
Kemna  
et al., 2007 
Nemeth  
et al., 2005 
Murphy  
et al., 2007 
Li  
et al., 2009 
Anderson 
et al., 2010 
Bansal  
et al., 2009 
This 
report 
Biofluid  Serum Urine Urine Urine Serum Serum Urine  Urine Urine 
Internal 
Standard 
External 
calibration 
(Hep-25) 
Hepc-24 
analogue 
External 
calibration 
(Hep-25) 
Rabbit anti-
human 
antibody 
calcitonin 
gene-
related 
peptide
 
Stable 
isotope 
Stable 
isotope 
Stable 
isotope 
Standard 
addition 
(Hepc-25) 
LOD
a  16 ND 22 ND  0.36  ND  ND  ND  1.25 
LOD  
(wrt Cr)
b  ND 3-37 ND 430 ND ND ND ND  80.5 
LOQ (nM)  ND ND ND ND ND 0.9 2.5 5.0 2.5 
Intra-day 
assay  7.5-9.2% 6.1-7.3%  12%  5-19%  ND  2.9%  12.1%  7-13%  9.0-9.5% 
Inter-day 
assay  25.7-27.5% ND  15-27%  12% 11.0-15.3%  5.1-13.4%  13.2% 10-20% 9.4% 
 
a Hepc-25 value (in pmole) is normalized to initial sample volume (mL). 
b Hepc-25 value (in pmole) is normalized to urinary creatinine (in mmole). 
ND: not determined. 
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